Entities

Hjörtur Sturluson is published in MedEye’s research-and-development team with responsibility for quality assurance. His issuer biography describes electrical and computer engineering studies at the University of Iceland and software development for hospital information systems. Current tenure is unverified beyond the published source.

Ívar Helgason co-founded MedEye and is published as product owner in the issuer’s legacy directory. A physician with software and hardware experience, he developed the medication-verification concept while studying at MIT and Harvard Medical School and previously founded a decision-support company acquired by deCODE Genetics. Current tenure is unverified beyond the published source.

Janneke Vos is published as MedEye’s marketing manager. Her issuer biography describes earlier healthcare-IT marketing work at ChipSoft and D&A Medical Group and responsibility for Dutch marketing strategy and activities. Current tenure is unverified beyond the published source.

Magni Mortensen is published as MedEye’s senior developer. His issuer biography describes more than 20 years in software design and development across industries, including earlier architecture and information-security work at Íslandsbanki. Current tenure is unverified beyond the published source.

Margrét Una Kjartansdóttir is published in MedEye’s research-and-development team. Her issuer biography describes information-sciences training at Columbia University and work on machine-learning projects. Current tenure is unverified beyond the published source.

Tim Wouters is published as MedEye’s Director Customer Value in its legacy Dutch and English directories. Further career history and current tenure are not established by the available issuer profile. Current tenure is unverified beyond the published source.

Steven Robert Lapkoff is listed as E1 Ventures LLC’s chief compliance officer fromJune2026 in its September8,2026 FormADV. His own professional profile identifies an ACA Group affiliation, a Pace University School of Law degree and New York attorney credentials. This regulatory role does not establish full-time investment-partner employment, portfolio decision authority or a personal investment. No authentic portrait bytes were verified during this audit, and an unrelated namesake photograph is not substituted.

Health Universe develops enterprise AI infrastructure that connects clinical records with configurable agents and healthcare workflows. Its platform retrieves and consolidates patient information through TEFCA, SMART on FHIR and uploaded records, then lets health systems, oncology practices, academic medical centers and life-sciences organizations deploy and govern autonomous and human-supervised agents. Navigator provides a patient-level workspace, while configurable agents and routines support repeatable workflows. Evaluation and governance tools help teams monitor agent behavior and operating costs. Published oncology tools produce source-linked case summaries covering diagnoses, disease stage, biomarkers and treatment history, while clinical-research workflows support trial matching, protocol development and research documentation. The platform includes evaluation, audit trails, access controls and human review to support use in clinical environments. The legal entity published in the company’s footer is Health Universe, Inc.; its March2026 issuer release identifies San Francisco as its headquarters.

Dan Caron founded Health Universe to develop infrastructure for deploying AI agents in healthcare. His earlier work includes co-founding Arrive Health, a prescription-optimization business.

Doug Cassidy works with health systems, academic medical centers and life-sciences organizations. His prior leadership includes Deep 6 AI and Manifold AI, alongside healthcare software, medical-record and cancer-detection work.

Doug Fridsma is a physician and biomedical informatics specialist. His earlier leadership includes AMIA and the US Office of the National Coordinator for Health Information Technology, with work on health-data standards and interoperability.

Jim Muir leads technical strategy and software engineering. His earlier work includes voice AI at iyO, mobile engineering at Rise Science, and healthcare-product engineering at CoverMyMeds.

Ross Cantor leads commercialization and strategic partnerships across health systems, laboratories and life-sciences organizations. His earlier work includes commercializing Proscia’s real-world data business.

Suzy Bureau leads product development for Health Universe. Her earlier work includes product leadership at CoverMyMeds, iyO and Thirty Madison, spanning healthcare workflows and consumer products.

Shruti Kumar is vice president at Tusk Ventures, leading sourcing and due diligence. Her primary biography describes prior investing at 01 Advisors and Long Arc Capital, operating experience at GlossGenius and technology investment banking at Citigroup. She holds a New York University finance degree and is based in New York.

David Kolata is a Tusk Ventures adviser working on policy and regulatory growth strategy. He has served as vice president of policy at Sealed and previously led Citizens Utility Board, including Illinois energy-policy initiatives. He holds Notre Dame, University of Toronto and Vanderbilt degrees. His work with outside clients is not treated as an investment by the platform.

Christina Esposito advises Tusk Ventures on government relations and regulation. Her biography describes work on travel, gaming, labour, energy and other policy areas and prior New York State digital-project and New York City media-office roles. Her current published advisory affiliation is not recast as a fund-manager position.

Anaxis Pharma is an Australian biotechnology company developing small-molecule inhibitors and modulators of necroptosis, an inflammatory form of programmed cell death involving kinases and pseudokinases. Its discovery programs seek treatments for acute and chronic inflammatory diseases, including inflammatory bowel disease, Crohn’s disease, liver fibrosis and reperfusion injury. The company combines Walter and Eliza Hall Institute biological and structural-research expertise with SYNthesis Research medicinal chemistry, conducting hit-to-lead work, lead optimisation, screening and preclinical candidate selection. It describes two preclinical programs supported by pharmaceutical partners. SYNthesis BioVentures identifies Anaxis as the wholly owned main operating subsidiary of Catalyst Therapeutics. Published plans to advance candidates towards clinical studies are not evidence that human trials have started or that a medicine is approved.

Gabby Goldberg is published as operations manager of SYNthesis Research and its investee companies Anaxis Pharma and Catalyst Therapeutics. Her biography describes translational immunology and industry-linked preclinical development experience; she is distinct from venture investor Gaby Goldberg.

Guillaume Lessene is published as Anaxis’s chief scientific officer. His research and medicinal-chemistry background includes targeting apoptotic and necroptotic cell-death pathways.

Helene Jousset, identified in the biography as Hélène Jousset Sabroux, is Anaxis’s published head of screening. Her background includes high-throughput drug-discovery screening in academic and pharmaceutical settings.

James Murphy is published as Anaxis Pharma’s director of biology. Its biography identifies the WEHI cell-death researcher who studies MLKL and necroptosis, distinct from the existing Forum Ventures managing-partner identity.

Jean-Marc Garnier is Anaxis’s published lead medicinal chemist. His biography describes medicinal-chemistry work on epigenetic and necroptosis inhibitors.

Peter Colman is published as an Anaxis board member. A structural biologist, his biography describes influenza neuraminidase research and prior biotechnology board work.

Peter Czabotar is Anaxis’s published lead structural biologist. His work examines proteins regulating cell-death signalling and uses structure-based methods to develop potential therapeutics.

Ueli Nachbur is Anaxis’s published lead biologist. His research background covers inflammatory signalling, cell death and preclinical disease models.

Xian Bu is an Anaxis board member and medicinal chemist. His published biography describes drug-discovery and contract-research management experience.

Catalyst Therapeutics is an Australian drug-discovery investment and project-management company formed as a joint venture between the Walter and Eliza Hall Institute of Medical Research and SYNthesis Research. It supports early translational research through chemical screening, medicinal chemistry, proof-of-concept funding and partnering or licensing. Its published projects include selective BET bromodomain inhibitors for cancer and inflammatory disease, a pseudokinase screening platform, and computational drug design combining AI, machine learning, molecular dynamics and quantum chemistry. Its wholly owned operating subsidiary, Anaxis Pharma, develops small molecules that modulate inflammatory cell death. Catalyst’s programs are research and drug-development projects; computational modelling is not quantum-computer hardware, and a licensing agreement does not imply medicine approval.

Cory Epstein is listed as senior vice president of communications in Tusk Ventures’ roster. His biography clarifies that his executive post is at parent Tusk Holdings and that he provides communications advice to Tusk Ventures companies. He previously led communications at Transportation Alternatives and worked at Lyft, including Citi Bike. He attended Vassar. The parent employer qualification is retained.

Tim Sullivan advises Tusk Ventures on economic development and public-sector partnerships. He led the New Jersey Economic Development Authority from 2018 to 2025 and previously held Connecticut economic-development and New York City deputy-mayoral staff roles. His government programme budgets are not attributed as venture-fund capital or personal investments.

Anna von Finckenstein is communications associate at Tusk Ventures. She previously worked at Aptos Labs on public relations and executive communications and at communications consultancies supporting regulated finance and technology clients. She holds a McGill degree in modern European history with political science studies.

Ed Manzi is a Tusk Ventures adviser focused on state policy and healthcare regulatory strategy, including coverage and reimbursement. His earlier work includes WebMD healthcare operations, Everly Health channel strategy and investing at Social Impact Capital. He co-founded the public discussion programme UNMUTED. He holds Harvard and Northeastern degrees and is a licensed CPA. His role is advisory, not an assumed partner or personal investor.

Michael LaCerda, displayed as Mike LaCerda in the directory, is chief financial officer of Tusk Venture Partners. His primary biography describes responsibility for fund finance, accounting, reporting, planning, valuation oversight and compliance. The firm’s 2022 founder announcement identifies prior alternative-asset finance experience at BlackRock, Blackstone and KKR. The Mike/Michael name variant is established by the same named team page and biography.

Quinn Shean is listed on Tusk Venture Partners’ platform team. Her primary biography describes regulatory strategy, policy development, communications and partnerships for companies operating in regulated markets. She helps translate regulatory challenges into execution strategies. She is absent from the current separate Tusk Ventures roster; that affiliation is not inferred.

Marla Kanemitsu is an adviser at Tusk Ventures and a named platform affiliate at Tusk Venture Partners. She advises regulated businesses on legal, growth and policy strategy, including fintech and e-commerce. She previously practiced law as a partner and handled complex commercial disputes and regulatory risk. She holds a Cornell law degree and a University of Texas undergraduate degree. Current advisory roles are distinguished from any inferred permanent investment employment.

Cynthia Matar leads communications and public affairs at Tusk Ventures and is separately listed on Tusk Venture Partners’ platform team. Her work connects positioning, media and policy for emerging technology businesses. Her own biography describes prior venture-platform operating work, including chief-of-staff experience at a neurotechnology-focused VC firm. She holds a Pace University business degree. Titles are tied to each publisher’s roster rather than assuming the two operating platforms are identical.

Bob Greenlee is president of Tusk Ventures and a regulatory member of the Tusk Venture Partners platform team. His work spans healthcare, financial services, energy, education and manufacturing. He formerly served as Illinois deputy governor and deputy director of its budget office and practiced law. He holds Yale and University of Chicago degrees and teaches non-market strategies at Columbia. Both firms’ own pages explicitly describe his portfolio-company regulatory work.

John Hooie is a publicly listed member of Tusk Venture Partners’ investment team. His biography describes prior investing work at Forté Ventures, including collaboration with strategic corporate investors across technology industries. His current named manager affiliation is retained without inventing a managing-partner title or membership in the separate Tusk Ventures roster.

Jordan Nof is co-founder and managing partner of Tusk Venture Partners. His own biography identifies investment work in Lemonade, FanDuel and Coinbase and board affiliations with Alma, Wheel, Sunday and Elaborate. Before Tusk he worked on Blackstone’s corporate venture portfolio and in institutional investment management at AllianceBernstein. He holds a Rollins MBA and Florida State finance degree and teaches at Columbia. The newer Tusk Ventures public roster does not list him; no new-platform role is inferred.

Bradley Tusk co-founded Tusk Venture Partners with Jordan Nof and leads Tusk Ventures as founder and CEO. His career includes Bloomberg’s 2009 mayoral campaign and service as Illinois deputy governor. His 2025 founder announcement distinguishes traditional venture funds from the renewed equity-for-regulatory-services platform, which can also make small balance-sheet investments and deal-specific SPVs. He founded Tusk Strategies and leads Tusk Holdings, identified by the current team page as the parent of Tusk Ventures.

Kylee Haller — Synapticure publishes the following professional biography and affiliation: is a speech-language pathologist specializing in neurodegenerative diseases, with extensive experience treating ALS, Parkinson's, and other neurologic conditions. She is dedicated to improving patient quality of life through personalized assessment, therapy, and assistive technology integration. VA Pittsburgh Healthcare System (Speech-Language Pathology) Graduate - University of Minnesota (Speech-Language Pathology) Undergraduate - University of Minnesota (Speech-Language-Hearing Sciences & Neuroscience) American Speech-Language-Hearing Association (ASHA) Certificate of Clinical Competence in Speech-Language Pathology (ASHA) Huntington’s Study Group (HSG) Rehab Committee, Member Kylee Haller is a speech-language pathologist with advanced training in neurodegenerative diseases. She completed her undergraduate and graduate degrees in speech-language pathology at the University of Minnesota. During her fellowship at the VA Pittsburgh Healthcare System, Kylee gained specialized experience treating a range of neurologic conditions in the veteran population, with a focus on ALS and Parkinson's disease through the PADRECC program. Prior to joining Synapticure, Kylee served as the sole speech-language pathologist at the Penn Medicine Movement Disorders Clinic, where she worked with multidisciplinary teams to treat patients with ALS, Parkinson’s disease, atypical parkinsonism, Huntington’s disease, and ataxia. She also collaborated closely with the Penn Memory and FTD Center, further refining her expertise in cognitive and motor disorders. Kylee is dedicated to providing personalized assessment and treatment for speech, language, cognition, swallowing, and the use of alternative and augmentative communication (AAC) devices. With a strong focus on functional outcomes, she is committed to improving her patient's quality of life through innovative therapy and the integration of assistive technologies. Invited Presentations ‍ - “Communication with a Tracheostomy – The Role of Speech-Language Pathology”, April 2022, PEEPS Talking PAP Conference (International – Virtual) - “Evaluation of cognitive-communication deficits following treatment of primary brain tumors”, October 2017, Mayo Clinic Radiation Oncology Grand Rounds (National – Rochester, MN) ‍ Presentations at National Meetings ‍ - “Cognitive-linguistic deficits following treatment of brain tumors: Results of a prospective pilot study”, October 2018, American Society of Radiation Oncology, San Antonio, TX. ‍ American Speech-Language-Hearing Association (ASHA) Certificate of Clinical Competence in Speech-Language Pathology (ASHA) Huntington’s Study Group (HSG) Rehab Committee, Member Current directory role is Speech-Language Pathologist.

April Stowers — Synapticure publishes the following professional biography and affiliation: With over 25 years of experience across specialties like cardiology and neurology, April is a dedicated nurse practitioner, educator, and certified dementia practitioner. Beyond her professional work as an adjunct professor and guest lecturer, she is a devoted West Virginia Mountaineer and Girl Scout co-leader who enjoys life with her family and dog. Purdue University, West Lafayette, IN Master of Science in Nursing West Virginia University, Morgantown, WV Bachelor of Science in Nursing American Association of s Florida Nurse Practitioner Network I am passionate about medical education. I have worked as an adjunct professor at Florida Gulf Coast University, as well as a guest lecturer for several other universities, medical programs, and conferences. With over 25 years of experience in the medical industry, I have expertise in various medical specialties, including cardiology, vascular surgery, primary care, and neurology. I am most passionate about working with Alzheimer’s patients and families, having expanded my knowledge base further to become a certified dementia practitioner. In addition to working as an educator and a nurse practitioner, I am an avid reader, WVU Mountaineer, and Star Wars fanatic. I spend my free time with my husband, son, daughter, and dog. My daughter and I are active in Girl Scouts, where I am a co-leader, and she is currently working on her Gold Award. ‍ American Association of Nurse Practitioners Florida Nurse Practitioner Network Current directory role is Nurse Practitioner.

Ashley Tanton — Synapticure publishes the following professional biography and affiliation: Dr. , a clinical neuropsychologist specializing in various neurological and psychological disorders, joined Synapticure in 2024, bringing extensive experience from her work at VA Medical Centers and her diverse educational background. Phoenix VA Medical Center (Neuropsychology) Graduate- Alliant International University Undergraduate- American University Dr. Ashley Tanton joined Synapticure in 2024, providing psychotherapy and neuropsychology services to patients and their families. She is a clinical neuropsychologist and her areas of specialization include cognitive impairment, neurodegenerative disorders (i.e., dementia), traumatic brain injury, stroke, movement disorders (i.e., Parkinson’s Disease), medical diagnoses, mood disorders, posttraumatic stress disorder, attention-deficit/hyperactivity disorder, and learning disabilities. Dr. Tanton completed her undergraduate studies in international studies at American University in Washington, DC. Following a brief career in legal marketing, she decided to pursue her passion for psychology by completing a doctoral degree in Clinical Psychology. In addition to a Psy.D., she also holds an M.A. in Clinical Forensic Psychology and an M.A. in Health Psychology. Dr. Tanton’s clinical training included a predoctoral practica at the Northern California VA Medical Center specializing in neuropsychology, a predoctoral internship at the Gulf Coast VA Medical Center specializing in neuropsychology, and a two-year neuropsychology postdoctoral residency at the Phoenix VA Medical Center. Most recently, Dr. Tanton served as the sole clinical neuropsychologist for the West Palm Beach VA Medical Center, where she provided neuropsychological services for our nation’s heroes and supervised psychology interns in the administration and interpretation of neuropsychological evaluations. In early 2024, Dr. Tanton decided to devote her time to private practice full-time. In her free time, Dr. Tanton enjoys spending time with her husband and two fur babies, reading, traveling, baking, and being near the water. Current directory role is NeuroPsychologist.

Jennifer Green — Synapticure publishes the following professional biography and affiliation: With more than 17 years of clinical experience, specializes in Parkinson’s disease and movement disorders, focusing on thoughtful care that supports both neurologic and emotional well-being. East Carolina University, Greenville, NC (Bachelor of Science in Multidisciplinary Studies with a concentration in Neuroscience) Honors: General Education Honors, Cum Laude, Order of Omega East Carolina University, Greenville, NC (Master of Science in Physician Assistant Studies) American Academy of Physician Assistants (AAPA), Member Movement Disorder Society, Member American Academy of Neurology, Member Parkinson’s Study Group, Member Huntington Study Group, Member Jennifer Green, PA-C is a physician assistant specializing in the care of patients with Parkinson’s disease and other movement disorders, with over 17 years of clinical experience, including 13 years focused specifically on movement disorders. Born and raised in the Appalachian Mountains of North Carolina, Jennifer values community, authenticity, and caring for people as individuals—not just diagnoses. After completing her education, she settled in the Triad region of North Carolina, where she lives with her two children. Jennifer takes a holistic approach to neurologic care, with a particular interest in the connection between neurologic disease and mental health. She believes that emotional well-being, confidence, and feeling understood play a critical role in quality of life, especially for patients navigating chronic neurologic conditions. Her clinical style emphasizes education, thoughtful medication adjustments, and helping patients feel supported and confident in their care plan. Through Synapticure’s virtual care model, Jennifer provides expert neurology care directly to patients in their homes, working closely with caregivers to address both motor and non-motor symptoms, reduce symptom fluctuations, and support long-term quality of life. Outside of work, Jennifer spends most of her time with her children and enjoys reading personal growth literature and watching true crime documentaries. American Academy of Physician Assistants (AAPA), Member Movement Disorder Society, Member American Academy of Neurology, Member Parkinson’s Study Group, Member Huntington Study Group, Member Current directory role is Physician Assistant, Movement Disorders.

Lisa Diamond — Synapticure publishes the following professional biography and affiliation: Dr. is an esteemed psychiatrist, former Chief of Psychiatry at notable hospitals, now a leading telehealth consultant and Medical Director shaping modern mental health policies New York University Medical school - Columbia University Undergraduate - Yale University ‍ Lisa Diamond, MD is a graduate of Columbia University, College of Physicians and Surgeons, and attended Yale University for her undergraduate studies, where she graduated Magna Cum Laude with a Bachelor of Arts degree in Psychology. Dr Diamond trained at New York University in the department of Psychiatry during her residency. Dr Diamond started a private practice in New York City, and continued in private practice when she moved to New Milford, CT. In 1998, she become Chief of Psychiatry at New Milford Hospital where she expanded the staff to include Advanced Practice Nurse Practitioners for the first time. After 12 years at New Milford Hospital, Dr Diamond left to become Chief of Psychiatry at Charlotte Hungerford Hospital, which is part of Hartford Healthcare Corporation. At Charlotte Hungerford, her responsibilities included oversight of a 17 bed inpatient unit, extensive adult outpatient services, a partial hospital program, a dual diagnosis intensive outpatient program, and the Center for Youth and Families. Currently, Dr Diamond is a consultant to Charlotte Hungerford Hospital, and, in addition,  is working remotely via telehealth. Her telehealth work includes both direct patient care, as well as work in Medical director positions at Wellbrook Health, LinqCare and Catholic Charities, to guide development of policies and procedures. Current directory role is Psychiatrist.

Anuj Dhir — Synapticure publishes the following professional biography and affiliation: Dr. is a fellowship-trained neurologist who specializes in caring for patients living with neuromuscular diagnoses like ALS. Emory University School of Medicine (Neurology) ‍ Emory University School of Medicine (Clinical Neurophysiology, focus in EMG/Neuromuscular) Medical school - Emory University School of Medicine (MD) Undergraduate - University of Georgia (BS Biology, minor Spanish) American Academy of Neurology (AAN): Member Dr. Anuj Dhir completed both his residency and fellowship at Emory University, focusing on neurology during his residency and on EMG/neuromuscular during his fellowship. He is a Member of the American Academy of Neurology. Dr. Dhir is passionate about helping patients understand the nuances of their diagnoses and what is happening in their “fascinatingly complex neurologic system.” He was initially drawn to Synapticure for its commitment to democratizing access to specialized care. Having practiced medicine internationally in resource-limited settings (Tanzania, Indian Himalayas), access to adequate healthcare is a challenge he cares about deeply, and so he welcomes the opportunity to support patients across the country access the care they deserve. Radiographic Improvement of Larval Cysts in Neurocysticercosis. David R. Landzberg, Anuj Dhir, Dinesh V Jillella. Annals of Neurology 2021 Feb 1 A, not so uncommon, uncommon cause of acquired epilepsy: A Case Report. Valerie Jeanneret 1 , Anuj Dhir 1 . Department of Neurology, Emory University School of Medicine; Atlanta, GA, USA. (March 9 th , 2019) American Academy of Neurology (AAN): Member Current directory role is Neuromuscular Neurologist.

Benjamin Williams — Synapticure publishes the following professional biography and affiliation: Dr. Benjamin J. Williams is a renowned neurologist, Alzheimer's researcher with 20+ years in clinical trials, and Adjunct Professor at Atrium Wake Forest with a deep-rooted history in Memory Disorders Clinics University of California San Diego School of Medicine Medical School - University of California San Diego School of Medicine Graduate - The University of Texas at Austin Undergraduate - The University of Texas at Austin 2018-2023: Atrium Wake Forest Baptist Health, active staff 2012-2017: Parkland Memorial Hospital, active staff 2012-2017: UT Southwestern Medical Center University Hospitals, associate staff 2004-2012: University Medical Center, Lubbock, TX, full staff 1997-2008: Covenant Health System, Lubbock, TX, full staff Benjamin J. Williams, MD, PhD is a graduate of the University of Texas Medical Branch at Galveston, Texas. He attended the University of Texas at Austin for both his undergraduate and graduate studies,  receiving both a Bachelor of Arts degree with high honors and a PhD in Zoology.  He Attended the University of Texas at Galveston where he received his MD and went on to complete a neurology residency at the University of California San Diego School of Medicine. Dr. Williams practiced general neurology and sleep medicine for many years at several practice locations in California, North Carolina, and Texas. He joined the neurology faculty at the Texas Tech School of Medicine and subsequently had neurology faculty appointments at the University of Texas Southwestern Medical School in Dallas, TX and at Atrium Wake Forest Baptist Health in Winston-Salem, NC. At these institutions Dr. Williams’ clinical efforts were primarily in the outpatient Memory Disorders Clinics. Dr. Williams has been involved in clinical trial work for over 20 years. Most of this work has been in the field of therapeutic trials for Alzheimer disease, and he remains currently active in Alzheimer disease research in his current position as an Adjunct Professor at Atrium Wake Forest Baptist Health. His research has included the use of monoclonal antibody therapies such as lecanemab, which is now FDA approved, in the treatment of Alzheimer disease. Dr. Williams is still an active member of the Wake Forest Alzheimer Disease Research Center, which has ongoing grant funding from the National Institutes of Aging. Williams BJ, Larimer JL & Gordan WH (1977). Production of localized lesions in the nervous system using silver nitrate. Comp. Biochem. Physiol., 57: 37-40. Garlick RL, Williams BJ & Riggs AF (1979). The hemoglobins of Phoronopsis viridis , of the primitive invertebrate phylum Phoronida: characterization and subunit structure. Arch. Biochem.Biophys., 194: 13-23. Williams BJ & Larimer JL (1980). Abdominal extension-evoking interneurons in crayfish: characteristics of the ganglionic driving networks. J. Exp. Zool., 214: 189-197. Williams BJ & Larimer JL (1981). Neural pathways of reflex-evoked behaviors and command systems in the abdomen of the crayfish. J. Comp. Physiol., 143:27-42. Williams BJ, Droge MH, Hester K & Leonard RB (1981). Induction of swimming in the high spinal stingray by L-DOPA. Brain Res, 220:208-13. Williams BJ, Livingston CA & Leonard RB. (1984). Spinal cord pathways involved in initiation of swimming in the stingray, Dasyatis sabina : spinal cord stimulation and lesions. J. Neurophysiol, 51:578-91. Ritchie TC, Roos LJ, Williams BJ, & Leonard RB (1984). The descending and intrinsic serotonergic innervation of an elasmobranch spinal cord. J. Comp. Neurol, 224:395-406. Williams BJ, Droge ME & Leonard RB (1988). Intracellular recording from pectoral fin motorneurons in the stingray, Dasyatis sabina , an elasmobranch fish. J. Neurophysiol, 51:666-79. Clark WM, Williams B, Selzer KA, Zweifler RM, Sabounjian Gammans RE (1999). A randomized efficacy trial of citicoline in acute ischemic stroke. Stroke, 30:2592-97. Warren MW, Hynan LS, Weiner MF, Doody R, Roundtree S, Capriles V, O’Bryant SE, Williams BJ, et al (2012). Lipids and adipokines as risk factors for Alzheimer’s disease. Journal of Alzheimer’s Disease , 29 , 1, 151-157. O’Bryant SE, Johnson LA, Balldin V, Edwards M, Barber RC, Williams BJ, Devous M, Cushings B, Knebl J, & Hall J (2012). Characterization of Mexican Americans with Mild Cognitive Impairment and Alzheimer’s Disease. Journal of Alzheimer’s Disease, 33(2), 373-9. PMID: 22976076 Szerlip, HM, Edwards ML, Williams BJ, Johnson LA, Vintimilla RM & O’Bryant SE.  (2015). Association of cognitive impairment with chronic kidney disease in Mexican Americans. Journal of the American Geriatric Society 63(10), 2023-2028. Edwards M, Hall J, Williams B, Johnson L & O'Bryant SE (2016). Molecular markers of amnestic mild cognitive impairment among Mexican Americans. Journal of Alzheimer’s Disease 49, 221-228. Lockhart SN, Schaich CL, Craft S, Sachs B, Rapp SR, Jung Y, Whitlow C, Sai KKS, Cleveland MJ, Williams BJ, Burke G, Bertoni A, Hayden KM, Hughes TM. Associations among vascular risk factors, neuroimaging biomarkers, and cognition: Preliminary analyses from the Multi-Ethnic Study of Atherosclerosis (MESA). Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 05 September 2021 Tugce Duran, James R Bateman, MD, MPH; Benjamin J Williams, MD, PhD; Mark A Espeland, PhD; Timothy M Hughes, PhD; Stephanie Okonmah-Obazee, MS; Melissa M Rundle, PhD; Suzanne Craft, PhD; Samuel N Lockhart (December 2021). Neuroimaging and clinical characteristics of cognitive migration in community-dwelling older adults. Alzheimer’s & Dementia, Vol 17, Issue S1, e056241 Samuel N. Lockhart, Tim M. Hughes , Cynthia Suerken , Youngkyoo Jung , Christopher T. Whitlow , James R. Bateman , Benjamin J. Williams , Mark A. Espeland , Bonnie C. Sachs , Kathleen M. Hayden, Laura D. Baker , Suzanne Craft (December 2021). Cardiometabolic disorders are associated with reduced cerebral perfusion and white matter microstructure. Alzheimer’s & Dementia, Vol 17, Issue S1, e055791 Claudia Coffin, Cynthia K. Suerken, James R. Bateman, Christopher T. Whitlow, Benjamin J. Williams, Mark A. Espeland, Bonnie C. Sachs, Maryjo Cleveland, Mia Yang, Samantha Rogers, Kathleen M. Hayden, Laura D. Baker, Jeff Williamson, Suzanne Craft, Timothy M. Hughes, Samuel N. Lockhart. (July 2022). Vascular and microstructural markers of cognitive pathology. Alzheimer’s Dement.2022;14:e12332 2018-2023: Atrium Wake Forest Baptist Health, active staff 2012-2017: Parkland Memorial Hospital, active staff 2012-2017: UT Southwestern Medical Center University Hospitals, associate staff 2004-2012: University Medical Center, Lubbock, TX, full staff 1997-2008: Covenant Health System, Lubbock, TX, full staff 1994-1997: Forsyth Memorial Hospital, Winston-Salem, NC, full staff 1994: Craven Regional Medical Center, New Bern, NC, full staff 1991-1993: French Hospital Medical Center, San Luis Obispo, CA, full staff 1991-1993: Sierra Vista Regional Medical Center, San Luis Obispo, CA, full staff Current directory role is Cognitive Neurologist.

Brook Croke — Synapticure publishes the following professional biography and affiliation: Brook is a genetic counselor with 15 years of experience, specializing in neurodegenerative disorders, neurogenetics, and newborn screening initiatives. M.P.H. University of Illinois (2015) M.S. in Genetic Counseling, Northwestern University (2011) B.S. in Biochemistry, University of Illinois (2006) National Society of s CLINGEN ALS Spectrum Disorders Gene Curation Expert Panel Brook has counseled hundreds of individuals and families regarding genetic testing options for the past 15 years. She has a passion for helping families living with neurodegenerative disorders. Prior to joining Synapticure in 2022, she worked as a genetic counselor at SIU Medicine, with a focus on neurogenetics and cardiomyopathies. She also has experience working in several genetic testing laboratories and worked with the Illinois Department of Public Health Newborn Screening Program to implement screening for lysosomal storage disorders. She resides in Springfield, Illinois with her husband and four children. ‍ https://www.synapticure.com/author/brook-croke https://pubmed.ncbi.nlm.nih.gov/23881473/ National Society of Genetic Counselors CLINGEN ALS Spectrum Disorders Gene Curation Expert Panel Current directory role is Genetic Counselor.

Caryn Glosch — Synapticure publishes the following professional biography and affiliation: Dr. Glosch is a clinical psychologist specializing in neuropsychological evaluation, dementia care, and psychotherapy, blending expertise in CBT, ACT, and neuropsychology to support patients and caregivers with clarity and compassion. VA Puget Sound Healthcare System - Neurocognitive Disorders Across the Lifespan Track Louis Stokes VA Medical Center - Health Psychology - Geropychology Track University of Houston - PhD in Clinical Psychology - Neuropsychology emphasis Purdue University- BA in Psychology Dr. Glosch is a clinical psychologist with 15 years of experience in neuropsychological evaluation of dementia, caregiver support, and psychotherapy. An integral part of her career is ensuring that patients and caregivers understand the information given to them and empowering them to manage stress with resilience and dignity. Dr. Glosch earned a Bachelor’s degree in Psychology from Purdue University and a PhD in Clinical Neuropsychology from the University of Houston. She completed a Neuropsychology internship at the VA Pittsburgh Healthcare System, a Neuropsychology post-doctoral fellowship at the VA Puget Sound Healthcare System, and a Geropsychology post-doctoral fellowship at the Louis Stokes Cleveland VA Medical Center. Over the past several years, Dr. Glosch has incorporated her background in neuropsychology into her psychotherapeutic work, helping patients understand how cognitive/neurological issues impact mood and vice versa. She has combined this unique perspective with extensive training in Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT). In her free time, Dr. Glosch enjoys listening to audiobooks while cooking dishes from all over the world, photography, and traveling with her husband. Current directory role is Neuropsychologist.

Christian Schenk — Synapticure publishes the following professional biography and affiliation: Dr. Schenk is a board-certified Behavioral Neurologist with over 13 years of experience in clinical care and research trials. His work focuses on advancing cognitive neurology through the development of innovative diagnostic and treatment modalities for dementia. University of Puerto Rico - Medical Sciences Campus University Hospitals - Case Medical Center, Cleveland University of Puerto Rico - School of Medicine Hospital UPR Dr. Federico Trilla University District Hospital San Juan University of Puerto Rico - Medical Sciences Campus Dr. Schenk is a Behavioral Neurologist with over 13 years of experience in clinical neurology care and clinical trials. He holds specialized training and certification in behavioral neurology. His research interests focus on cognitive neurology and dementia, with interest in exploring new diagnostic and treatment modalities for neurological disorders. Hospital UPR Dr. Federico Trilla University District Hospital San Juan University of Puerto Rico - Medical Sciences Campus Current directory role is Cognitive Neurologist.

Danielle Geraldi-Samara — Synapticure publishes the following professional biography and affiliation: Synapticure’s ALS care team is led by Dr. , who has has diagnosed and treated ALS patients for over fifteen years. The Mount Sinai School of Medicine (Neurology) The Mount Sinai School of Medicine (Clinical Neurophysiology with Neuromuscular/EMG focus) Medical school - State University of New York at Syracuse Undergraduate - Georgetown University (BS Biology, minor Philosophy) member American Academy of Neurology (AAN) member American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Yu, Edward H, Geraldi-Samara D. Pharyngeal-Cervico-Brachial/Miller Fisher Overlap  Syndrome With Infliximab Exposure. J Clin Neuromuscular Disease. 2020 March; 21(3): 157-158 Salem A, Shah N, Geraldi-Samara D, Elangovan N, Kryzak M. Late Onset Bipolar Disorder  Type I. Cereus. 2018 Aug 31;10(8) him Cracking the Crack Dance: A Case Report on Cocaine-induced Choreoathetosis Poster at the Chest Annual Meeting Toronto, Canada 2017 Reduced Heart Rate Variability in Familial Amyloidosis Due to the TTR Leu 64 Mutation Abstract at the 58 th annual AAN meeting, San Diego, CA 2007 member American Academy of Neurology (AAN) member American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Current directory role is Neuromuscular Director.

Erin Leahy — Synapticure publishes the following professional biography and affiliation: Dr. Leahy is a board-certified geriatrician specializing in dementia and the complex medical needs that often come with aging. She takes a compassionate, patient-centered approach to care and works closely with individuals and their caregivers to support what matters most. University of Wisconsin Hospital and Clinics (Internal Medicine) Vanderbilt University (Geriatrics) Medical School: Medical College of Wisconsin (Doctor of Medicine) Postbaccealuareate: University of Wisconsin - Madison Undergraduate: New York University (BS Mathematics and Finance) American Geriatrics Society American Association of Geriatric Psychiatry Dr. Leahy was born and raised in Wisconsin. She attended New York University and worked in finance and consulting before earning her medical degree from the Medical College of Wisconsin. She completed her Internal Medicine residency at the University of Wisconsin and worked in hospital medicine before pursuing a Geriatrics fellowship at Vanderbilt University. She is board certified in both Internal Medicine and Geriatric Medicine. She has practiced Geriatrics since 2015 in a variety of care settings, including outpatient primary care at a PACE (Program of All-Inclusive Care for the Elderly) clinic, as medical director of an ACE (Acute Care of the Elderly) unit in an academic hospital, and most recently as a cognitive assessment specialist in consultative practice. She is committed to helping people age with grace and values a holistic, collaborative approach to care - always guided by what matters most to patients and their caregivers. Dr. Leahy currently lives in Milwaukee, WI, with her partner. In her spare time, she loves live music, good food, traveling and going on self-curated adventures involving hiking, backpacking and biking. American Geriatrics Society American Association of Geriatric Psychiatry Current directory role is Geriatrician.

Jaime Hatcher-Martin — Synapticure publishes the following professional biography and affiliation: Synapticure’s Movement Disorders team is led by Dr. , a Movement Disorder Specialist who has cared for people with neurodegenerative diseases such as Parkinson’s and Huntington’s Disease for over a decade. Emory University School of Medicine (Neurology) Emory University School of Medicine (Movement Disorders) Medical school - Emory University School of Medicine (MD/PhD) Undergraduate - University of South Florida (BS Biology, minor Gerontology) 2023-current: Huntington Study Group (HSG) Education Committee 2023-current: Huntington Study Group (HSG) Credentialing Committee 2021-current: American Academy of Neurology Medical Economics and Practice (MEP) Telehealth Subcommittee 2019-current: Huntington Study Group (HSG) Family Day Planning Committee 2017-current: International Parkinson’s Disease and Movement Disorders Society Telemedicine Work Group Synapticure’s Parkinson’s care team is led by neurologist Dr. Jaime Hatcher-Martin. For over a decade, Dr. Martin has been caring for people with neurodegenerative diseases, specializing in movement disorders like Parkinson’s. With this insight, she recognized the unique burdens on her Parkinson’s patients. Coupled with the fact that many people living with Parkinson’s have no access to specialists, she became a leading advocate to partner telemedicine with expert neurological care. Prior to joining Synapticure, Dr. Martin practiced at Emory University where she started her own telemedicine clinic for patients with movement disorders in Georgia in 2016, and later at SOC Telemed (now Access Telecare). She is a Fellow of the American Academy of Neurology, served as co-Chair for their Telemedicine Workgroup, where she co-authored their practice guidelines. She also serves on the Telemedicine Study Group for the International Parkinson and Movement Disorder Society and serves on several committees for the Huntington Study Group. Dr. Martin continues to be involved in research related to understanding the toxic exposures that cause or contribute to the meteoric rise in the incidence of Parkinson's Disease. Hatcher-Martin JM , McKay J, Sommerfeld B, Howell J, Goldstein F, Factor SA. “Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis.” 2021. NPJ Parkinsons Dis. 29(7): 105. Hatcher-Martin JM and Factor SA. 2016. Freezing of Gait: A Rare Delayed Complication of Whole Brain Radiation. Parkinsonism Relat Disord. 29:129-130. Factor SA, Hatcher-Martin JM , Morse AS, Nocera JR, Revuelta FJ. 2016. Freezing of gait that disappears: Should there be rest before Rehab? Parkinsonism Relat Disord. 28:169-170. Hatcher-Martin JM, Shaikh AG, Factor SA. 2015. Chapter 22: Stereotypies in Parkinson’s Disease and Movement Disorders. Jankovic J and Tolosa E (eds). Wolters Kluwer. pp 233-39. Hatcher-Martin JM , Gearing M, Steenland K, Levey AI, Miller GW, Pennell KD. 2012. Association between polychlorinated biphenyls and Parkinson's disease neuropathology. Neurotoxicology. 33 (5): 1298-1304. Hatcher JM , Miller GW, Jones DP, Pennell KD. 2008. Chapter 16: Neurotoxicity of manufactured nanoparticles, in Nanoscience and Nanotechnology: Environmental and Health Impact. Grassian, VH (ed). John Wiley & Sons; 405-428. Hatcher JM , Pennell KD, Miller GW. 2008. Parkinson’s diseases and pesticides: a toxicological perspective. Trends Pharmacol Sci. 29 (6): 322-329. Hatcher JM , Richardson JR, Guillot TS, McCormack AL, Di Monte DA, Jones DP, Gearing M, Levey AI, Pennell KD, Miller GW. 2007. Elevated levels of the pesticide dieldrin are associated with Parkinson’s disease. Experimental Neurology. 204 (2): 619-630. Hatcher JM , Delea KC, Richardson JR, Pennell KD, Miller GW. 2008. Disruption of dopamine transport by DDT and its metabolites. Neurotoxicology. 29 (4): 682-690. Hatcher-Martin JM , Anderson EA, Busis NA, Bove RM, Cohen BH, Fritz JV, Jones EC, Shook SJ, Wolf RA. AAN Telehealth Position Statement. 2021. Neurology. 98(7): 334-339. Cubo E, Hassan A, Bloem BR, Mari Z… Hatcher-Martin JM … on behalf of the International Parkinson and Movement Disorder Society (MDS) Telemedicine Work Group. 2020. Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson’s Disease During the COVID-19 Pandemic: New Expectations for the Future. J Parkinsons Dis. 10(3):911-913. Hatcher-Martin JM , Adams JL, Anderson ER, Bove R, Burrus TM, Chehrenama M, Dolan O'Brien M, Eliashiv DS, Erten-Lyons D, Giesser BS, Moo LR, Narayanaswami P, Rossi MA, Soni M, Tariq N, Tsao JW, Vargas BB, Vota SA, Wessels SR, Planalp H, Govindarajan R. 2020. Telemedicine in neurology: Telemedicine Work Group of the American Academy of Neurology Update. Neurology. 94(1):30-38. Ben-Pazi H, Browne P, Chan P, Cubo E, Guttman M, Hassan A, Hatcher-Martin JM , Mari Z, Moukheiber E, Okubadejo NU, Shalash A, and the International Parkinson and Movement Disorder Society Telemedicine Task Force. 2018. The Promise of Telemedicine for Movement Disorders: An Interdisciplinary Approach. Invited article for Movement Disorders. Curr Neurol Neurosci Rep. 18(5):26. Hu WT, Howell JC, Ozturk T, Gangishetti U, Kollhoff AL, Hatcher-Martin JM , Anderson AM, Tyor WR. 2019. Front Immunol. 10:480. Hatcher-Martin JM, Armstrong KA, Scorr LM, Factor SA. 2016. Propranolol therapy for Tardive Dyskinesia: A retrospective examination. Parkinsonism Relat Disord. 32:124-126. Arendash GW. King DL. Gordon MN. Morgan D. Hatcher JM . Hope CE. Diamond DM. 2001. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Research. 891(1-2):42-53. Arendash GW. Gordon MN. Diamond DM. Austin LA. Hatcher JM. Jantzen P. DiCarlo G. Wilcock D. Morgan D. 2001. Behavioral assessment of Alzheimer's transgenic mice following long-term A-beta vaccination: task specificity and correlations between A-beta deposition and spatial memory. DNA & Cell Biology. 20(11):737-44. Gordon MN. King DL. Diamond DM. Jantzen PT. Boyett KV. Hope CE. Hatcher JM , DiCarlo G. Gottschall WP. Morgan D. Arendash GW. 2001. Correlation between cognitive deficits and A beta deposits in transgenic APP+PS1 mice. Neurobiology of Aging. 22(3):377-85. Morgan D. Diamond DM. Gottschall PE. Ugen KE. Dickey C. Hardy J. Duff K. Jantzen P. DiCarlo G. Wilcock D. Connor K. Hatcher J. Hope C. Gordon M. Arendash GW. 2000. A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408(6815):982-5. 2023-current: Huntington Study Group (HSG) Education Committee 2023-current: Huntington Study Group (HSG) Credentialing Committee 2021-current: American Academy of Neurology Medical Economics and Practice (MEP) Telehealth Subcommittee 2019-current: Huntington Study Group (HSG) Family Day Planning Committee 2017-current: International Parkinson’s Disease and Movement Disorders Society Telemedicine Work Group 2020-2021: Children Neurology Foundation Telehealth Initiative 2020-2021: American Academy of Neurology Innovation in Practice Work Group 2020-2021: American Academy of Neurology Teleneurology Education Curriculum for Residents Workgroup 2019-2021: Cerner Neurology Physician Advisor Council 2019-2021: American Academy of Neurology Practice Management and Technology Subcommittee 2020: American Academy of Neurology Telemedicine Reimbursement Work Group 2020: American Academy of Neurology Emergency Telemedicine Work Group 2017-2020: American Academy of Neurology Innovation Hub Working Group 2015-2019: American Academy of Neurology Telemedicine Working Group (Co-Chair) Current directory role is Movement Disorders Neurologist.

Jeremy Pruzin — Synapticure publishes the following professional biography and affiliation: Dr. is a behavioral neurologist researching and treating Alzheimer’s and related dementias, with a focus on prevention through lifestyle and risk factor management. Rush University Medical Center Harvard Medical School Arizona State University (Masters in Healthcare Innovation) University of Santa Barbara California (BS in Biopsychology) University of Santa Barbara California (BA in Spanish) ‍ ‍ Dr. Pruzin is Board Certified in Neurology specializing in cognitive/behavioral neurology. He has been involved in Alzheimer’s disease research before starting medical school and continued this pursuit throughout his training. He spent three months in Medellin, Colombia during his final year of medical school interning for the Grupo de Neurociencias de Antioquia conducting research on the kindred affected by Autosomal Dominant Alzheimer’s Disease. He then completed his neurology residency at Rush University Medical Center. He investigated how diabetes influences the risk for Alzheimer’s disease, authoring original articles, a review, and a book chapter on the topic. Dr. Pruzin moved on to a fellowship at Harvard Medical School with additional clinical training at Brigham and Women’s Hospital. He was a sub-investigator on over ten clinical trials at the Center for Alzheimer's Research and Treatment during this period. He concurrently conducted observational research with the Harvard Aging Brain Study at Massachusetts General Hospital, focusing on the intersection of vascular risk factors, physical activity, and how their interactions with AD molecular pathology influence cognitive decline and dementia. He was awarded an Alzheimer’s Association Clinical Scientist Fellowship award to continue this work. Dr. Pruzin is an Associate Professor of Neurology at the University of Arizona College of Medicine and Banner Alzheimer’s Institute. His current research focus is modifiable risk factor interventions, especially in midlife, with the goal of reducing future risk of Alzheimer’s disease and related dementias by addressing risk factors like hypertension, diabetes, physical inactivity, and others earlier in life, when the impact of these interventions is likely to make the greatest difference in lowering future risk for dementia. ‍ Current directory role is Cognitive Neurologist.

Jessica Tate — Synapticure publishes the following professional biography and affiliation: Dr. Tate is a Movement Disorders specialist passionate about patient-centered care and expanding access to expert treatment. She enjoys birding, reading, and family time in North Carolina. Wake Forest University School of Medicine (Neurology) Wake Forest University School of Medicine (Movement Disorders) Doctor of Medicine, West Virginia University School of Medicine Bachelor’s of Science in Biology, College of William & Mary American Academy of Neurology International Parkinson and Movement Disorder Society Dr. Tate has been working as an academic Movement Disorders specialist since 2014 and has extensive experience caring for patients with Parkinson’s Disease, other forms of Parkinsonism, and Huntington’s Disease. She is passionate about educating patients and care partners and involving them in shared decision-making about treatment options. She is excited about expanding access to subspecialty expertise with Synapticure. ‍ Dr. Tate grew up in small towns in West Virginia and Virginia. She currently lives in North Carolina with her husband and two children. In her spare time, she loves reading and spending time outside enjoying the natural world, especially birding. American Academy of Neurology International Parkinson and Movement Disorder Society Current directory role is Movement Disorders Specialist.

Krista Savage — Synapticure publishes the following professional biography and affiliation: Krista is a genetic counselor with 10 years of experience in neurogenetics, working with conditions like ALS, dementia, and Parkinson’s disease. Based in Salt Lake City, she enjoys hiking, skiing, and exploring national parks. University of Cincinnati (Genetic Counseling Graduate Program) Marquette University (Undergraduate) National Society of s Association for Utah Genetic Counselors Krista is a genetic counselor with ten years of clinical experience in neurogenetics. She has worked with many individuals and families with ALS, dementia, Parkinson’s disease, and other neurodegenerative conditions. Her experience includes working as a clinical and research genetic counselor in an academic medical center and providing telehealth genetic counseling services across multiple platforms. She received her M.S. degree in Genetic Counseling from the University of Cincinnati in 2014. Krista grew up in Wisconsin and enjoys spending time with animals and in the outdoors. She currently lives in Salt Lake City, Utah and enjoys hiking, skiing, and visiting national parks. Youmans and Winn Neurological Surgery E-Book: 4-Volume Set, HR Winn, Elsevier Health Sciences ‍ 5p deletions: Current knowledge and future directions, Joanne M Nguyen, Krista J Qualmann , Rebecca Okashah, Amysue Reilly, Mikhail F Alexeyev, Dennis J Campbell Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease, K Kerr, K Qualmann , Y Esquenazi, J Hagan, DH Kim THSD1 (Thrombospondin Type 1 Domain Containing Protein 1) Mutation in the Pathogenesis of Intracranial Aneurysm and Subarachnoid Hemorrhage, Teresa Santiago-Sim, Xiaoqian Fang, Morgan L Hennessy, Stephen V Nalbach, Steven R DePalma, Ming Sum Lee, Steven C Greenway, Barbara McDonough, Georgene W Hergenroeder, Kyla J Patek, Sarah M Colosimo, Krista J Qualmann , John P Hagan, Dianna M Milewicz, Calum A MacRae, Susan M Dymecki, Christine E Seidman, JG Seidman, Dong H Kim Family history of cluster headache: a systematic review, MW Waung, A Taylor, KJ Qualmann , MJ Burish Behavioral assessment of acute inhibition of system x c - in rats, Victoria Lutgen, Jon Resch, Krista Qualmann , Nicholas J Raddatz, Cristina Panhans, Ellen M Olander, Linghai Kong, SuJean Choi, John R Mantsch, David A Baker Synthesis of chiral GABAA receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression, Guanguan Li, Michael R Stephen, Revathi Kodali, Nicolas M Zahn, Michael M Poe, VVN Phani Babu Tiruveedhula, Alec T Huber, Melissa K Schussman, Krista Qualmann , Cristina M Panhans, Nicholas J Raddatz, David A Baker, Thomas D Prevot, Mounira Banasr, Etienne Sibille, Leggy A Arnold, James M Cook Pediatric epilepsy surgery: the prognostic value of central nervous system comorbidities in patients and their families, Krista J Qualmann , Christine G Spaeth, Melanie F Myers, Paul S Horn, Katherine Holland, Francesco T Mangano, Hansel M Greiner Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system x c − activity in the medial prefrontal cortex, V Lutgen, K Qualmann , J Resch, L Kong, SJ Choi, DA Baker Lynch Syndrome With Germline MSH2 Mutation in a Patient With Primary Anaplastic Glioneuronal Tumor, S Azam, LY Ballester, SH Ramkissoon, S Hsu, JJ Zhu, KJ Qualmann Genetic counselor approaches to BRCA1/2 direct‐to‐consumer genetic testing results, S Burke, M Mork, K Qualmann , A Woodson, M Jin Ha, B Arun, M Kaulfus Germline and somatic mutations in the pathology of pineal cyst: A whole‐exome sequencing study of 93 individuals, Yuanqing Yan, Rebecca Martinez, Maria N Rasheed, Joshua Cahal, Zhen Xu, Yanning Rui, Krista J Qualmann , John P Hagan, Dong H Kim Investigating Medical Examiners' Practices: Genetic Evaluation for Fatal Acute Aortic Dissection, B Power GENE-04. CHARACTERISTICS OF PATIENTS WITH A PRIMARY BRAIN TUMOR UNDERGOING HEREDITARY CANCER MULTI-GENE PANEL TESTING, Sarah Azam, Krista Qualmann , Syed Hashmi, Aarti Ramdaney, David Rodriguez-Buritica, Leslie Dunnington, Michelle Jackson 頭蓋内動脈瘤およびくも膜下出血の病態形成における THSD1 (Thrombospondin Type 1 Domain Containing Protein 1) の変異, Teresa Santiago-Sim, Xiaoqian Fang, Morgan L Hennessy, Stephen V Nalbach, Steven R DePalma, Ming Sum Lee, Steven C Greenway, Barbara McDonough, Georgene W Hergenroeder, Kyla J Patek, Sarah M Colosimo, Krista J Qualmann , John P Hagan, Dianna M Milewicz, Calum A MacRae, Susan M Dymecki, Christine E Seidman, JG Seidman, Dong H Kim NGTS-04SUGGESTION OF TP53 GERMLINE GENETIC TESTING BASED ON RESULTS FROM NEXT GENERATION SEQUENCING OF TUMOR SPECIMEN: A CASE REPORT, KJ Qualmann , DH Kim, S Papasozomenos, JJ Zhu NGTS-03CHARACTERIZATION OF PRIMARY GLIOMAS IN INDIVIDUALS WITH LI-FRAUMENI SYNDROME: A CASE SERIES, Krista J Qualmann , Nitin Tandon, Dong H Kim, Scott R Shepard, Meenakshi Bhattacharjee, Sozos Papasozomenos, Angel I Blanco, Jay-Jiguang Zhu Examining the Pediatric Epilepsy Surgery Population: The Prognostic Value of Central Nervous System Comorbidities in Probands and their Families, KJ Qualmann National Society of Genetic Counselors Association for Utah Genetic Counselors Current directory role is Genetic Counselor.

Monica Lavian — Synapticure publishes the following professional biography and affiliation: Dr. is a fellowship-trained neurologist who specializes in caring for patients living with neuromuscular diagnoses like ALS University of California, Irvine (Neurology) University of California, Irvine  (Neuromuscular Medicine) ‍ Medical school - Western University of Health Sciences, College of Osteopathic Medicine of the Pacific Undergraduate - University of California, Irvine (BS, Biological Sciences) American Academy of Neurology (AAN): Member Dr. Monica Lavian completed both her Neurology residency and Neuromuscular fellowship at the University of California, Irvine. She is a Member of the American Academy of Neurology. Dr. Lavian is especially enthusiastic about the field’s ever-expanding arsenal of tests and treatments for neurologic diseases. In her words, “I was drawn to Synapticure not only because it provides comprehensive care for our patients in a convenient manner, but also Synapticure is at the forefront of ever expanding diagnostic and treatment advancements in Neuromuscular diseases with offering genetic testing, comprehensive treatment plans, and overall access for our patients so they can experience top notch comprehensive care.” ‍ Tim Lai MD, Monica Lavian DO , Lama Al-Khoury MD, Shuichi Suzuki MD, Wengui Yu MD, PhD. Individualized Time Window for Endovascular Therapy in Acute Basilar Artery Occlusion: Case Report and Literature Review.  Neurological Cases.  December 2016; 3(2): 1-4. Lavian, M ., Goyal, N., Mozaffar, T. “Sporadic inclusion body myositis misdiagnosed as granulomatous myositis.” Neuromuscular Disorders. September 2016. 25, S239 - S240. Article in Press Huaiyu Gu, Shaojuan Amy Jiang, Jorge M. Campusano, Jorge Iniguez, Hailing Su, Andy An Hoang, Monica Lavian , Xicui Sun, and Diane K. O'Dowd. “Ca v 2-Type Calcium Channels Encoded by cac Regulate AP-Independent Neurotransmitter Release at Cholinergic Synapses in Adult Drosophila Brain”. J Neurophysiol. 2009 January; 101(1): 42–53. American Academy of Neurology (AAN): Member Current directory role is Neuromuscular Neurologist.

Pritika Patel — Synapticure publishes the following professional biography and affiliation: Pritika brings nine years of experience caring for older adults, with a background in cognitive neurology, movement disorders, and palliative care. She takes a collaborative approach that centers patients and their families. Pritika joins Synapticure with extensive experience acquired over nine years in various roles dedicated to the care of elderly patients. As a Registered Nurse in a memory care unit and adult day health program, she gained firsthand insight into the daily lives of those with cognitive impairments as well as the impact on their families. Transitioning to a Nurse Practitioner role in neurology, she specialized in cognitive impairments and movement disorders. In this capacity, she contributed to the organization and implementation of two new multidisciplinary clinics along with several research studies and publications, with the goal of enhancing patient care. Most recently, she served as a palliative care Nurse Practitioner, focusing on symptom management and goals-of-care discussions for patients with chronic illnesses in their homes. Her clinical practice is characterized by a collaborative approach with the patient and their support system, which includes loved ones, clinicians, and caregivers. She is committed to empowering patients and their families to advocate for their health and wellness. Originally from Massachusetts, where she currently resides, Pritika enjoys traveling and is working toward her goal of visiting all 50 US states (29 so far!). Current directory role is Cognitive Nurse Practitioner.

Tracey Meyers — Synapticure publishes the following professional biography and affiliation: Dr. is a seasoned clinical neuropsychologist at Synapticure, leveraging over 25 years of experience in brain injury, neurodegeneration, and mental health, and is a published author and leader in integrative wellness practices like yoga and mindfulness. University of Miami - Jackson Memorial Medical Center (Neuropsychology/Geropsychology) Graduate - Florida Tech Undergraduate - Skidmore College St. Francis Hospital, Hartford, CT The Rehabilitation Hospital of Connecticut - Hartford, CT Dr. Tracey Meyers joined Synapticure in 2023, providing psychotherapy and neuropsychology services to patients and their families. She is a clinical neuropsychologist with over 25 years of experience working in with people living with traumatic brain injury and stroke along with other neurodegenerative disorders. She also has worked extensively with people living with mental health and addictions challenges in psychiatric clinics and hospital settings. In addition to her neuropsychological assessment and psychotherapy experience, Dr. Meyers has a strong commitment to integrative medicine for mental health and wellness and leads mindfulness and yoga programs for groups, individuals, and professionals in the workplace. Dr. Meyers graduated from Skidmore College in 1992 and completed her doctorate in clinical psychology from Florida Tech in 1997. She completed her internship in neuropsychology at the Miami VA and her postdoctoral fellowship in neuropsychology and geropsychology  at the University of Miami/Jackson Memorial Medical Center. She is a member of the American Psychological Association, the National Association of Neuropsychology, the International Neuropsychological Society, and the National Register of Healthcare Providers in Psychology. In addition, she is an advanced yoga teacher, certified C-IAYT yoga therapist, MBSR and Mindful self-compassion instructor, Breath-Body-Mind teacher, and iRest teacher. Dr. Meyers has authored several publications and book chapters around neuropsychological assessment, autism spectrum disorders, behavioral treatment for different mental health conditions, yoga for addiction, and has written a book on yoga and mental health, Yin Yoga Therapy (Singing Dragon, 2022). Meyers, T. (2022). Yin Yoga Therapy and Mental Health . Singing Dragon: London. Meyers, T . (2021). Relationships in Yoga Therapy: Developing Collaboration within a healing presence. In Yoga Therapy Foundations, Tools, and Practice edited by Laurie Hyland Robertson and Diane Finlayson.  Singing Dragon: London. Meyers-Sondik , T.M.. (2019). Pain, Addiction, and Yoga. In Yoga and Science in Pain Care: Treating the Person in Pain edited by Neil Pearson, Shelly Prosko, Marlysa Sullivan, Jessica Kingsley:  London. Tolisano, P, Meyers - Sondik, T.M, Dike, C, (2017). A positive behavioral approach for aggression in forensic psychiatric settings.  The Journal of the American Academy of Psychiatry and the Law, 45 (vol 1); p.31-39. Meyers-Sondik , T.M. (2016) . Positive Behavioral Supports for Managing Violence Risk in an Inpatient Forensic Setting .  In  Forensic Psychiatry and Psychology Practice: Bearing Witness to Change edited by Drs. Ezra Griffith, Michael Norko, Alec Buchanan, Madelon Baranoski and Howard Zoana, CRC Press: London. Matuskey, D & Meyers-Sondik, T.M . (2014)  Case  Report:  Memory reconsolidation paradigm to treat aggression and self-injurious behaviors.  Journal of Clinical Psychopharmacology (vol 35) p. 1-2. Hillbrand, M.& Meyers-Sondik, T.M. (2012) Commentary: Treatment and Violence Risk Mitigation in High-Functioning Autism Spectrum Individuals. The Journal of the American Academy of Psychiatry and the Law, 40 (vol 2); p.191-192. Gass, C.G., Luis, C.A., Meyers, T.L ., and Kuljis, R.  (1998).  Familial Creutzfeldt-Jakob Disease:  A Neuropsychological Case Study.  Archives of Clinical Neuropsychology. 15 (2), 165-175. Peake, T.H., Meyers, T.L ., & Duenke, S. (1997). Options for brief psychotherapy: Cognitive and psychodynamic variations. Journal of Mental Health 6 ( 3) 217-235. St. Francis Hospital, Hartford, CT The Rehabilitation Hospital of Connecticut - Hartford, CT Current directory role is Neuropsychologist.

Victoria Shada — Synapticure publishes the following professional biography and affiliation: Born and raised in Indiana, Dr. Shada is a geriatric medicine specialist with a focus on primary care, memory and cognitive assessment, and dementia care, and is actively involved in research on cognitive health. Carolinas Medical Center (Internal Medicine) Wake Forest Baptist Medical Center (Geriatric Medicine) Creighton University School of Medicine Atrium Health Wake Forest Baptist I was born and raised in a small town in Indiana. Blessed with the unwavering support of my parents, the unchecked adoration of my grandparents, and the temporizing tough love of an older brother, I had all the elements I needed to achieve my dream of becoming a doctor. My training has taken me from Indiana to Nebraska, and from there to Arizona and North Carolina, where I currently live. I received my medical degree from Creighton University School of Medicine, completed my internal medicine residency at Carolinas Medicinal Center, and performed my fellowship in geriatric medicine at Wake Forest Baptist Health. I currently specialize in geriatric medicine, with expertise in primary care, long-term nursing home care, and memory/cognitive assessments, with a particular passion and focus on dementia care. I am engaged in multiple different research studies involving cognitive health and dementia care. In addition to being a physician, I am a devoted mother ( 1 human and 2 fur babies) and avid reader. Atrium Health Wake Forest Baptist Current directory role is Geriatrician.

Lyndsay Mentgen — Synapticure publishes the following professional biography and affiliation: Lyndsay has more than a decade of experience in cognitive neurology and is passionate about providing comprehensive dementia care for patients and their families. Lyndsay is an with more than a decade of experience in cognitive neurology. She is passionate about providing comprehensive dementia care that addresses medical, behavioral and caregiving implications for patients and their families. Current directory role is Advanced Practice Registered Nurse.

Penelope Cox is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Terri Long is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Gerry Shultz is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Heather Walker is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Hope Maruzo is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Jim Contreras is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Mary Stevens is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Patti Stevens is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Alan Curtis is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Amy Armstrong is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Shane A. Liddelow is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Associate Professor, Department of Neuroscience and Physiology and Associate Professor, Department of Ophthalmology. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Todd Park is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Co-Founder, Executive Chairman at Devoted Health. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Gene Yeo is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Sanford Stem Cell Institute Endowed Chair Professor, Dept of Cellular and Molecular Medicine, University of California, San Diego. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Glen Finney is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Director of Neurology, Geisinger and Member of the American Academy of Neurology. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Jinsy Andrews — Synapticure publishes the following professional biography and affiliation: Dr. Andrews has over 15 years of experience caring for people with neuromuscular disorders, primarily Amyotrophic Lateral Sclerosis. In addition, she has extensive experience conducting and overseeing clinical trials in both the academic and industry setting and has held several leadership positions in organizations that focus on ALS clinical trials and care. Dr. Andrews received B.S. from Union College, M.Sc. in Biostatistics (Patient-Oriented Research) from Columbia University's Mailman School of Public Health, and M.D. from Albany Medical College. Dr. Andrews completed her residency in Neurology at the University of Connecticut and completed fellowship training in both Neuromuscular Medicine and Clinical Neurophysiology at Columbia University. Dr. Andrews is board certified in Neurology, Neuromuscular Disease, and Electrodiagnostic Medicine. ‍ The affiliation is scientific/strategic advice; outside employer and university titles remain external.

Nathan Bays is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Board of Directors, Unite US. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory. FINRA’s2026 public report for Nathaniel Martin BaysIII, CRD6778354, lists LifeForce Capital LLC as a healthcare venture-capital outside affiliation begun March25,2019, with the precise title Venture Advisor and approximately two hours monthly advising the founder. The same report identifies a Unite US board role begun April2020, providing an exact career bridge to Nathan Bays’ existing Synapticure adviser biography. This is a part-time advisory affiliation rather than a presumed full-time investment partner; the original named Synapticure portrait and all other roles are retained.

Sarah DeVos is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Senior Director, Drug Maker, Oligonucleotides, Curie.Bio. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Adam Schlifke is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Stanford Anesthesia Digital Health Lead. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Amy DuRoss is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Advisor. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Anton Arbatov is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Digital Health Expert, Adjunct Professor and Member of the Board of Advisors, College of Public Health, George Mason University. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Chris Hogg is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Life Sciences Advisor. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Eric Anderson — Synapticure publishes the following professional biography and affiliation: Dr. Anderson is passionate about leveraging technology to develop novel specialty practice models focused on creating the greatest value, outcomes, and experiences for patients. He is recognized as a national leader in telemedicine, mobile health, and alternative practice models. He trailblazed the use of mobile telemedicine in emergency neurology and was the first to demonstrate and publish that remote stroke assessment could be performed with an iPhone. He speaks nationally on the topics of telemedicine, mobile health, and practical applications of technology in the enhancement of patient care. He joined Synapticure from SOC Telemed where He had previously served as the Director of Scientific Affairs, National EEG Director, and Chair of Neurology, where he developed and managed the largest teleneurology practice group, seeing a volume of 8500 consults per month across 300 hospitals. Dr Anderson has led multiple efforts to support and define the practice of teleneurology with the American Academy of Neurology and other organizations. The affiliation is scientific/strategic advice; outside employer and university titles remain external.

Evangelos Kiskinis is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation Assistant Professor of Neurology and Neuroscience, New York Stem Cell Foundation, Robertson Investigator, Scientific Director Stem Cell Core Facility. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Aaron Gitler — Synapticure publishes the following professional biography and affiliation: Aaron Gitler is the Stanford Medicine Basic Science Professor in the Department of Genetics at Stanford University. He received his B.S. degree from Penn State University and did his PhD studies on cardiovascular development in the laboratory of Dr. Jonathan Epstein at the University of Pennsylvania. Then he performed his postdoctoral training with Dr. Susan Lindquist at the Whitehead Institute for Biomedical Research and MIT. In 2007, he established his laboratory at the University of Pennsylvania and moved to Stanford in 2012. His laboratory has been using a combination of yeast and human genetics approaches to investigate pathogenic mechanisms of ALS. He and his colleagues discovered mutations in the ATAXIN2 gene as a genetic contributor to ALS and has identified several therapeutic targets for ALS. He is a scientific co-founder of Maze Therapeutics The affiliation is scientific/strategic advice; outside employer and university titles remain external.

Alex Muresan — Synapticure publishes the following professional biography and affiliation: Alex is an engineering and product leader who has built a career delivering patient- and provider-facing healthcare technology at scale, with a strong focus on reliability, security, and user experience. At Synapticure, he is excited to help build scalable engineering systems and high-quality product experiences that make care easier for patients, caregivers, and clinicians, and to support a culture that values collaboration, clarity, and outcomes. Prior to joining Synapticure, Alex scaled Foodsmart’s engineering and product teams as well as the platform from seed stage through Series D. In that work, he partnered closely with cross-functional leaders to translate business and clinical needs into technical strategy and execution, while strengthening the foundations that enable teams to move quickly and safely, including architecture, developer productivity, planning and delivery processes, and operational excellence. Earlier in his career, Alex was a full-stack developer and iOS app developer, which continues to shape his hands-on approach to building end-to-end products and mentoring teams. He brings a pragmatic leadership style that balances velocity with quality, and he is passionate about delivering great user experiences, especially in healthcare, where thoughtful design and dependable systems can have an outsized impact on real people. Current directory role is VP, Product & Engineering.

Anay Patel — Synapticure publishes the following professional biography and affiliation: Specialty virtual care models make access possible for every patient—not just those who live close enough to receive care. Pairing this with comprehensive care coordination ultimately drives better outcomes for patients, their families, and the caregivers who support them. That belief drives Anay Patel, Synapticure's Chief Operating Officer, who brings unique experience at the intersection of healthcare operations, finance, and strategy, along with a track record of scaling and building growth-stage companies. Prior to joining Synapticure, Anay served as COO of QualDerm Partners, a national dermatology medical group and MSO, where he held full P&L accountability across a network of more than 250 clinics and 450 clinicians nationwide. Before that, he was President & COO of QuartetHealth, where he helped scale the business and its provider network through to a successful exit. Earlier in his career, Anay held leadership roles at MDInsider and Accolade, and began his career in healthcare management consulting and investment banking, advising health systems, payers, and medical groups on strategy and M&A. Anay holds an MBA from the University of Chicago's Booth School of Business, a Master's in Health Systems Management from Rush University, and a BS from Indiana University. Current directory role is Chief Operating Officer.

Elizabeth Ferluga — Synapticure publishes the following professional biography and affiliation: Dr. Ferluga was born in Kennewick, WA.  She completed her undergraduate degrees in psychology and neuroscience in 2003 at Washington State University.  She went on to University of Iowa Carver College of Medicine.  She graduated with AOA honors in 2007.  She completed her residency in Neurology at Vanderbilt in Nashville, TN. She served as neurology chief resident in 2011.  She subsequently went on to be a general neurology attending and movement disorder fellow, graduating in 2013.  She then joined faculty at Vanderbilt as an assistant professor practicing both general neurology and movement disorders.  She further participated development of a pediatric movement disorder clinic. In 2015, she moved to Chattanooga, TN.  She was hired at Erlanger medical center to develop a movement disorder program.  While working at Erlanger, she served as Clinic Director and Medical Director of the neurology service line.  She also served as the director of Erlanger’s HD center of excellence (partner with Vanderbilt since 2016). She left Erlanger medical center in 2023.  She is now practicing teleneurology with synapticure focusing on total care for patients with neurodegenerative diseases such as Parkinson’s disease and Huntington’s disease. Current directory role is Director of Movement Disorders.

Jason Langheier — Synapticure publishes the following professional biography and affiliation: Jason Langheier, MD, MPH, is the CEO and Founder of Foodsmart – the leading provider of telenutrition and value-based foodcare -- making eating well simple and affordable for millions of Americans. Dr. Langheier did neuroscience, genetics and bioinformatics research at Williams, Duke, Cambridge and NIH, and received his MD from Duke, and his MPH from Harvard. Applying behavioral neuroscience and nutritional epidemiology training, he developed the pediatric obesity clinic at Boston Medical Center (Nutrition & Fitness for Life), Fitness Forward and the Coach K Drive 2 Fitness. He was the CTO and Co-Founder of Proventys (now US Oncology/ McKesson), collaborating with the National Comprehensive Cancer Network to deliver personalized cancer care decision support. He is an active member of the Partnership for a Healthier America (PHA) Board of Directors, and loves hiking, playing sports and music with family and friends. ‍ Current directory role is Co-Founder, Board Co-Chair.

Kathleen Beach — Synapticure publishes the following professional biography and affiliation: Kathleen leads People Strategy at Synapticure. She is passionate about building scalable people systems that empower employees to do their best work. She specializes in embedding company values and empowering leaders to drive team performance through a positive and impactful culture. Her career began with a focus on scientific rigor in a CDC-funded HIV prevention trial, followed by strategic planning for organizations in the social sector. This unique blend of experience led her to discover a passion for HR, which she pursued by leading the people function at her consulting firm. She then went on to serve as Head of HR at a mission-driven technology startup. Prior to joining Synapticure, Kathleen spent nine years at Twist Bioscience, where she helped guide the company through a period of immense growth from 150 to over 1,000 employees and its IPO. As a leader in HR operations and analytics, she built comprehensive talent management programs, including performance frameworks, culture, and total rewards, that established the company as a leading biotech employer. Kathleen holds dual degrees in Biology and Music from UC San Diego and an MA from San Francisco State University. Current directory role is VP, People.

Melissa Yu — Synapticure publishes the following professional biography and affiliation: Melissa Yu, MD, FAAN is a board-certified neurologist and Fellow of the American Academy of Neurology with extensive expertise in neurodegenerative diseases and brain health. She is a graduate of the Mount Sinai School of Medicine and completed her neurology training at Baylor College of Medicine. Prior to joining Synapticure, Dr. Yu served on the faculty at Baylor College of Medicine for more than a decade, advancing through the academic ranks to Professor of Neurology. During her tenure, she also served as a Physician Informaticist, as Director of the Alzheimer’s Disease and Memory Disorders Center, and was the site Principal Investigator for numerous clinical trials, including the landmark U.S. POINTER study. In addition, Dr. Yu has held multiple leadership positions within the American Academy of Neurology, contributing to national initiatives in clinical care, education, and research. Dr. Yu is deeply dedicated to helping patients and their families navigate the complexities of neurodegenerative diseases with clarity, compassion, and evidence-based care. Current directory role is VP, Clinical Operations.

Mike Payne — Synapticure publishes the following professional biography and affiliation: At Synapticure, Mike is focused on expanding access to the most effective treatments for patients with serious neurological conditions, whether those medicines are already on the market or in pre-approval testing. This mission is deeply personal for him, driven by the fact that neurological diseases represent the largest and fastest-growing epidemic the U.S. will face over the next 50 years, and informed by his own experience losing his mother to complications from Alzheimer’s disease in 2021. Mike leads the company’s strategic engagements with pharmaceutical and biotechnology firms, as well as major CROs, enabling them to leverage Synapticure’s specialized capabilities. These services include clinical trial outsourcing and enablement for both observational and interventional studies, RWE/RWD data collection and analysis, lab services via advanced organoid models, Expanded Access Programs for pre-market drugs, and Direct-To-Patient (DTP) programs for marketed products. Alongside his colleagues, he oversees every aspect of these initiatives, from initial business development and sales to final delivery and patient outcomes. Current directory role is SVP, Life Sciences Business Development.

Noreen Flanagan — Synapticure publishes the following professional biography and affiliation: For over two decades Dr. Flanagan has been caring for people with neurodegenerative diseases. Her professional career began in Boston as a Physical Therapist for people with movement disorders and other neurological conditions. Her second career, as a physician, began in Maine where she developed a regional interdisciplinary Memory Clinic for patients with cognitive decline. Concurrently, Dr. Flanagan also developed an interdisciplinary tele-psychiatry program for patients with neurodegenerative disease living in assisted living and long term care homes. Access to comprehensive compassionate care for all patients, regardless of their location, was the driving force behind Dr. Flanagan’s development of these programs, and the reason she chose to continue her career at Synapticure. She appreciates the team approach to each individual’s care at Synapticure, and the inclusion of loved ones in the process. ‍ Current directory role is Director of Behavioral Health, Psychiatrist.

Oleg Yerstein — Synapticure publishes the following professional biography and affiliation: Dr. Yerstein joins us from Beth Israel Lahey Health, where for five years he served as Director of the Center for Memory and Cognitive Disorders. In that role, he helped implement both clinical and research use of the latest dementia biomarkers, founded the anti-amyloid therapies clinic, and led numerous clinical trials for Alzheimer’s disease and other neurodegenerative disorders. Oleg brings extensive experience building collaborations across clinical care programs, academic centers, trial sites, and the healthcare industry to expand access to the latest therapies and accelerate the development of interventions that improve patient outcomes. Current directory role is Director of Cognitive Care Service Line, Neurologist.

Peter Wallach — Synapticure publishes the following professional biography and affiliation: Peter entered the healthcare space after Brian’s diagnosis, originally focusing on investing in targeted therapeutics that had the potential to be truly disease altering in ALS. With Synapticure, Peter hopes to resolve the lack of early intervention, access to quality care, holistic patient data and clear subgrouping of people living with ALS. These shortcomings of the current system have hindered the success of ALS trials broadly and made it difficult to bring forward drugs that focused on specific subsets of the ALS patient population and could better the lives of all people living with ALS. Prior to working to help solve ALS, Peter worked in the cleantech industry before becoming a consultant at Bain & Company in their Chicago office. Peter received his MBA from Columbia University and undergraduate degree from The University of Virginia. ‍ Current directory role is Co-Founder, Life Sciences.

Sam Magidsohn — Synapticure publishes the following professional biography and affiliation: Sam has built a career at the intersection of healthcare finance, strategic planning, and operational execution. Sam serves as the Head of Finance at Synapticure, leading financial strategy and driving value creation through innovative financial modeling, risk management, and business optimization. Prior to joining Synapticure, Sam grew his expertise in healthcare investing, and has a deep understanding of market dynamics, regulatory complexities, and the evolving landscape of healthcare innovation. Sam's experience spans across private investing, mergers & acquisitions, and startup finance, where he demonstrated the ability to identify high-growth opportunities, execute complex deals, and support companies in scaling for success. In addition to investment leadership, Sam has extensive experience in operational strategy, partnering with cross-functional teams to streamline processes, enhance financial performance, and foster sustainable growth. With a passion for creating strategic partnerships and driving operational efficiency, he works to bridge the gap between financial performance and healthcare outcomes. Sam holds a MBA from University of Chicago and a BBA from the University of Michigan. Current directory role is Chief Financial Officer.

Suzie Sheetz — Synapticure publishes the following professional biography and affiliation: Suzie Sheetz is a seasoned healthcare executive with a track record of driving strategic growth and transformative partnerships. With deep expertise in go-to-market strategy and execution, she has helped early-stage companies scale by forging high-impact relationships across the provider and payer landscape. Before joining Synapticure, Suzie served as VP of Growth & Business Development at Cityblock Health, where she led value-based care initiatives and was responsible for health plan sales across Medicaid, Medicare, and dual-eligible business lines. She has also held commercial roles at digital healthcare startups, Ronin and Included Health, focusing on innovative healthcare solutions. Suzie is committed to improving healthcare access for vulnerable populations and ensuring sustainable access to care. She holds a BA from Northwestern University and an MPH from the Harvard School of Public Health. Current directory role is Head of Growth & Business Development.

Brian Wallach — Synapticure publishes the following professional biography and affiliation: Brian Wallach, ALS patient, Co-Founder and Board-Co-Chair of Synapticure, a specialty telehealth clinic transforming the experience & outcomes of neurodegenerative disease for patients and caregivers across the U.S. Brian was diagnosed with ALS in November 2017 and since then has become an outspoken, well-known and impactful patient advocate in the neurodegenerative disease space. In addition to co-founding the nonprofit I AM ALS, Brian was an Assistant United States Attorney in the Northern District of Illinois and Senior Vetting Counsel in the Obama White House. Brian received his BA from Yale University and his JD from the Georgetown University Law Center. Current directory role is Co-Founder, Board Co-Chair.

Sandra Abrevaya — Synapticure publishes the following professional biography and affiliation: Sandra Abrevaya is the Co-Founder and CEO of Synapticure, a leader in neurodegenerative virtual care. Synapticure provides transformational support for patients and caregivers through access to specialized neurologists, cutting-edge medical treatments and trials, and personalized, wraparound services. She is also the Co-Founder of I AM ALS, an advocacy organization she established with her husband, Brian Wallach, after his ALS diagnosis in 2017 at the age of 37.Before Brian's diagnosis, Sandra served as the founding CEO of a nonprofit organization and held senior roles in public service, including positions with the City of Chicago, the U.S. House of Representatives, the U.S. Senate, the U.S. Department of Education, and the White House.Sandra's journey is shaped by her dual role as a caregiver—to Brian and mom to their two spunky daughters, aged 7 and 9—and as an advocate. Their story is the subject of the documentary For Love and Life, which highlights their fight against ALS and their commitment to making a difference in the lives of others facing similar challenges. Current directory role is Co-Founder, Chief Executive Officer.

Yangyang Wang is one of three WearWorks co-founders named in Pratt’s May2018 primary account, alongside Kevin Yoo and Keith Kirkland. A2015 Master of Industrial Design alumnus, he worked on haptic-motor navigation concepts and the Wayband prototype. He is named as a co-inventor on US10371544B2. The current Haptic leadership roster does not name him; no present COO position, unrelated academic homonym or unverified portrait is adopted.

Frances West is the accessibility and partnerships adviser named in Haptic’s older unlinked team roster. Its former IBM chief accessibility officer description is explicitly historical. Her absence from the current linked adviser section leaves the present company affiliation unconfirmed; no current IBM job or personal financing is inferred.

Peter Chang is the lead UX/UI designer published on Haptic’s older unlinked roster, with apps and wearables design responsibilities. The named original company portrait supports this specific identity. He is absent from the current linked team roster, so current employment is unconfirmed; unrelated Chang or Peter identities are not merged.

Rehan Saleem is the senior iOS developer named in Haptic’s older unlinked roster, with iOS SDK and app/Apple Watch work. He is not named on the current linked leadership/advisory page. His genuine older company portrait and affiliation are retained with current status unconfirmed, rather than a presumed present executive position.

Stephen Sheetz is the senior Android developer named on Haptic’s older unlinked team roster, which assigns Android SDK work. He is absent from the currently linked team page; this is a source-aged published development affiliation, without an invented current employment term or departure date.

RJ Krawiec is the policy and strategy adviser published by Haptic. The site supplies an undated Deloitte chief-marketing-officer caption without specifying a presently verified global or regional mandate. This scoped advisory affiliation is distinct from a current outside employment claim, statutory company board appointment or investor ticket.

Ravi Kolli is the technology-strategy adviser named and pictured on Haptic’s linked team page. Its external Sr Pago CTO caption is undated context and does not independently prove a current outside appointment. The affiliation does not establish company equity ownership or an individually allocated check.

Merantix Capital is a Berlin-based venture capital firm and venture studio investing in AI-native companies across Europe, from the pre-idea stage through pre-seed and Seed. It focuses on applied AI embedded in industry workflows, including healthcare and life sciences, manufacturing, logistics, energy, enterprise software, finance, robotics and physical AI. Its model combines direct investments in independently formed startups with company creation: the studio helps founders validate business cases, find co-founders and talent, develop early AI applications, reach customers and raise financing. Portfolio founders can draw on the wider Merantix Group ecosystem, including the Berlin AI Campus, London AI Hub, corporate design partners and Merantix Momentum’s engineering and enterprise AI expertise. The firm publishes a usual investment range of EUR500,000 to EUR4 million, which describes its strategy rather than any particular investment. The legal operator of the Capital website and fund manager is Merantix Fund Management GmbH, Berlin commercial register HRB254046B; the wider Merantix Group and its services businesses are distinct entities.

Adrian Locher co-founded Merantix and builds and invests in AI companies. His entrepreneurial background spans more than twenty companies.

Matthieu Dederichs is a UK-based technology investor whose published Merantix remit includes software, AI, financial technology, healthcare technology and consumer businesses.

Nicole Büttner is a founding partner of Merantix Capital and leads enterprise AI solutions business Merantix Momentum. Her background combines economics and entrepreneurship.

Rasmus Rothe co-founded Merantix and invests in applied AI. He holds a doctorate in computer vision and deep learning and helped establish the German AI Association.

Rockman Law invests in early-stage European AI, enterprise software, financial technology and deep technology. He previously founded a cybersecurity company and invested as an angel.

Shaun Stewart is Haptic’s published growth and strategy adviser. Its current linked page describes him as a former Waymo chief business officer. The appointment is a company advisory affiliation, without a presumed current Waymo job, statutory directorship, or personal financing check.

Enzo Caruso is the Head of Operations named and pictured on Haptic’s current linked leadership page. An older company roster also described operations and growth responsibilities. This role concerns the WearWorks/Haptic navigation and tactile-interface business; no unrelated Caruso identity or private investment is inferred.

Abha Nath is identified as Wonder Venture Partner on the firm’s official founder-LP community page, which also describes her Whatnot affiliation. Dustin Rosen’s November2018 announcement records her earlier joining as investment analyst. The venture-partner affiliation is explicitly distinct from the main five-person team directory and does not make the wider LP community staff.

Dustin Rosen founded Wonder Ventures after building and selling consumer-technology startup Pose. His earlier investing career included the Mailroom Fund, following work at William Morris Agency. He studied economics at Wharton and leads Wonder as managing partner.

Jiyoung Jeong is a senior associate investor at Wonder Ventures. Her background includes Wellspring Consulting, Primary Venture Partners’ Factor Fellowship, entrepreneurship and Fulbright teaching in Taiwan. She studied history at Stanford, graduating with honours and Phi Beta Kappa.

Lida Vandermeer heads platform at Wonder Ventures. Her operating background includes Box, Apple and early-stage AI and crypto businesses. She supports founders, community and growth. Her education included Dartmouth and UC Berkeley, earning a cognitive-science degree.

Taylor Bolhack is Wonder Ventures’ advisor and former head of platform. Her prior work included Bird’s market expansion, Square sales and Citibank recruitment and project management. She studied organisational development and corporate strategy at Vanderbilt.

Valentina Rodriguez is a general partner at Wonder Ventures. Earlier Morgan Stanley work spanned credit analytics, trading and Latin American equity research. She studied industrial and labour relations at Cornell. Her promotion is corroborated by the founder’s recent announcement.

Atish Banerjea joined The Biological Computing Co. inSeptember2026 as strategic adviser for real-time inference and biological compute. His published company biography describes previously serving as Meta CIO after joiningFacebook in2016, NBCUniversal executive vice president and CIO, and earlier technology leadership at DexOne and Pearson. His advisory remit covers systems architecture, infrastructure strategy, organizational design, technical milestones and strategic partnerships. The advisory appointment is not classified as ordinary company employment or an investment, and no unverified portrait is substituted.

Keith Kirkland is the Haptic/WearWorks co-founder and current Chief Haptics Officer. His TED biography describes mechanical-engineering, industrial-design and accessories-design training. Pratt identifies him as a2015 industrial-design master’s alumnus. NSF names him principal investigator on wearable haptic-navigation award1746671, separately from any personal venture investment.

Janice Fong Hansen is Office Manager at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Bayer. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Kevin H Yoo is the Haptic/WearWorks co-founder and CEO named on the current linked leadership page. Pratt identifies Kevin Yoo among its2015 Master of Industrial Design alumni who co-founded WearWorks and developed accessible tactile navigation. He works on communicating information through vibration and product design; the company’s precise2017 demonstration involved15miles of the New York City Marathon.

WearWorks, Inc. is the Brooklyn haptic technology company now operating the Haptic brand. Its former wear.works domain redirects to haptic.works, whose privacy policy retains WearWorks. The company develops tactile communication and accessible navigation through its HapticNav phone/Apple Watch app and enterprise SDK, Wayband wrist device, and HapticLab vibration-design tools. Its HapticAI page describes machine-learning-assisted HapticCorridor navigation and adaptive vibration feedback. These are company product claims, rather than independently validated performance benchmarks or a medical-device authorisation. The technology communicates through touch and skin sensory receptors; no implant, brain-computer-interface approval or treatment claim is inferred. Pratt’s May2018 primary report names three industrial-design alumni co-founders: Kevin Yoo, Keith Kirkland and Yangyang Wang. The current linked team page names CEO Kevin H Yoo, Chief Haptics Officer Keith Kirkland, operations lead Enzo Caruso and three advisers. An older unlinked team page additionally names three software/design staff and accessibility adviser Frances West; those affiliations are explicitly source-aged, with current status unconfirmed. Wang’s founding role is historical, with no presumed present executive position. The company’s own current team account, TED and Pratt describe a blind runner navigating15miles of the2017 NYC Marathon using tactile feedback, not a complete unaided marathon. NSF award1746671 records USD225000 obligated for SBIR PhaseI research into a wearable haptic navigation device for blind and visually impaired users, notice18December2017 and project start1January2018. This research award is distinct from equity proceeds and bank disbursement. Quake Capital’s own portfolio proves backing but its Seed category does not disclose a priced round, date, check or subscribing fund. A firsthand Rutgers account published20September2021 separately reports a USD10000 CUEED pitch award, USD25000 Black and Latino Angel Investment Fund of New Jersey investment, and USD115000 additional unnamed syndicate financing. Exact investment dates and instruments are unpublished; publication dates are not closing dates. SoundBoard Venture Fund and ERA publish WearWorks in their portfolios/company listings, and Remarkable’s2024 accelerator account identifies it among startups invested in. Those providers require full identity/profile verification before financial links. Partner-logo collages alone do not prove cash checks by Apple, Google, BMW, EY or every programme sponsor. Crowdfunding targets and cumulative interview estimates are not added as new closed rounds.

Aleks Keser is Lead Recruiter at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Plenty, Coinbase, Intuit. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Sandeep Ankin is Product and Sales Engineer at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Satsyil. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Liz Cahill is Operations Manager, EA at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Maryland Neurosurgery. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Marissa Muller is VP of Communications at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Tesla. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Vik Chaudhary is VP of Products & Partnerships at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Meta, Dropbox, Oracle, MIT. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Katie Greenfield is VP of Finance and Operations
 at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Culture, Solugen. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Doyin Olaoye is AI Performance Engineer at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: AWS. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Harsha Musunuri is Senior AI Researcher at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Dolby. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Jason Ngo is AI Researcher at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: United Health Group. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Filip Marić, PhD is Senior AI Researcher at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Meta. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Mansour Abtahi is Senior AI Researcher at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: UCSF . The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Cheng-Yang Fu is Staff AI Researcher at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Meta. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Xudong Ma is Staff AI Researcher at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Causal, Meta, Apple. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Yuan Yen Tai is Staff AI Researcher at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Apple, Amazon. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Tai-peng Tian is Head of Computer Vision at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Meta, Apple. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Brian Mullen is Computational Neuroscientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: University California, Santa Cruz . The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Patrick Honma, PhD is Computational Neuroscientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Gladstone Institutes . The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Michael Silvernagel is Computational Neuroscientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Stanford. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Bheema Subramanyeswar Reddy Tatiparthi announces starting as a cloud engineer at EigenH, thanking founder DheerajInampudi. His own professional biography describes full-stack development and associate cloud-engineering work on reliable cloud infrastructure, automation,CI/CD,AWS andGCP. His profile lists RGUKT Ongole education during2022–2026 and software projects, while a named EigenH colleague corroborates his team affiliation. Exact appointment day and a fuller unpublished executive rank are not inferred.

Harsha Sanamandra’s own professional profile identifies EigenH affiliation in the Austin metropolitan area and describes a healthcare product-management focus on AI-powered products. BaladityaSaiChinni’s first-hand EigenH voice-workflow announcement names Harsha among colleagues building the platform alongside founder DheerajInampudi. These primary disclosures support a scoped public product-team affiliation; no CEO,cofounder,board or engineering executive title, exact appointment day or unrelated namesake career is assumed.

Lawson Fuller is Computational Neuroscientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Imagia, UCSD. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Baladitya Sai Chinni is an EigenH AI engineering-team member who describes his work on the platform’s healthcare voice workflow in a first-hand product-launch post. His engineering includes grounding agent responses in actual scheduling-tool results, confirming bookings before writes, defined escalation paths, low-latency conversational performance and configuration-driven practice setups. His own professional biography identifies AI automation and agentic-workflow experience, including RAG and LLM projects. His original individually named post portrait is genuine and visually inspected. An exact formal company rank and appointment day are unpublished.

Haggai Agmon is Computational Neuroscientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Stanford. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Han de Jong is Senior Computational Neuroscientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: University California, Berkeley . The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Shaik Mahammad Jani announces in his own professional post that he joined EigenH AI as a founding engineer at its V1 launch. He describes contributing across the full stack to healthcare AI products that simplify administrative workflows. His published technical background includes React,Node,Express,Django and AWS serverless; BaladityaSaiChinni independently names him among the team engineering the practice-controlled voice and scheduling product. Exact appointment day, equity ownership and clinical credentials are not established in reviewed sources.

Karthik Rommula identifies himself as EigenH AI founding AI engineer in his own professional launch post. He describes developing an agent-first healthcare SaaS product with DheerajInampudi to address missed calls, no-shows and manual front-desk work in smaller healthcare organisations. His own profile also describes agent grounding and software systems work, including the Saidso grounding-firewall project. He graduated from KG Reddy College of Engineering and Technology, where he previously served as AIClub vice-president and later returned as a workshop speaker. Exact company appointment day is unpublished; founding engineer does not establish a separate personal equity check.

Steven Jerjian, PhD is Neuroscientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Johns Hopkins, UCL Queen Square. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

William Barnes, PhD is VP of Technology at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Max Planck Society. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

John Wittig, PhD is VP of Engineering at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: iBoss, NIH. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Sasha Nikolaeva is Biology Research Associate at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Turku Bioscience . The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Dominique Cajanding is Biology Research Scientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Sonoma Bio. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Simone Chiola is Biological Scientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Stanford. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Marisol Cortes, PhD is Biological Scientist at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: Johns Hopkins. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Cristina Florio is Director of Biology, Baltimore at The Biological Computing Co. (TBC), according to its current public team directory. The same primary biography card identifies previous experience: NIH. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Jon Pomeraniec is COO & Co-Founder at The Biological Computing Co. (TBC), according to its current public team directory. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

Alex Ksendzovsky is CEO & Co-Founder at The Biological Computing Co. (TBC), according to its current public team directory. The affiliation belongs to its biological-neural computing and AI research company, not an unrelated similarly named organisation.

EigenH AI builds an AI patient-access and front-desk software platform for independent healthcare practices. Its agents manage patient calls, appointment scheduling and rescheduling, recalls, follow-up and insurance-eligibility preparation within practice-approved rules, escalating urgent, uncertain or clinical questions to staff. The current official site identifies US nephrology groups as its first live specialty. Scheduler, Recaller and Verifier are labeled live; Referrer, Authorizer and Nourisher are labeled beta. Prior-authorization paperwork and nutrition appointment/education workflows remain staff-supervised. Its optional AI Ops services combine human operational teams with AI for revenue cycle, coding, verification, credentialing, scribing, marketing and websites. These are administrative healthcare tools, not established clinical diagnostic or treatment products. The vendor describes scheduling integration through NexHealth. Security and compliance claims are vendor disclosures; its written business-associate agreement and AWS hosting statements are not independent clinical validation or an asserted regulatory product clearance. Identity reviewed October8,2026: its own company page, privacy policy and August7,2026 terms identify EigenH AI, Inc., a Delaware corporation, with registered corporate office at131 ContinentalDrive,Suite305,Newark,Delaware19713. The office is explicitly corporate identification only, not an operating or support office. Its own linked corporate LinkedIn identifies Austin,Texas as headquarters and founded2026; exact statutory registration identifier and incorporation day are not established in reviewed primary material. The official domain eigenh.ai is directly linked by founder DheerajInampudi on his personal site. Native and read-only SQL aliases/domain checks found no existing company, only a mention within his former employer Circuitry.ai. This company is distinct from Circuitry.ai and no historical employer finance or roles are transferred. Older dental-focused five-agent launch descriptions are time-qualified; current live/beta and nephrology scope follow the official website rather than stale secondary profiles. Published public-team scope comprises six individually evidenced people: founder DheerajInampudi, founding AI engineer KarthikRommula, founding engineer ShaikMahammadJani, AI automation/voice-workflow engineer BaladityaSaiChinni, cloud engineer BheemaSubramanyeswarReddyTatiparthi, and healthcare product professional HarshaSanamandra. Own individual professional posts and the named engineering-team acknowledgement corroborate the affiliations. Harsha’s exact formal company rank is not published, so the role is scoped to the publicly evidenced team rather than assuming an executive title. Appointment days and a complete private payroll roster are unpublished; the directory’s seven-employee count does not supply a seventh identifiable person. Dheeraj’s authentic personal-site portrait and substantive biography are reused without changing his historical Circuitry engineering role. Authentic new portraits are used only where individually named first-hand assets can be obtained; inaccessible or anonymously labeled directory pictures remain documented gaps, with no guessed image/name associations. Financing and investments: no primary announcement of an equity/debt financing, investor, grant, valuation, ticket or outbound investment was found in the reviewed official company pages, founder/team disclosures and focused funding searches. This is an evidence gap, not a claim that no private financing exists. No round or investor participation is invented. Its2026 AIBoomi VerticalVelocity/Caravan participation is source-reported founder-market-learning activity, not proof of a paid grant or institutional equity check. Service pricing, customer revenue, platform demonstrations and illustrative operational examples are not investment proceeds.

Daniel Tully, also publicly referred to as Dan Tully, is a 111° West Capital investment-team affiliate identified by his own current professional profile and investment commentary. His public statements discuss institutional backing of Healia, Arine and Cherry; these statements do not establish personal contributions. Secondary directories describe a principal title and earlier healthcare investment banking, but the retrieved primary profile hides the employment details. Those titles and education are therefore not asserted here. He is distinct from existing David, Michael, Mike and Tim Tully records.

Sarah Pennebaker, CIPM, confirms a continuing 111° West Capital affiliation in her own professional statement announcing Outlier CFO with Oscar Ku. She describes strategic CFO support for venture firms and growing companies. Her own profile documents prior Aduro Advisors work, Texas Christian University attendance and CIPM certification. Secondary directories describe a senior director of finance title, but the retrieved primary statement does not independently confirm it. The manager role records the verified affiliation without that title or guessed employment dates. Her authentic portrait was not retrievable.

Andrew Brooks is a physician investor publicly affiliated with 111° West Capital. Fund I’s July 16, 2021 primary Form D names him managing member of the issuer’s general partner; this historical filing does not establish a separately verified current statutory manager office. His current own professional profile describes healthcare software investing. TigerConnect’s current leadership biography identifies him as co-founder and chief medical officer, a board-certified orthopedic surgeon and fellow of the American Academy of Orthopedic Surgeons. He previously founded Specialty Surgical Center and Cardo Medical, sold in 2005 and 2011 respectively. His named native TigerConnect portrait was identified but publisher retrieval is blocked, so no substitute image is supplied.

Michael Matly is a physician-trained healthcare software investor and co-founder/managing partner of 111° West Capital. The manager’s March 31, 2026 Form ADV identifies him as its statutory managing member. Orexo’s 2022 own nomination biography documents an MBA from Harvard Business School, medical doctorate from Mayo Clinic College of Medicine and Cornell BS. His earlier career includes Montreux Growth Partners and Mayo Clinic business development and investments. His own current professional profile confirms the 111° West affiliation and healthcare software focus. Orexo board service is historical: its 2024 AGM notice says he declined reelection. No present Orexo board appointment or personal investment check is inferred.

111° West Capital is the healthcare enterprise-software investment brand of 111 West Capital LLC, SEC exempt reporting adviser CRD325776 / file802-127943, verified in its March31,2026 annual FormADV. Its own site describes a multi-stage approach to commercial-stage companies, with an investment team and operator network supporting healthcare software businesses. Public first-party statements and statutory filings identify physician investors Michael Matly and Andrew Brooks, investment-team affiliate Daniel Tully and finance affiliate Sarah Pennebaker; the minimalist public website does not publish a complete staff directory. Matly is the current statutory managing member; Brooks signed FundI’s2021 filing as managing member of its general partner. Verified issuer announcements identify participation in Codoxo’s AI healthcare payment-integrity financings; own professional posts also identify Arine, Cherry, KODEHealth, Canopy and Healia backing, without transferring the founders’ earlier Montreux or personal portfolios to the manager. FundI and FundII are distinct Delaware pooled vehicles, with separate named investment LLCs. Reported securities subscriptions are distinguished from offering targets, asset values and issuer tickets: FundII’s May27,2026 amendment reports119,645,000USD sold in an indefinite offering, not a confirmed final close. Three smaller2025 filings report their stated offerings fully sold. Missing public-directory coverage, three authentic portrait gaps and unverified current titles are explicit research gaps; no unnamed fund or exact issuer allocation is inferred.

Sean Cunliffe is a Birmingham-based investment-team member of450 Ventures, the corporate venture arm of Blue Cross and Blue Shield of Alabama. His own public professional profile identifies his affiliation and investment work, and his own2025 Codoxo funding commentary confirms450 Ventures increased its investment in generative-AI healthcare payment integrity. He has also publicly described450 Ventures’ collaboration with Greens by Xplosion Technology on adolescent and young-adult diabetes technology. A precise current managerial rank, appointment day and complete career chronology are not independently verified here. He is distinct from the Canadian biotechnology executive with the same name.

450 Ventures is the corporate venture investment arm associated with Blue Cross and Blue Shield of Alabama. Alabama Department of Insurance’s examination of BCBS Alabama as of December31,2022 identifies the exact legal entity 450 Ventures LLC as a wholly owned subsidiary, with an administrative services agreement effective January1,2022. That agreement describes services supporting administration of health benefit plans; it does not establish a separately closed venture fund. This profile is distinct from the unrelated 2025 Florida company with the same name. Its source-verified investment activity includes healthcare technology and artificial intelligence. Codoxo’s December17,2025 SeriesC issuer announcement names450 Ventures as an existing investor participating in the35M financing, and explicitly identifies it as BCBS Alabama’s venture arm. Sean Cunliffe’s own public statement confirms additional investment in Codoxo and describes its generative-AI payment-integrity applications. These are administrative healthcare software claims, not independent clinical validation. The verified publicly attributable investment-team member is Sean Cunliffe, whose own profile and posts explicitly identify his450 Ventures affiliation. No complete unit-specific public staff directory or standalone authentic unit logo was located. Parent-company executives are not inferred to be venture-unit employees, and its parent’s brand is not substituted for a missing unit mark. No standalone unit domain, verified founding year or closed LP capital pool has been established. Corporate budgets, insurer surplus and the2022 administrative agreement are not treated as LP fund closes.

John, with over 20 years of experience in Irish and international financial services, currently serves as a Senior Adviser in Corporate Finance at Key Capital. His expertise spans corporate finance, corporate lending, debt restructuring, and equity investment. John has a proven track record in strategy development, team leadership, and managing complex transactions, demonstrating strong commercial and financial acumen. He has held notable roles at Key Capital, Allied Irish Banks, and other major financial institutions, contributing significantly to their strategic and financial initiatives.

Bridget is a seasoned finance and strategy corporate executive with nearly 30 years of professional experience. Her areas of expertise include Life Sciences, AI and Automation. Bridget's career encompasses various global roles, including former Chief Financial Officer of a global AI and Automation group, financial advisory on transactions, exit and liquidity events, fundraising, growth and value creation strategies in addition to financial management. Bridget has held board member positions in multiple companies. She is a Chartered Director(IoD, London), a Fellow Member of the Association of Chartered Certified Accountants (FCCA) and holds a diploma in Company Direction.

Colin is former chair of the Medtech Syndicate and boasts over 20 years of senior leadership experience in various sectors and regions. His skills include business transformation, startup leadership in Ireland and Asia, and operational excellence. Colin has a PhD from the University of Zurich, a BSc from University College Galway, and is a certified Qualified Person. His career includes significant roles at Abbott, Pfizer, Allergan, and Novartis, reflecting his extensive experience in the medical field.

Pat has a diverse professional background with 30 years’ experience in project management, contract management, and negotiation. Currently serving as Services Director at Secure-All Security Group and Investment Manager at FGP Holdings Ltd., Pat has 6 years’ experience as an angel investor focusing on medtech but also in fintech, energy and cleantech, reflecting his interests in multiple sectors. Pat holds a BE in Electronic Engineering from University College Galway and an MBA from OU Business School.

Yvan has extensive experience in the Life science & business angel industry. He is the founder of TAHO, where he invests in and coaches early-stage startups. Former entrepreneur, Yvan now serves as an independent board member to various startups & scale-ups in Europe, focusing on sectors like MedTech, Ed-Tech & SaaS. His background includes former operational roles in Pharma/MedTech, Biopharma, and company director. As a company director, he facilitated various activities such as equity fund raising, start-up acquisition, executive team overhaul, and company liquidation.

HBAN MedTech Syndicate is the Irish medical-technology business-angel syndicate identified by the national HBAN network and its own medtechsyndicate.com website. Its own current history dates formation to2014. HBAN describes the community as Galway-based; its own administrative correspondence address is No1 Grant’s Row, Dublin2. It backs early-stage medical devices, diagnostics and digital health, including neurological technologies NeuroBell, Neuromod and Vertigenius and AI pathology company Deciphex. It is distinct from the unrelated plural-domain medtechsyndicates.com venture business. The syndicate is a club owned by its business-angel members, not a regulated venture-capital fund. Individual members make final investment decisions; pooled holdings use a nominee limited company and investment funds pass through solicitors’ client accounts. Its own FAQ identifies Medtech Syndicate Nominee Ltd as a Department of Justice-registered trust/company service provider and explicitly says it is not regulated by the Central Bank. The primary Irish CRO2024 annual-return gazette identifies that nominee as company543136, Medtech Syndicate Nominee Limited. A2018 CRO name-change gazette records an earlier HBAN-prefixed nominee name; the later name-restoration date is unpublished. The club and nominee are related operational/legal scopes, not assumed identical treasury accounts or duplicate institutional buyers. The exact subscribing nominee or member vehicles in individual company financings remain unpublished unless expressly named. No separate LP fund, fund close or club balance-sheet investment is inferred. All five people published in its own current leadership directory are recorded with genuine named original portraits: chair Yvan Gouttebelle and directors Bridget O’Brien, Colin Henehen, Pat Coakley and John Sisk. Colin’s former chairship is historical. Public testimonials use abbreviated names and are not treated as an identifiable full member roster. The website’s80members,25companies and EUR31M invested describe cumulative syndicate activity, not a new fund close, available corpus or individual company cash allocation. NeuroBell’s primary university announcements expressly identify the HBAN MedTech syndicate as a co-leader of the EUR2.1M seed secured in Q4,2023 and announced January8,2024, and a returning participant in the USD5.5M financing announced June30,2026. These published syndicate relationships represent member-mediated backing; individual tickets and the exact nominee subscriber are undisclosed. The company owner records one qualified participation per actual financing. Other public portfolio names are audited separately before company or cash attribution.

Chris Klug announced joining bundleIQ as VP of Sales in a public professional post reshared by CEO Nicholas Mohnacky. The announcement establishes the affiliation; an exact present-day tenure and authentic bound portrait were not independently established.

Eric Berkowitz's own Forbes Business Council profile identifies him as bundleIQ's president and partner. He founded Humble TV and co-founded Singtrix and Drumscape. His professional profile supplies a named portrait; his personal companies page separately lists bundleIQ.

Sam Lapine announced a summer legal internship with bundleIQ focused on AI, intellectual property and product strategy. His own announcement thanks Eric Berkowitz and Nicholas Mohnacky. This is a historical internship affiliation, with no current employment claim.

Jeff Robbins identifies himself as a bundleIQ co-founder on his own Jeff52 brain-health and learning website. His site publishes a named personal portrait. His exact current operating responsibilities and tenure dates are unpublished.

Andres Espinosa is bundleIQ's technical co-founder and CTO. His own professional profile uses Espinosa; eMerge's January2026 interview spells the surname Espinoza. The2023 founder interview names him as technical co-founder, and his Cursor community event identifies the CTO affiliation.

Nicholas Mohnacky co-founded bundleIQ and leads it as CEO. Organizer eMerge Americas identifies him in its January2026 interview on AI knowledge graphs; his firsthand2023 interview describes the company's AI knowledge assistant and Florida Opportunity Fund backing.

bundleIQ is the US AI knowledge-management and enterprise intelligence company operating bundleiq.com. Its February2026 terms identify bundleIQ, Inc., a Delaware corporation, and three Alani products: Hub for personal content, Connect for publisher communities, and Insights for enterprise data. The platform supports document and media ingestion, AI-assisted discovery, semantic search and conversational analysis over users' own information. Primary January2026 event coverage identifies Nicholas Mohnacky as CEO and Andres Espinosa as technical co-founder and CTO. Additional public affiliations are explicitly qualified by source and tenure; a complete internal staff census is unpublished. Florida Opportunity Fund's official portfolio confirms backing. In an August2023 firsthand interview, Mohnacky states that pre-seed financing was raised with Fund participation, without disclosing cash or an exact closing date. This US AI company is distinct from bundleiq.co.uk's procurement business; that business's projected fundraising figures are excluded. Founding-year and private financing details remain unverified.

Brian G. Neer is founder and chiefinvestmentofficer of Neer Venture Partners, an exact identity corroborated by the official biography, FloridaLLC statutorymanager record and FINRA2522448 report. He spent roughly30years onWallStreet focused oncredit, derivatives and dealstructuring, including a23yearMorganStanley career. His own biography names leadership of derivatives/structuredproducts, XVA/corporatederivatives trading, Europeancredit and creditderivativeproducts businesses; he previously foundedCournotCapital. He holds aBSinFinance fromRutgersCollege and anMBAinFinance/StrategicManagement fromWharton. The current ownsite describes sevenyears of earlystage investing and approximately70investments as biography figures, not a claim that every historic personalcheck belongs to the2023manager. Founder primary posts confirm currentAI/deeptech portfolio diligence and support for entrepreneurs.

Holden Neer is publicly identified by Neer Venture Partners founderBrianNeer as a technical due-diligence contributor assessing Rasyn’sAIchemistry technology and portfolio work involvingSiPhoxHealth,Adaptyv andMaverickX. The founder calls him achemicalengineeringgraduate student. His own primary profile andPrincetonNuEnergy’s publicinternintroduction confirm ChemicalEngineeringMSstudy atColumbiaUniversity, aNanoEngineering bachelor’sdegree atUCSanDiego, and battery/electrochemistry/nanomaterials research with silicon-based compositeanodes. These facts identify the namedtechnical contributor; they do not establish investmentpartnership, salariedemployment, a completedColumbiaMSdegree, personalchecks or exactappointmentdates. A genuine caption-boundpublicheadshot was not verified; no syntheticportrait substituted.

Neer Venture Partners is an early-stage venture investment platform founded by Brian Neer, concentrating on fintech and emerging markets while also backing B2B software, AI and selected deep technologies. Its own current strategy covers seed through Series A, targets150–200 investments with typicalUSD100,000–500,000 checks and considers established founding teams, product-market-fit evidence and large addressable markets. These figures are strategy parameters, not actual company allocations. The own website excludes healthcare, pure cryptocurrency and vice as its general mandate, although the actual published portfolio includes health/biotechnology-related holdings; no neuroscience specialization is asserted. The legal operator is active Florida Neer Venture Partners LLC, documentL23000329216, filedJuly11,2023 and effectiveJuly3,2023. BrianGNeer is its statutorymanager and registeredagent, and the January27,2026 annualreport confirms continuity. His FINRA record independently identifies Neer Venture Partners as an investment-related owner activity beginningApril2023. The public brand is distinct from similarly named Pioneer and other unrelated managers. An own founder announcement identifies a newer operating office at319ClematisStreet in WestPalmBeach’s1909 ecosystem; the PalmBeachGardens registration address is separate. The official website publishes founder and chiefinvestmentofficer Brian Neer, with an authentic original portrait and primary biography describing credit/derivatives/deal-structuring experience atMorganStanley, foundingCournotCapital and Rutgers/Wharton degrees. A recent founder-owned technical-investment announcement also explicitly names HoldenNeer as a technical due-diligence contributor, including work onRasyn,SiPhoxHealth,Adaptyv andMaverickX; his affiliation is recorded as a contributor, not an inferred investmentpartner or salariedemployee. His genuine portrait remains an unresolved public-asset gap. The own companyLinkedIn description calls the platform aUSD25Mseedfund. No source-proven closed amount, legal subscribingLPvehicle or completedclosingday is available, so this is qualified marketing scale rather than a recorded fundraise or AUM. The website’s current selected portfolio has94 linkedcards including positive and negative exits; repeatedlogos and legacy domainchanges require issueridentity audits. bundleIQ is explicitly listed and separately welcomed by Brian with its threefounders. Portfolio evidence alone doesnot establish an exact fundingdate, ticket, fundallocation or stage. Relevant AI/deeptechnology discoveries include Rasyn’s chemistrymodels, Adaptyv’s automatedbiology, EarthGrid, opticalfilters, developer/agenttools and enterpriseAI software; missingcompanyprofiles are queued for full primary audits.

Mark Morgan is publicly listed by Elkstone as Real Estate Investment Manager. This is an affiliated real-estate platform role; own real-estate footer distinguishes unregulated Elkstone Capital Partners Limited from regulated Elkstone Private Advisors Limited.

Jack Fox is publicly listed by Elkstone as Real Estate Structure Finance Manager. This is an affiliated real-estate platform role; own real-estate footer distinguishes unregulated Elkstone Capital Partners Limited from regulated Elkstone Private Advisors Limited.

Simon English is publicly listed by Elkstone as Real Estate Planning Director. This is an affiliated real-estate platform role; own real-estate footer distinguishes unregulated Elkstone Capital Partners Limited from regulated Elkstone Private Advisors Limited.

Peter Sproule is publicly listed by Elkstone as Real Estate Design Director. This is an affiliated real-estate platform role; own real-estate footer distinguishes unregulated Elkstone Capital Partners Limited from regulated Elkstone Private Advisors Limited.

Aidan Durkin is publicly listed by Elkstone as Real Estate Director of Finance and Operations. This is an affiliated real-estate platform role; own real-estate footer distinguishes unregulated Elkstone Capital Partners Limited from regulated Elkstone Private Advisors Limited.

Jeremy Debono is publicly listed by Elkstone as Senior Venture Investment Associate. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Cillian Sugrue is publicly listed by Elkstone as Venture Associate. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Ruth Skehan is publicly listed by Elkstone as Venture Operations. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Dara O'Shea is publicly listed by Elkstone as Senior Venture Investment Associate. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Caolfhionn McCarthy is publicly listed by Elkstone as Venture Platform Associate. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Barry Brennan is publicly listed by Elkstone as Venture Partner. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Sarah Bogossian is publicly listed by Elkstone as Venture Partner. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here. The September8,2025 own FundII announcement names her Venture Partner and Head of Capital Formation; that dated title supports her fundraising responsibility but does not establish a closed fund amount.

Ciarán McIntyre is publicly listed by Elkstone as Co-Founder. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Ruairí O'Neill is publicly listed by Elkstone as Co-Founder. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Alan Merriman is publicly listed by Elkstone as Co-Founder & Executive Director. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here. Own September2025 FundII release called him co-founder and CEO; the current public directory instead names Joe Bergin CEO and Merriman co-founder/executive director, so CEO tenure is historical.

Alex Walsh is publicly listed by Elkstone as Real Estate Project Director. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Shane Scannell is publicly listed by Elkstone as Chief Financial Officer. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here.

Niall McEvoy is publicly listed by Elkstone as Head of Venture. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here. Dublin Chamber’s primary programme states he joined from Enterprise Ireland, where he led the High Potential Start-up team. Current venture responsibility is supported by issuer/EnterpriseIreland announcements for LaNua Medical, Lative and Barespace.

Joe Bergin is publicly listed by Elkstone as CEO. Elkstone is an Irish private-market investment platform spanning venture capital, wealth and alternative investment services. The role is verified from its current own directory; exact appointment date and further career details are not independently established here. ISIF’s September2024 release identifies him as Managing Director and Head of Private Clients at the firm’s Galway office, opened2019; that earlier title is separate from the current CEO roster.

ECFG is an Eindhoven-based investment and advisory group that helps technology businesses finance and manage growth. Its venture-capital business backs Dutch B2B scale-ups in high-tech manufacturing, agrotech and ICT, especially companies combining proprietary hardware and software. It takes minority stakes and supports commercial expansion, organisation and operations through hands-on portfolio work. Its separate corporate-finance practice advises on acquisitions, business financing and valuations, while its investment-services practice supports other investors with investment processes, strategy and ESG. ECFG Venture Capital B.V. manages its venture funds; the wider brand also includes ECFG Finance & Growth B.V. and ECFG Investment Services B.V. Ventures III closed at EUR40 million in September2024 and targets minority investments of EUR0.5–4 million.

Davey Senders was introduced inJuly2022 as a member of ECFG’s venture-capital team. His issuer biography describes legal studies, an earlier graduation project with TAMI and business, legal and compliance experience in legal practice and banking.

Giel Nendels joined ECFG’s venture-capital and finance-and-growth teams inJuly2022. The issuer describes business-economics training, M&A and strategy-consulting experience, earlier management work in camera technology and study towards Register Valuator qualification.

The September2024 ECFG announcement names Godfried de Jongh as a venture-capital professional collaborating with Sophie Manigart in the governance and advisory context. The precise board assignment and current tenure are not established by this source.

Hans Bloemen co-founded ECFG in2007. He combines economics and law training with experience supporting small and medium-sized businesses through financial, operational and strategic decisions. The current group directory publishes him as Director Business Development, Managing Director and Partner.

Helmy van Kollenburg handles office management and communication at ECFG. Her issuer biography describes earlier sales, marketing and office-management work and responsibility for organising the firm’s internal processes.

Hubert Bosch is published by ECFG as Allied Partner | Corporate Finance. This affiliation belongs to the group’s published professional network; no legal subsidiary employment or appointment date is inferred.

Hugo Hamoen is published by ECFG as Analyst. This affiliation belongs to the group’s published professional network; no legal subsidiary employment or appointment date is inferred.

Ifrensly Mathilda manages portfolios and funds at ECFG. His own2019 biography describes accounting and business-administration training, earlier accounting work in Curaçao and joining ECFG through an internship in2015.

Jenna Reijnders is published by ECFG as Investment Manager | Transactions. This affiliation belongs to the group’s published professional network; no legal subsidiary employment or appointment date is inferred.

Johan van Dijk is ECFG’s allied partner for investor relations. His issuer introduction describes a career in construction, banking and business advice, and bringing an entrepreneurial investor network to the group.

Jord Adema was published by ECFG inSeptember2023. Published as an Eindhoven University of Technology innovation-management master student working on workflow optimisation. Current tenure is not established by the current directory.

Koen van 't Hof is published by ECFG as Associate. This affiliation belongs to the group’s published professional network; no legal subsidiary employment or appointment date is inferred.

Leo van Schijndel directs transactions at ECFG and is published as Register Valuator. His issuer introduction describes earlier banking and acquisition-finance work and management of a public-private venture fund before joining ECFG in2023.

Lesley Daris was introduced by ECFG inNovember2024 as an analyst supporting investments, valuations and strategic analysis. Current tenure is unverified.

Marcel Clerx is published by ECFG as Allied Partner | Strategy & Leadership. This affiliation belongs to the group’s published professional network; no legal subsidiary employment or appointment date is inferred.

Mark Bulsink was named by ECFG as a Business & Control contact inSeptember2020 for management reporting, financial indicators and business-process analysis. Exact rank and current tenure remain unpublished.

Mathijs Snijders was published by ECFG inSeptember2023. Studied economics and business economics and pursued a finance master at Tilburg University. Current tenure is not established by the current directory.

The September2024 ECFG announcement names Miriam Dragstra as a venture-capital professional collaborating with Sophie Manigart in the governance and advisory context. The precise board assignment and current tenure are not established by this source.

Nick Lammers was published as an ECFG advisor in2022, after joining as an analyst in2020. His issuer biography describes Tilburg University international-business and finance degrees, the QTEM programme and an earlier M&A internship at Improved Corporate Finance.

Ole van der Horst was published by ECFG inSeptember2023. Published as a Tilburg University finance master student moving from part-time to full-time analyst work. Current tenure is not established by the current directory.

Philippe de Weerdt is published by ECFG as Analyst. This affiliation belongs to the group’s published professional network; no legal subsidiary employment or appointment date is inferred.

The September2024 ECFG announcement names Ronald Slaats as a venture-capital professional collaborating with Sophie Manigart in the governance and advisory context. The precise board assignment and current tenure are not established by this source.

Ruben Baijens co-founded ECFG in2007 and directs its portfolio. His issuer biography describes more than15 years of investment and corporate-finance experience, including valuation, due diligence, risk assessment and transactions.

Tanya Bakker is ECFG’s allied partner for ESG. Her issuer biography describes a physics doctorate at Eindhoven University of Technology, earlier sustainability and ecodesign work at Canon, and translating sustainability policy into measurable investment and business criteria.

John Vecchio is a published partner at Mosley Ventures and a software entrepreneur associated with N2 Broadband and Clearleap. His manager biography also describes product and organisational work at Cisco/Scientific Atlanta and The Weather Channel, a technical Emmy for video-on-demand systems, and patents in video transcoding and distribution. He holds a mathematics degree from Florida State University. This is the exact Mosley-directory identity; the undated roster does not independently prove continuous2026 employment. His authentic original portrait URL is published but currently returns an access page.

Scott Hrastar is published as entrepreneur in residence at Mosley Ventures. He co-founded AirDefense as CTO before its acquisition by Motorola and held leadership roles around Intellisync’s acquisition by Nokia. His earlier technology career includes Pathfire, Lancope and Scientific-Atlanta; his biography describes wireless security, mobility and technology acquisitions. He holds an electrical engineering degree from Ohio State and masters/doctoral degrees from Georgia Tech. The manager roster is undated and treated as a published affiliation rather than independently verified current employment. His original portrait is inaccessible.

Sig Mosley is the published managing partner of Atlanta-based Mosley Ventures and previously led Imlay Investments. His career includes accounting at Peat Marwick and finance leadership at Management Science America. He earned his BBA at Emory University in1968. The Georgia2016 registration identifies the authorizer as Sig Mosley and registered agent as Ivan Sigmund Mosley Jr. His genuine portrait is published by the Emory Impact Investing Group alongside his exact managing-partner affiliation. Legacy investment and board counts in his manager biography are not asserted as current2026 totals.

Wei-Chun Tai is published as partner and general partner at Mosley Ventures. She co-founded loan-qualification software business LenderFlex, subsequently sold to eBank Mortgage, and previously founded fashion label Jara. Earlier analyst experience spans telecommunications, manufacturing, consumer goods and financial services. She earned an engineering degree from Feng-Chia University and an MBA from the University of Hartford. Her public biography describes interests including digital manufacturing and AI prediction. The undated legacy directory affiliation is source-qualified; original portrait bytes are currently inaccessible.

Mosley Ventures is an Atlanta-based seed and early-stage technology investor focused on the southeastern United States, including security software, big data, digital media, mobility and healthcare IT. Primary Invest Georgia reporting dates the platform’s founding to2013 and identifies investment partners Sig Mosley, Wei-Chun Tai and John Vecchio. Its own published directory additionally names entrepreneur in residence Scott Hrastar; the undated legacy biographies are retained as published affiliations, not a claim that every person remains a2026 employee. Georgia’s January2016 annual registration verifies MOSLEY VENTURES LLC, control12072732, at75 Fifth Street NW Suite328 Atlanta; this historical legal proof does not establish current registration status. The separate MOSLEY VENTURES LP is independently identified in Lucena Research’s SEC ownership schedule, not as this manager’s own adviser registration. The manager announced onDecember2,2022 that its first fund is fully deployed, it will not raise another fund, and it will continue supporting existing portfolio companies; the current homepage repeats that status. Invest Georgia’s3.25M commitment and December2016 payment of50% describe one LP subscription, not total fund corpus or new company financing. Fund size and final closing day remain unpublished in the verified primary sources. Actual issuer announcements identify Mosley as a participant in FraudScope/Codoxo’s2017 seed and2020 SeriesA. Original manager logo and three original team portraits are currently inaccessible; these asset gaps are explicit, and no unrelated or generated branding is substituted.

Genesia Ventures is an independent venture capital firm founded in 2016, investing primarily at pre-seed and Seed stages in Japan, Southeast Asia and India. It combines early capital with support for hiring, organizational development, fundraising, corporate partnerships and cross-border expansion, through teams in Tokyo, Jakarta, Ho Chi Minh City and Bengaluru. Its investment approach follows structural and technological change rather than a fixed sector list. Published interests include generative AI and enterprise software, energy and advanced materials, quantum and nuclear-fusion technologies, life sciences and healthcare, alongside platforms for commerce, financial access and industrial supply chains. The firm’s Asia Origin strategy backs companies emerging from regional market needs with the potential for global impact. Its legal Japanese operator is 株式会社ジェネシア・ベンチャーズ (Genesia Ventures, Inc.); its numbered venture funds are separate investment limited partnerships.

Aero Aribowo works in Genesia’s Indonesia investment team. He studied international relations and economic development and previously worked as a marketing analyst at a finance company.

Ai Yoshida supports communications, branding and portfolio-company public relations at Genesia. She also runs the firm’s Players interview and media project.

Aki Ito advises on startup HR and organization building. Her experience includes people operations for new ventures at Mercari and establishing Kyash’s first HR function.

Chika Kashiwazaki works on Genesia’s brand. Her background includes managing promotional events at Dentsu Live and developing events and business-leader communities at Forbes Japan.

Elsha Eliasa Kwee leads Genesia’s Indonesian investing. Her career spans venture investing, software engineering and product management, including CyberAgent Ventures and payments company Xfers.

Hoang Thi Kim Dung works with founders in Vietnam. Her experience includes enterprise technology sales at IBM Japan, startup support and publishing the Zunzunstartup knowledge channel.

Kaori Kitakata supports Genesia’s portfolio and partnerships. She previously managed venture-fund operations and worked in communications at startups and international agencies.

Kent Kajitani advises on product growth and generative AI as a published Genesia expert. He leads POSTS and previously ran XR and metaverse business MESON.

Koki Mizutani supports seed-stage companies across industrial technology. Before joining Genesia, he worked on investment risk and M&A involving renewable energy and automotive steel at Sumitomo Corporation.

Masakuni Iida develops corporate alliances and supports portfolio companies. His background includes corporate banking, M&A finance and venture-fund formation at Mizuho Bank and Mizuho Capital.

Michiko Kohyama brings digital-business operating and venture-investing experience from Disney Japan and Eight Roads. She also works on inclusion in startups and founded nonprofit-support organization Public Mind.

Naoki Kurosaki invests in enterprise IT. He worked in enterprise sales at Fujitsu and helped build commercial teams, recruiting and organizational systems at Sansan through its IPO.

Shu Sokabe invests in materials, energy, biotechnology, AI infrastructure and space. His engineering background includes battery-materials research, university startup development and student rocketry.

Shuku Yushu works on portfolio support and partnerships. His experience includes strategy consulting in China, transaction advice at EY and corporate M&A and integration work at SMFG.

Shun Sagara leads Genesia’s India investing, focused on enterprise software, AI, healthcare and B2B marketplaces. He previously helped build Treasure Data and moved to Bengaluru to establish the firm’s local investment presence.

Soichi Tajima founded Genesia Ventures in 2016. He previously led CyberAgent Ventures and worked in banking at SMBC, combining regional venture-investing and financial-services experience.

Takahiro Suzuki invests across Southeast Asia. He previously built and led CyberAgent’s regional venture activities, with earlier experience in influencer marketing and mobile gaming.

Vo Thanh Truc supports startup operations and community development at Genesia’s Orbit ecosystem in Vietnam, drawing on economic-law studies and experience building collaborative startup communities.

Yuto Kono invests in AI-native services, entertainment and wellness. He helped launch Genesia’s Indonesian office and led its Vietnam office before returning to Tokyo, with earlier experience at CyberAgent Capital and Quipper.

Rodney Sampson is the founder and executive chairman of Opportunity Hub. His own first-person CodeStart account documents a collaboration in which TechSquare Labs housed a youth cohort and provided corporate innovation and entrepreneurial training. Opportunity Hub’s primary 2020 presentation documents the late-2015 merger of its coworking assets with TechSquare Labs. This records a historical collaboration and venture-building affiliation, without inferring a current salaried TechSquare position or assigning an unsupported partner title. His current own Opportunity Hub page identifies his leadership separately.

Ben Dyer joined TechSquare Capital as a venture partner by December 2017, according to the primary Invest Georgia annual report. Georgia Tech’s Winter 2018 alumni biography separately describes his late-2017 return to Atlanta as a TechSquare Labs partner and his appointment as entrepreneur in residence at Morris, Manning & Martin. He founded Peachtree Software, Comsell and Intellimedia and previously taught entrepreneurship at the University of Texas at Austin. His documented TechSquare affiliation is historical; no current role or appointment day is inferred. No sufficiently verified identity-specific primary portrait was recovered.

Tanya Sam’s current self-published biography identifies her as director of partnerships at TechSquare Labs, mentoring women and minority entrepreneurs. She founded The Ambition Fund and co-led Ascend 2020 Atlanta and co-founded BuiltxWomen. Her earlier career included oncology nursing. She is an entrepreneur, educator and advocate focused on access to capital and mentorship. Her own page establishes the named role but does not disclose an appointment date; aggregate personal investment and supported-company revenue figures are not treated as institutional TechSquare allocations.

Allen Nance co-founded TechSquare Labs with Paul Judge in 2014. Invest Georgia’s own 2017 annual report identifies him as managing partner of TechSquare Capital, the associated Atlanta seed-stage software and technology fund established in 2016. His operating background includes founding WhatCounts, later sold to Riverside, and co-founding e-commerce marketing-automation company Springbot. The League VC’s public community directory identifies him as a founder and TechSquare Labs partner. These affiliations are source-qualified; an inactive original firm domain does not independently establish a current employment contract.

Wipro Ventures is the corporate venture-investment arm of Wipro Limited, established in 2015. It backs early- and mid-stage enterprise technology businesses and helps portfolio companies reach Wipro’s business units and customers. Relevant investments include healthcare-payment AI company Codoxo and software, data infrastructure, cybersecurity and automation businesses. It is represented as the corporate investment platform, not an independently verified third-party LP fund manager or an additional parent-company buyer. The official current directory publishes nine investment, business-development, finance and marketing professionals. Wipro describes Fund II’s January 2020 USD150 million closing as an additional internal capital allocation. The original 2015 USD100 million programme and February 2025 USD200 million commitment to Fund III are corporate commitments; cumulative USD500 million capital under management is not another fund close. Exact underlying legal subscriber vehicles and capital-call payment schedules remain unpublished. Wipro Ventures is distinct from Wipro Consumer Care Ventures, Wipro Enterprises and similarly named investment firms.

Ali Wasti is a managing partner of Wipro Ventures. He previously headed Hewlett Packard Enterprise’s Pathfinder Ventures and invested at Azure Capital Partners, focusing on AI, enterprise software, cloud infrastructure and security. His earlier IBM career included engineering, product and business-development roles in data management and analytics. He holds an MBA from Harvard Business School and a computer-science degree from McMaster University. Former-firm investments are not assigned to Wipro.

Angeline Barrozo is a partner in business development at Wipro Ventures; her official biography also identifies her as global head of business development. She helps portfolio businesses reach Wipro business units and enterprise customers. She previously led Wipro’s Oracle alliance and worked at Oracle and PwC across partnerships, consulting and project management. She studied accounting and Japanese language and culture at San Francisco State University, with a computer-science minor.

Bijal Vasant is senior manager of investments in Wipro Ventures’ current team directory. Her named biography describes identifying and assessing early- and mid-stage technology investments, following consumer-focused private-equity and investment-banking experience. She is a chartered accountant through the Institute of Chartered Accountants of India, has completed the three CFA programme levels and studied commerce at Mumbai University.

Biplab Adhya is a managing partner of Wipro Ventures and helped launch the corporate venture platform in 2015. His official biography describes enterprise-software investment and commercialisation work, following operating roles at Wipro and other corporations. He studied computer science and engineering at IIT Kharagpur and finance and systems at IIM Bangalore, and is a Kauffman Fellow. Investment and exit track-record figures do not establish personal checks or a separate closed fund.

Gideon Wilk is director of business development at Wipro Ventures and leads strategy for the platform. He previously operated a search fund through which he acquired and led tax-preparation software company ezTaxReturn. His experience spans venture and private-equity investment, software engineering, cloud infrastructure, security, AI and marketing. He studied industrial engineering at the University of Toronto and holds a Harvard Business School MBA.

Jason Chern is listed as senior manager of investments in Wipro Ventures’ current team directory; his individual page still says manager of investments, a title discrepancy preserved explicitly. He focuses on machine learning, software development and enterprise infrastructure. Earlier roles included product management at Fountain, investment at Presidio Ventures and consulting at Deloitte. He studied economics and computer science at the University of California, Berkeley.

Sneha Kadam is senior manager of marketing in Wipro Ventures’ official directory. She leads events, communications, content and social media for the venture platform and has worked in Wipro marketing since 2016. Her experience includes partner and analyst relations, brand and account-based marketing and demand generation. She holds an information-technology degree from Mumbai University and an MBA in marketing from IIM Raipur.

Vasudha Dhandhania is manager of finance at Wipro Ventures, identified in its current official nine-person team directory alongside an authentic name-bound portrait. The investment platform is Wipro Limited’s corporate venture arm. The reviewed site does not publish an individual biography or education history for her, so those details and an appointment date are not inferred.

Virinchi Gurram is director of business development at Wipro Ventures. He works with portfolio companies and Wipro business units to encourage adoption of startup technologies. His earlier Wipro roles covered financial-services sales and presales, infrastructure and cloud services. His biography records information-systems certifications and an MBA in finance and marketing from Loyola Institute in Chennai.

TechSquare Labs is an Atlanta company-building studio and seed-investment platform founded by Allen Nance and Paul Judge in 2014. Invest Georgia’s primary annual report identifies the original business as Tech Square Labs LLC and distinguishes the associated TechSquare Capital fund, established in 2016, from Blake Patton’s unrelated Tech Square Ventures. Its documented strategy backs early-stage software and technical founders in Atlanta, including AI healthcare fraud-detection company FraudScope, now Codoxo. The studio provided coworking, corporate innovation and founder support, with Atlanta Startup Battle as a sourcing programme. The associated fund held its final close in November 2017 with USD12.65 million of capitalization. This is closed fund capitalization, not proof that all commitments were paid in cash; the state LP reported only 47 percent of its USD1 million commitment contributed by year end. Portfolio counts can include purchased or contributed securities, and founder operating businesses are not automatically institutional investments. The original techsquare.co domain is unavailable and techsquarecapital.com currently returns a site-not-configured page. Current operating status and a complete current payroll roster are not established. Founder and venture-partner affiliations are qualified by their historical source dates, while Tanya Sam’s current self-published biography still lists the partnerships role without an appointment date. The authentic historical wordmark is retained from the firm’s own publication. Neither the unrelated Tech Square Ventures manager nor techsquare.ai services company is merged into this identity.

Randy Brouckman is publicly named Randy Brouckmann in Lookout Ventures’ current directory, serving as Operating Partner. Multi-time CEO, most recently EdgeConnex in data center / cloud infrastructure space (multi $B exit) EdgeConneX’s own executive biography uses Randy Brouckman and independently confirms his prior TDF partner and entrepreneur-in-residence role. The Lookout double-n surname is a published spelling variant, not a separate person. The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

Lei Tung is publicly named Lei Tung in Lookout Ventures’ current directory, serving as Operating Partner. Product and engineering executive, principal architect at Marketo ($1.8B exit) The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

John Schanz is publicly named John Schanz in Lookout Ventures’ current directory, serving as Operating Partner. Hyperscale technology and operations leader, formerly Chief Network Officer roles at Comcast and AOL The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

Steve Mankoff is publicly named Steve Mankoff in Lookout Ventures’ current directory, serving as Operating Partner. Ran Customer Success, Support, Education, Professional Services, Q&A, and Offshore Dev + member of Founder’s Circle at Siebel Systems (IPO) The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

Tiffany Kleemann is publicly named Tiffany Kleemann in Lookout Ventures’ current directory, serving as Operating Partner. SaaS and cybersecurity CEO & sales leader, background in White House & US military The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

Dennis Ainge is publicly named Dennis Ainge in Lookout Ventures’ current directory, serving as Operating Partner. GTM and data strategy expert, founding executive at TARGUSinfo (>$500M exit) The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

James J. Pastoriza is publicly named Jim Pastoriza in Lookout Ventures’ current directory, serving as Chairman. Chairman at Lookout. 25 year venture career across TDF Ventures, JPMorgan Capital, and AT&T Ventures. Ex-operator at AT&T and Lucent. Fatally devoted to Boston sports, committed Deadhead. The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

William Rayner is publicly named Will Rayner in Lookout Ventures’ current directory, serving as General Partner. General Partner at Lookout. Previously at TDF Ventures and Accion Venture Lab. Recovering management consultant. Proud Midwesterner, college football fan, fishing enthusiast & corgi owner. The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

Matthew Bressler is publicly named Matt Bressler in Lookout Ventures’ current directory, serving as General Partner. General Partner at Lookout. Previously at TDF Ventures and GE Ventures. Recovering management consultant. Never misses a New Yorker captions contest & keeps 6+ different bottles of hot sauce in his fridge at all times. The affiliation is source-published current; no exact appointment date or personal investment ticket is inferred.

Amy S. Kelley joined NIA as deputy director on September11,2022. Her official appointment biography describes geriatrics and palliative-care research, prior leadership at the Icahn School of Medicine at Mount Sinai, an M.D. from Cornell and a health-services master’s from UCLA. The historical appointment is preserved while2026 reports identify Kenneth Santora as acting deputy; no exact end date or current neuroscience-director role is inferred.

Patrick Shirdon appears in NIA’s public about directory as director of management. The listing is recorded as published institutional affiliation, with current tenure explicitly unverified. No identification with similarly named external college executives or unrelated professional biographies is assumed.

Samir Sauma appears in NIA’s public about directory as acting associate director for scientific strategy, innovation and management. His2022 NIH oral history describes work directing the Office of Planning, Analysis and Evaluation and previous National Cancer Institute experience. The directory title is retained with current tenure unverified because direct NIA directory retrieval is blocked.

Chee Chia is named by NIA as a staff clinician. Its May2021 director’s report records appointment as deputy clinical director of the Intramural Research Program in February2021. The earlier deputy appointment is explicitly dated and is not an assumed uninterrupted current title.

Rachel Saré is a programme officer in the Neurobiology of Aging and Neurodegeneration Branch of NIA’s Division of Neuroscience. Its May2026 report records her April28 congressional briefing hosted by the Sleep Research Society and names her as a scientific programme contact.

Chhanda Dutta is named as acting deputy director of NIA’s Division of Geriatrics and Clinical Gerontology in its September2026 report. She briefed congressional appropriations staff with director Richard Hodes on menopause research in May2026. This institutional research role does not imply individual investment activity.

Xin Yuan, M.D., Ph.D., is the acting director of NIA’s Division of Extramural Activities Office of the Director in its September10,2025 directory. The office oversees advisory-council coordination, grant application assignments, human-subjects review and extramural-policy guidance. The profile does not assume identity with differently credentialed Jean (Xin) Yuan in a historical neuroscience listing.

Evan Hadley describes the priorities and translational research of NIA’s Division of Geriatrics and Clinical Gerontology in a June2024 first-person official article as its director. That dated leadership role is retained with subsequent tenure unverified, without assigning an invented departure date.

Stacy Carrington-Lawrence is identified as acting director of NIA’s Division of Aging Biology in its FY2025 congressional justification. Its September2026 report names her as an aging-intervention research workshop contact. The older acting-director title is dated, rather than asserted as an independently confirmed October2026 appointment.

Lisbeth (Lis) Nielsen directs NIA’s Division of Behavioral and Social Research. Its current public listing describes social, behavioral, psychological and economic aging and Alzheimer’s research. Her March2020 appointment announcement describes prior NIA programme and branch leadership and research on affect, decision-making and aging.

Josephine M. Egan is NIA clinical director and a senior investigator in its Laboratory of Clinical Investigation. Her NIH biography describes endocrinology training at the University of Virginia, joining NIA in July1990, and research on aging, pancreatic beta-cell function, diabetes and incretin biology.

Luigi Ferrucci is NIA scientific director and a geriatrician studying the biological and clinical processes of aging. NIH’s own investigator biography dates his scientific-director appointment to May2011 and describes longitudinal aging research and links between aging biology and functional decline.

Kenneth Santora is NIA’s acting deputy director in its May2026 report and the named director of the Division of Extramural Activities in the September2025 office directory. His published responsibilities include extramural research policy, grant oversight and communication of aging research priorities.

The National Institute on Aging (NIA) is a United States federal biomedical research institute within the National Institutes of Health, established in1974 under PublicLaw93-296. It conducts and supports research on aging, older adults’ health and well-being, Alzheimer’s disease and related dementias through intramural laboratories, extramural grants, training and small-business research programmes. Its neuroscience and deep-technology relevance includes neurobiology of aging, dementia prevention and care, clinical and imaging technologies, sleep research, behavioral science, genomics and translational aging research. NIA is a public institutional grant provider, not a private venture capital firm or a separately inferred NIH investment fund. Richard Hodes remains institute director inSeptember2026 reports; Kenneth Santora is acting deputy director in2026 and directs extramural activities. NIH’s own investigator biographies verify LuigiFerrucci as scientific director and JosephineEgan as clinical director. The profile records publicly named institute/division leaders and relevant programme staff with source-date qualifications. Older public-directory titles for AmyKelley, EvanHadley, StacyCarrington-Lawrence, SamirSauma and PatrickShirdon are not silently treated as independently verifiedOctober2026 appointments. July2026 recruitment for the neuroscience division director does not establish an incumbent. NIA’s site currently returnsHTTP405 for direct directory and portrait retrieval; this prevents verification of the complete institute-wide staff directory and some public headshots. Two original caption-bound NIH IntramuralResearchProgram portraits and the authentic archived government NIA wordmark are verified, and existing shared NIH person images and roles are preserved. Federal appropriations, proposed budgets and programme envelopes are not LP fund closes, fundraising proceeds or paid issuer cash. NIH RePORTER identifies NIA as the administering/funding institute for six separately sourced SleepSpace/ProactiveLife small-business awards; the issuer owner links exact award amounts and notice dates, without duplicating a parent NIH participation or asserting disbursement dates.

Cancer-focused investor whose prior work includes Optum Ventures, Alpha Partners and health-plan partnerships and operations at Thyme Care. He studied economics at Duke University.

Former chief executive and current vice chairman of The Oncology Institute. His previous work includes healthcare investment at TA Associates, General Atlantic and RLH Equity.

Flatiron Health chief executive focused on using real-world patient data in cancer care and research. Her earlier work includes commercial, product, operations and strategy leadership.

Gynecologic oncologist and cancer-hospital leader whose work includes clinical practice, scientific research and leadership of the hospital’s strategic direction.

Healthcare quality and affordability executive at Blue Shield of California, following research-and-development leadership at UnitedHealth Group.

Healthcare executive associated with Navista at Cardinal Health. Her previous work includes community oncology development at McKesson and The US Oncology Network and growth leadership at DispatchHealth.

Threshold Ventures co-founder and healthcare investor. She is a founding member of All Raise and has backed companies developing healthcare services and technology.

Hematology and oncology physician at Massachusetts General Hospital and Harvard Medical School faculty member. Trained in internal medicine, hematology and oncology at Brigham and Women’s Hospital.

Ethan Zohn co-founded Grassroot Soccer, which provides health education and services to young people. He is a cancer survivor and winner of Survivor: Africa.

Texas Oncology chief operating officer. His earlier McKesson work included finance and leadership across oncology practice management, provider technology, imaging and clinical operations.

Accounting and financial-planning professional and partner emeritus of a New York accounting firm. His prior leadership includes professional accounting and financial-planning committees.

Physician with experience in value-based oncology, genetics and reimbursement, including prior leadership at Optum and UnitedHealthcare and developing Anthem’s cancer-care quality program.

Atlantic Health Venture Studio manager working on strategic partnerships, venture development and clinical innovation. Her background includes healthcare technology and clinical systems.

Operations and executive-support professional with experience spanning healthcare, technology, public policy and research. He studied anthropology at the University of the Philippines.

Physician and former UnitedHealth Group chief medical officer whose work included oncology payment models and combined clinical and claims data. Previously practiced medical oncology.

Oak HC/FT general partner focused on healthcare growth and venture investment. Her earlier executive work included McKesson, athenahealth and Harvard Community Health Plan.

Healthcare strategy and operations professional with prior work at Memorial Sloan Kettering, Flatiron Health and City of Hope. She holds a health-administration master’s degree from Columbia University.

Fred Hutch strategy and operations executive with prior cancer-services leadership at UChicago Medicine and strategy roles at UCSF Health and New York-Presbyterian Hospital.

Moffitt Cancer Center business-development and innovation leader. His previous life-sciences work includes Capricor Therapeutics, Genentech and Gilead Sciences.

Abby Maxius is an Administrative Assistant coordinating with CVS Health Ventures’ partners. Her background includes administration, legal, risk and compliance work and roles at New York City Health + Hospitals, Memorial Sloan Kettering and Mount Sinai institutions, with paralegal and nursing studies. No licensed clinical credential or investment authority is inferred.

Alex James is a General Partner and founding member of CVS Health Ventures. He leads financial planning, capital strategy and portfolio management across direct and LP investments. Earlier he advised healthcare companies in management consulting, including Deloitte’s healthcare M&A practice. He holds a Cornell MBA and Syracuse economics/mathematics degree. The published overUSD1B invested-portfolio figure describes managed investments rather than a new fund close.

Alex Ramos is an Associate evaluating, executing and supporting digital-health and healthcare-technology investments. His published focus includes payer–provider connectivity and operating workflows. He studied economics at Tufts and previously worked with CVS external growth and development before joining the venture team.

Andrea Messina is a General Partner leading market development and portfolio-company collaboration at CVS Health Ventures. She joined CVS in2021 to develop clinical solutions and previously led business development and strategic planning at Mass General Brigham, including care-delivery, AI/ML and digital-health commercialization. Her current card says General Partner while the biography uses Executive Director and Partner; these formulations do not establish an appointment date.

Camille Wiggins is a Senior Analyst supporting growth-equity sourcing, evaluation and portfolio work. She holds a Dartmouth bachelor’s degree and previously worked as an associate consultant at Bain & Company in New York.

Carter Prince is a Partner whose responsibilities span direct investments, fund strategy, operations and instruments such as warrants. Earlier he was Chief Growth Officer at Syntegra, an issuer-described generative-AI healthcare company, and led data partnerships at Aetion. His prior technology/data roles include Janssen Pharmaceuticals, SymphonyAI and Epic Systems.

Courtney Fondufe is an Associate focused on transactions, deployment strategy, portfolio management and fund operations. She previously helped launch healthcare companies at Redesign Health and covered healthcare companies in Bank of America equity research. She holds a Columbia economics degree and a University of Chicago Booth MBA.

Danielle Bradnan is a Senior Associate on the market-development team, leading communications and insights programmes. Her work supports investment-thesis research and external communications. Her published background spans digital-health market intelligence, pathogen prevention and laboratory research; no separate clinical qualification is inferred.

Desmond Bergin, also listed as Des Bergin, is a Senior Associate evaluating startups and developing investment perspectives. He joined CVS Health Ventures in2021 following strategy work at an early-stage startup and a professional minor-league hockey career. He studied government and economics at Harvard.

Julia Keene is an Associate working on early-stage sourcing, evaluation and investing. She previously worked in Deloitte strategy and analytics, then Carrot Fertility global strategy and operations, including launch and partnership projects. She completed her undergraduate studies at Indiana University.

Justin Aguado is a Senior Associate responsible for financial-model operations, investment execution, valuations, portfolio financial management and expenses. Earlier he worked in Aetna corporate finance, Deloitte finance consulting and CVS transfer-pricing operations. He holds University of Connecticut economics and MBA degrees.

Justin Brock is a General Partner leading CVS Health Ventures’ growth-equity programme, working with enterprise teams on later-stage healthcare investments. His prior work includes corporate development and strategic planning at behavioral-health company Quartet Health. He studied business at the University of Michigan and completed an MBA at Villanova. The current directory title is General Partner; an earlier issuer financing quote uses Partner without establishing a promotion date.

Krishna Shah is a Senior Associate focused on late-stage venture and growth-equity diligence in digital health, with interests in behavioral and women’s health and culturally competent care. She previously worked at Accenture, 7wireVentures and BBH Capital Partners. She holds a Cornell bachelor’s degree and a Wharton healthcare-management MBA.

Kyle Yamaguchi is an Associate supporting portfolio management, thematic diligence, advisory engagement and transactions. A Washington University in St. Louis alumnus, he completed CVS’s management development programme with rotations in network/provider strategy, retail-pharmacy analytics and the venture team.

Lily Wu is a Senior Associate managing venture-manager and LP relationships and supporting direct and growth-equity diligence. Earlier CVS roles included digital customer experience and strategic partnerships, following business-development and digital-product work elsewhere. She studied business at Babson College.

Marsida Tirana is an Executive Assistant supporting Managing Partner Vijay Patel and the wider venture team. Her published background includes executive support at Tufts University School of Medicine and Harvard Medical School, and business management and marketing studies. This is an administrative role, without an inferred investment decision-making appointment.

Michelle Yi is an Associate managing VC and LP relationships, supporting fund and growth-equity diligence and connecting portfolio companies with CVS teams. She studied economics at the University of Chicago and previously worked in Visa consulting and economic analysis, followed by portfolio-management and fund-of-funds work at a Palo Alto venture firm.

Nuha Saho is a Senior Analyst on strategy and operations, supporting fund operations, portfolio management and investment-vehicle initiatives. His published background spans development finance, public-sector consulting, venture philanthropy and private equity, focused on social enterprises and access to healthcare and financial services.

Payal Parikh is a Principal sourcing, diligencing and executing strategic healthcare investments and supporting portfolio companies. She began in management consulting and previously invested in digital health at Rock Health and Unseen Capital. Her work also includes researching representation and equity in startup and healthcare-investment ecosystems.

Riddhi Khincha is a Senior Analyst supporting market development, LP relationships and portfolio engagement. She studied economics at the University of Nevada, Reno and Boston University, and previously worked in economic analysis and research. Her directory and biography use Khincha while the individual heading has Kincha; the same exact profile/card establishes identity.

Rob Ryan is a Senior Associate engaging CVS business leaders on investment strategy and minority direct-investment opportunities. Earlier he worked in Rock Health consulting and Optum Insight healthcare strategy, and studied political science and economics at the University of Richmond. This New York healthcare-investment professional is distinct from the same-name Singapore EQT market-risk professional.

Sophia Michaels is listed as an Associate in the current CVS Health Ventures directory and profile heading; the biography still uses Senior Analyst. She supports venture sourcing and diligence and previously worked in CVS commercial and specialty-market strategy. She studied health and societies at Pennsylvania, with neuroscience and health-services-management minors. Published interests include neurotherapeutics, care delivery and digital health; no promotion date is assumed.

Vinay Raj is a Principal working on investments, deployment strategy and structured instruments. Previously he was a Principal at X, Google’s moonshot division, with earlier M&A, private-equity and investment-banking roles at Gap, Riverside and Evercore. He holds University of Pennsylvania degrees in systems engineering and economics from Wharton.

Zach Walsh is a Senior Associate managing accounting and treasury work, financial reporting, valuations and fund expenses. His career includes tax advisory, third-party fund controllership and finance leadership at a venture-backed cleantech company. He studied accounting and finance at the University of Colorado; the company reports that he obtained his CPA license in2016.

Yuri Sagalov is a published Spider venture adviser. He previously served as visiting or part-time partner at YCombinator and co-founded enterprise collaboration company AeroFS, acquired by RedBooth in2017. His biography identifies an angel portfolio separately from Spider institutional investments. He studied engineering science with a computer-engineering major at Toronto and began applied-science graduate study in distributed systems before leaving to build AeroFS; no completed graduate degree is inferred.

Alan Priest is a Spider venture adviser with startup finance and operations experience. As Anaplan’s first CFO he helped manage international expansion and later equity rounds; earlier he led finance at LiveOps and worked at other technology businesses. He advises enterprise-AI founders on fundraising, planning, process improvement and hiring. His education includes electrical engineering at GeorgiaTech and a Harvard MBA. Prior-company financings are distinct from Spider fund capital.

Jeff Ma is a published Spider venture adviser. His career includes founding GolfSpan, CircleLending, CitizenSports and tenXer, which were acquired by other companies, and later data-science and analytics leadership at Twitter and startup leadership at Microsoft. His manager biography identifies current digital leadership at Troon and prior work helping sports organizations use analytics. He was a member of the MIT blackjack team and wrote TheHouseAdvantage; these career details do not establish individual investment checks.

John Gengarella is a Spider venture adviser. Its biography describes executive leadership at ContractWrangler, Owsy and Netpulse and prior leadership at C3Energy, Voxify and Oracle, alongside StartX mentoring. He earned a computer-science BS from Pittsburgh and a Harvard MBA. Several biography outside-company titles may be historical; this profile records the current Spider affiliation without independently asserting those outside positions today.

Ron Frankel is the current directory’s senior adviser. He founded and led Synacor through growth, financing and public listing, and previously led MGMInteractive. The manager describes prior Zeitview chairman experience. He studied computer science at Berkeley and earned a USC law degree. Historical operating-company positions are not treated as newly verified current board appointments.

Charles Carmel is a Spider venture adviser with technology investing, corporate-development and investment-banking experience. He previously served as partner and managing director at WarburgPincus, focused on enterprise and communications technology, and led corporate development at Cisco, including acquisitions and venture investments. His education includes a Stanford MBA and a Tufts bachelor’s degree with honors. The manager’s transaction and portfolio figures describe prior career experience, not Spider fund closes or present issuer tickets.

Courtney Broadus is a venture adviser in Spider’s current directory. She advises startups on execution, scaling and team building. The published biography describes early Salesforce technology leadership, where she grew a small organization over a decade, and experience across startups and larger technology companies. It reports a personal startup portfolio but does not identify individual financings or amounts. She graduated from Colgate with honors; no unstated degree subject or employment day is supplied.

Ofir Bar Levav is a Spider venture adviser. Its biography identifies business leadership at IndoorRobotics and Insoundz, earlier open-innovation and venture responsibilities at JohnsonControls, CFO work at TycoIsrael and financial roles at P&G, including the DuracellPowermat joint venture. He began at Deloitte and studied accounting and philosophy at TelAvivUniversity. These external roles are published career affiliations, not assignments of outside-company cash checks.

Matt Fisher is a published Spider venture partner with sales and operations experience. The manager’s biography identifies COO and executive-vice-president responsibilities at TristarProducts, earlier US sales leadership at LiveOps, product management at Lycos and engineering at Netscape. His education includes applied mathematics at UCDavis and a Berkeley MBA. Outside operating titles are scoped to the published biography and are not assumed to establish current independent company-director positions.

Philippe Suchet is a Spider partner and entrepreneur turned investor. He co-founded marketing-software business Kefta and mobile-shopping business Zappli, acquired by Acxiom and Shopzilla respectively, and later served Shopzilla as chief strategy officer. Earlier affiliations include BostonConsultingGroup, GoldmanSachs, Abuzz and Keeboo. The manager describes angel investing and accelerator mentoring, distinct from its own institutional checks. His education includes entrepreneurship at HEC, statistics at ENSAE and a Harvard MBA.

Judy Loehr is an operating partner in Spider’s current directory. Its biography identifies product leadership at PartnerTap and early Salesforce experience, where she worked on ServiceCloud product management and later AppExchange development, launch and partnerships. Her subsequent work includes early-stage marketing leadership, venture investing and B2B SaaS advisory work. She supports female founders and mentors cloud executives, and holds an economics BA from Occidental. Outside-company titles reflect the manager’s published biography rather than separately verified current statutory offices.

Wilstar is an Oslo-based impact platform associated with the Arne and Lise Wilhelmsen family office. It combines grants for non-commercial solutions, catalytic impact-first investments and commercial venture investments. Its social priorities include education, economic inclusion and female empowerment; its environmental and technology priorities include marine conservation, ocean innovation, sustainable buildings and health. The platform traces its origins to the family’s nonprofit social-impact activities and now publishes two distinct investment arms: Wilstar Innovate, focused on financial returns and sustainable technology, and Wilstar Impact Investing, focused on measurable social and environmental outcomes. Its public portfolio classifies philanthropy separately from investments. Norwegian company records separately identify Wilstar AS, organization number 918306870; the group website’s board is presented as a published Wilstar board rather than assumed to be this company’s statutory board.

Wilstar Impact Investing is the impact-first arm of the Arne Wilhelmsen family office. It supports social entrepreneurs and environmental change-makers in Norway and internationally, aiming to produce measurable and lasting impact. Its published programme areas include education, female empowerment and marine conservation. Within Wilstar’s wider strategy, catalytic and blended capital can help organisations bridge financing gaps and scale social value, while grants support non-commercial work. The legal company is Wilstar Impact Investing AS, organization number 994211900, incorporated in 2009. It is a separate entity from the finance-first Wilstar Innovate AS. Neither corporate accounts, registered share capital nor philanthropic budgets are treated as a closed venture-fund corpus.

Wilstar Innovate is the finance-first impact investment platform within Wilstar and the Awilhelmsen family-office ecosystem. It invests in disruptive technologies and sustainable solutions that can generate competitive financial returns while strengthening Awilhelmsen’s businesses and creating long-term value. Its published investment context spans ocean innovation, the built environment and health. EQON’s issuer financing announcement names Wilstar Innovate as a co-leader, and Ava Ocean’s issuer announcement identifies Wilstar Innovate AS as a new shareholder. The Norwegian legal company is Wilstar Innovate AS, organization number 930784400, incorporated in 2022. It is distinct from Wilstar Impact Investing AS and the Wilstar umbrella; a published investment under the Wilstar brand does not by itself identify which subsidiary signed a subscription.

Wilstar publishes Agnes Wilhelmsen as published group board member. The group directory does not provide an individual career biography or appointment date.

Wilstar publishes Astrid Sørgaard as published group board chair; registered wilstar as board chair. The group directory does not provide an individual career biography or appointment date.

Wilstar publishes Carl Oscar Wilhelmsen as published group board member. The group directory does not provide an individual career biography or appointment date.

Wilstar publishes Emily Rider Wilhelmsen as programme manager; published group board member. The group directory does not provide an individual career biography or appointment date.

Wilstar publishes Francesca Wilhelmsen as co-founder; published group board member. The group directory does not provide an individual career biography or appointment date.

Wilstar publishes Hanne Mork Gentzel as investment director. The group directory does not provide an individual career biography or appointment date.

An active registered director of Wilstar Innovate AS in the official Norwegian company registry. The cited record does not provide a career biography or individual appointment date.

An active registered director of Wilstar Innovate AS in the official Norwegian company registry. The cited record does not provide a career biography or individual appointment date.

Wilstar publishes Marcus Bleasdale as managing director; registered wilstar as general manager. The group directory does not provide an individual career biography or appointment date.

An active registered director of Wilstar AS in the official Norwegian company registry. The cited record does not provide a career biography or individual appointment date.

Neal Goldman is a published Spider operating partner and adviser to portfolio chief executives. He founded and led CapitalIQ, later acquired by McGrawHill’s Standard&Poor’s division. Other own-biography affiliations include RelationshipScience chairman and GoodeHoldings co-founder; those outside titles are source-scoped career statements. Earlier he worked in Lehman Brothers M&A. He studied at the University of Pennsylvania and Columbia Business School and has held Aspen, World Economic Forum and Council on Foreign Relations affiliations. No outside-company cash check is inferred.

An active registered director of Wilstar Innovate AS in the official Norwegian company registry. The cited record does not provide a career biography or individual appointment date.

Wilstar publishes Paulina Rider Wilhelmsen as founder; published group board member. The group directory does not provide an individual career biography or appointment date.

Wilstar publishes Solveig A. Wilhelmsen as co-founder; published group board member. The group directory does not provide an individual career biography or appointment date.

David Berman is Spider Capital’s published operating partner, bringing enterprise software sales and go-to-market experience. Its biography identifies prior president positions at Zoom and RingCentral and worldwide sales-and-services leadership at WebEx. He helped those companies develop and scale their commercial operations, including periods leading up to IPOs. His education includes a business-administration BBA from the University of San Diego. Source statements about revenue growth are career claims, not independent performance measurements or fund fundraising.

Minsoo Chi is a partner at Spider Capital. He joined in May2018 as its first investment professional, covering deal sourcing, diligence, portfolio support and investor relations. He previously invested in digital health and SaaS at Nokia-backed NGP Capital and advised on strategy, acquisitions and private-equity diligence at Bain. Raised in Seoul, he moved to the UnitedStates for high school and earned a neuroscience BS from Brown. Exact joining day is unverified.

Michael Neril founded Spider Capital in2015 and serves as Founder and Managing Partner. Its current own biography describes two decades working with startups as investor, adviser, founder and operator. He previously co-founded Webb Investment Network with Maynard Webb and led its investments; earlier he directed business development at LiveOps after it acquired his second startup, and worked on technology M&A and finance at ING Barings. He holds a Tufts BA in international relations. The SEC filing identifies his full name Michael Joshua Neril and managing-member status since April2015. No personal investment check is inferred from portfolio board work.

Spider Capital is the US seed-stage venture brand of Spider Capital Partners Management, LLC, an SEC exempt reporting adviser CRD282546 / file802-107605. Its March21,2026 annual ADV and own legal copyright establish the exact manager, distinct from Spider Management, SpiderRock, Spider Forex and unrelated similarly named entities. Founded by Michael Neril in2015, Spider leads or co-leads early enterprise cloud and applied-AI software investments, principally in the UnitedStates and Canada with selected investments in Israel and Europe. Its current published roster includes three investment partners, three operating partners, a venture partner, seven venture advisers and a senior adviser; external operational/advisory roles are distinguished from statutory management. The team brings cloud software, data analytics, enterprise sales, robotics and digital-health experience. Its own portfolio spans AI healthcare fraud analytics, autonomous industrial inspection, manufacturing process optimization and enterprise software. The SEC filing reports four distinct Delaware fund vehicles including a separate FundI Select vehicle, with GPs and asset values qualified separately; targets and gross asset values are not represented as closed fundraising or issuer tickets. Public portfolio cards establish backing relationships but do not allocate checks or dates to specific vehicles.

Andy DeSoto is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Head (Acting) — Directorate for STEM Education. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Charisse Carney-Nunes is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Head — Directorate for STEM Education. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Emilda Rivers is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Director — National Center for Science and Engineering Statistics. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Erwin Gianchandani is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Assistant Director — Directorate for Technology, Innovation and Partnerships. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented. NSF’s own2023 biography states that he joined the agency in2012, previously served as CISE deputy assistant director and acting assistant director, helped develop the TIP directorate, and worked on SmartandConnectedCommunities, NationalAIResearchInstitutes and wirelessresearch programmes. Earlier work at the ComputingCommunityConsortium and degrees in computer science and biomedical engineering from the UniversityofVirginia are documented biographical context. Historical unit budgets are not attributed as personalcapital or fundclose.

Megan Wallace is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Inspector General (Acting) — Office of Inspector General. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Michelle Elekonich is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Director — National Center for Science and Engineering Statistics. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Anne Johansen is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Head — Directorate for Geosciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Christina Freyman is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Directorate Head — Directorate for Social, Behavioral and Economic Sciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Joydip Kundu is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Directorate Head — Directorate for Geosciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Junping Wang is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Mathematical and Physical Sciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Monya A. Ruffin is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Directorate Head (Acting) — Directorate for STEM Education. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Saul Gonzalez is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Mathematical and Physical Sciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Tie Luo is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Directorate Head — Directorate for Mathematical and Physical Sciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

William Olbricht is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Alexis Lewis is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Amy Walton is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Computer and Information Science and Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Don Millard is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Directorate Head — Directorate for Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Irina Dolinskaya is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Directorate Head — Directorate for Computer and Information Science and Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented. Northwestern’s primary biography describes transportation-science and logistics research, adaptive models using dynamic information, humanitarian logistics, vessel optimization and electric-vehicle routing. Its2015 academic-rank snapshot is not asserted as current.

Wendy Nilsen is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Computer and Information Science and Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Charles Cunningham is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Biological Sciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Clyde Richards is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief Information Officer and Chief Technology Officer — Office of the Chief Information Officer. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

James Deshler is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Directorate Heads — Directorate for Biological Sciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Theresa Good is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Directorate Head — Directorate for Biological Sciences. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Earl Andrews is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief Human Capital Officer (Acting) — Office of the Chief Human Capital Officer. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Jesse Simons is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief Financial Officer (Acting) — Office of the Chief Financial Officer. The named remit is Deputy Office Head — Office of the Chief Financial Officer. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Lisa Scott-Morring is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Office Head — Office of Award Management. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Jason Bossie is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Office Head — Office of Award Management. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Victor Powers is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Office Head — Office of Administrative Services. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Honeywell Ventures is Honeywell’s corporate venture-investment platform for early-stage technology companies. Honeywell’s May 2017 launch announcement states that investments are made through Honeywell Venture Capital LLC, a wholly owned corporate subsidiary. The Delaware LLC remains listed in Honeywell’s official affiliate list updated August 13, 2026; it is distinct from similarly named UK holding companies and unrelated Honeywell businesses. Its published technology scope covers industrial software and analytics, autonomous systems, aerospace, materials, life sciences and sustainability. Source-proven investments include pharmaceutical manufacturing AI company Aizon (formerly Bigfinite) and Electric Hydrogen. Aizon’s 2019 Series B investment is distinct from the parties’ later commercial collaboration. The launch’s expected approximately USD100 million initial investment allocation is a corporate programme announcement, not evidence of an externally raised LP fund or an actual final fund close; no such closed fund is asserted. Public 2026 and 2025 conference sources identify Victor Yang and Paul Kingston respectively; four former leaders are explicitly recorded as historical. The accessible Honeywell-authored venture microsite contains dated 2023 assets and stale staff information, so its team and portfolio are not asserted to be an exhaustive current directory. The logo is the genuine shared Honeywell brandmark published in Aizon’s own investor list; a distinct current venture-unit wordmark is not verified.

Kamal Vasagiri’s current Exposition Ventures biography identifies him as a venture partner and describes his earlier leadership of Honeywell Ventures investments. His Kauffman Fellows Class 24 biography records the Honeywell title Director of Venture Capital Investments. Earlier work included GE Ventures, software engineering and entrepreneurship. His education includes a Chicago Booth MBA, a Utah State electrical-engineering master’s degree and an engineering bachelor’s degree from JNTU. The Honeywell role is historical; current biographies also identify Yaletown affiliation.

Murray Grainger was the inaugural managing director of Honeywell Ventures, named in Honeywell’s May 2017 launch announcement. His current American Industrial Partners biography identifies him as a partner who joined that firm in 2023 and describes his earlier founding leadership of Honeywell’s venture-investment business. He is recorded here as a historical leader, with an authentic current AIP portrait, rather than current Honeywell staff.

Patrick Hogan was identified as managing director of Honeywell Ventures in Honeywell’s July 2022 Electric Hydrogen investment announcement. He subsequently joined Black & Veatch and is identified by its current official biography as Chief Business Evolution Officer. His career includes senior Honeywell commercial positions. He holds a Bristol science degree and a Cambridge doctorate in medicinal chemistry. His Honeywell venture role is historical, and the portrait is Honeywell’s own published original.

Paul Kingston is identified as Investment Director at Honeywell Ventures in the official 2025 Asia Venture Capital Forum programme published by the Hong Kong Venture Capital and Private Equity Association. His HKUST speaker biography describes responsibility for Asia investments and portfolio partnerships and earlier Honeywell corporate-development work. The role is dated to the public programme; a subsequent appointment or departure and a verified personal portrait were not established.

Stephane Fymat’s self-authored professional biography identifies him as former president and managing director of Honeywell Ventures. It also describes earlier leadership of Honeywell Aerospace’s urban-air-mobility and unmanned-aircraft business, entrepreneurship at Smartplane and enterprise-software experience. The Honeywell affiliation is historical. Portfolio-size claims in the biography do not establish a closed external investment fund or any individual investment allocation.

Victor Yang is identified as Senior Investment Manager at Honeywell Venture Capital in the official May 2026 SpaceTech Economic Forum programme. The 2026 Imagine Next summit biography describes his early-stage aerospace and defence investment focus at Honeywell Ventures. His affiliation is qualified to these dated published programmes, rather than an inferred appointment or complete current corporate team directory.

Dean Evasius is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief of Research Security Strategy and Policy (Acting) — Office of Research Security Strategy and Policy. The named remit is Deputy Office Head (Acting) — Office of Research Security Strategy and Policy. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Jean Cottam Allen is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Office Head, Office of Polar Programs — Office of Research Infrastructure. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Linnea Avallone is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief Officer for Research Facilities — Office of Research Infrastructure. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Robert Moller is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Office Head — Office of Legislative and Public Affairs. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Stacey Standridge is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Office Head (Acting) — Office of International Science and Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Jennifer Pearl is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Office Head (Acting) — Office of International Science and Engineering. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Stephen Meacham is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Deputy Office Head — Office of Integrative Activities. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Alicia Knoedler is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Office Head — Office of Integrative Activities. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Francisco Ruben is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Designated Agency Ethics Official — Office of the General Counsel. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Angel Williams is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is General Counsel — Office of the General Counsel. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Ellen Zegura is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Senior Science and Engineering Advisor, Artificial Intelligence — Office of the Director. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented. GeorgiaTech’s primary biography documents computer networking and computing-for-development research, degrees in computer science and electrical engineering from WashingtonUniversity, and ComputingforGood work. Earlier faculty affiliations are biographical context, not additional current NSF roles.

LeVale Jenkins is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Office Head — Office of Civil Rights. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Micah Cheatham is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief Management Officer — Office of the Director. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Yusuf Özdalga is a London-based partner at QED Investors with a focus on European fintech companies. Yusuf joined QED in 2017, and his career has spanned roles as an operator, advisor, entrepreneur and investor. His current portfolio of investments include Midas, Swap Commerce, Wagestream, Payhawk, Wayflyer, Shop Circle, GetGround, RemoFirst and Carmoola. Yusuf started his career at Capital One in 1997 where he helped develop many of the innovative lending solutions in the underserved credit segment. Subsequently he joined the Financial Institutions M&A Group at J. P. Morgan, as an advisor to banks and specialty finance companies. He started his professional investing career in 2006, with a focus on specialty finance and consumer credit companies in Europe, including early fintech investments such as some of the first online loan originators in Sweden and was also an investment director and Head of Turkey with a growth private equity fund. Yusuf holds an MBA from the University of Chicago with High Honors, and a BS in Finance and MIS from the University of Virginia with Distinction. Yusuf is fluent in English, Swedish and Turkish and has a working knowledge of German. He is currently studying Bosnian/Serbo-Croatian. ‍

The U.S. National Science Foundation (NSF) is an independent federal agency established by Congress under the National Science Foundation Act of1950, PublicLaw81-507. It promotes science, national health, prosperity and welfare, and national defense primarily through research and education grants, institutional partnerships and scientific infrastructure. The exact nsf.gov institution is retained independently of NIH, other federal agencies, private foundations, similarly named international research councils and individual public officials. It is a public grantmaking institution, not a commercial venture manager, investment bank or LP fund. NSF supports fundamental science and engineering, including AI, computing, biological and cognitive science, advanced engineering, quantum research, research infrastructure and technology translation. Its general basic-research mandate excludes medical sciences, while technology-focused awards can address health-related applications such as SleepSpace’s wearable-and-sensory sleep research. Directorates and administrative offices are internal NSF units and are not duplicate institutional cash buyers. General agency appropriations, programme budgets, planned allocations, grant award obligations and actual recipient bank disbursements are distinct. No agency budget is recorded as a raised venture fund. The current primary public leadership directory names44 individuals across46 scoped leadership roles. It explicitly lists the NSF Director and DeputyDirector posts as vacant. BrianStone is Chief ofStaff performing the duties of the NSFDirector; RebeccaKeiser is ActingChief ofStaff. Acting designations and each office/directorate scope are preserved. The current NationalScienceBoard member page says new appointments are pending, so no older chair/member roster is asserted as current. The leadership directory is the complete named public leadership scope captured here, rather than a claimed census of the agency’s wider staff, programme officers or external advisers. Eight genuine adjacent primary publisher portraits are included;36 individually named portraits remain unverified and are explicitly documented rather than represented by placeholders. Earlier biography/photo captions do not override current official leadership titles. The institutional funding graph can represent source-proven research awards without implying equity ownership. NSF award1622766 names MobileSleepTechnologiesLLC, principal investigator DanielGartenberg, STTRPhaseI sleep-wearables/sensory research, June24,2016 award notice and July1 project start. Its USD224,996 obligated amount and matching estimated award total identify the same award, not two financings; bank disbursement is unproved. SleepSpace’s issuer owner maintains its sole exact award relationship. Individual leadership, research-supervision and principal-investigator roles do not establish personal investments. No private LP funds or corporate financing rounds are invented for the federal agency.

Brian Stone is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief of Staff, Performing the Duties of the NSF Director — Office of the Director. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Rebecca Keiser is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief of Staff (Acting) — Office of the Director. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Shruti joined QED in January 2024 as a principal based in New York where she focuses on investments in early stage fintech. ‍ Prior to joining QED, Shruti played an integral role in building the strategic finance function at Robinhood. At Robinhood, she helped scale the brokerage, international, crypto and issuer/shareholder communications (Say Technologies) business segments. She also focused on cost efficiency implementation across the customer service, fraud and financial crimes functions. ‍ Shruti started her career in Investment Banking at Citigroup and thereafter worked at Standard Chartered Private Equity (now Affirma Capital) where she evaluated growth stage investment opportunities across APAC. ‍ Shruti graduated with a B.S. in Electrical Engineering from the Georgia Institute of Technology and earned her MBA at the Wharton School. Outside of work, Shruti enjoys traveling, pilates and discovering new restaurants in the city. ‍

Simon Malcomber is published in the U.S. National Science Foundation’s current public leadership directory. The named remit is Chief Science Officer — Office of the Director. This is a public institutional role, not personal investment authority or capital attribution. Acting status is retained exactly; appointment day and earlier career details are not invented.

Sov joined QED Investors in May 2023 and is an executive administrator. Sov has over 15 years of experience in executive support in software and financial services. Prior to QED, she was the executive assistant to the CEO at Mission Lane, she supported the Chief Marketing Officer as well as the marketing team at Atlantic Union Bank, the President of PIEtech, creator of MoneyGuide suite, which was acquired by Envestnet in 2019, and supported the CEO at Mapcom Systems, a telecom software company. Outside of QED, Sov enjoys spending time with her sweet toddler, Maxwell, and husband, Brook. She’s an avid crocheter and makes a valiant effort in keeping orchids alive. She is a graduate of Grand Valley State University.

Victoria is a partner at QED on the early stage domestic team. She joined QED in May 2022 as a principal based in San Francisco where she has a focus on investments in early stage fintech and commerce businesses. Prior to joining QED, Victoria helped lead fintech investing at Gradient Ventures, Google’s early stage venture fund, where she worked with founders building the next generation of fintech and commerce tech in categories like insurance, e-commerce, application software transaction processing and core fintech infrastructure. Victoria started her career in tech M&A at Qatalyst Partners, advising founders in their sell-side processes on more than $20 billion in M&A transactions. Victoria received her B.A. and M.S. in economics and engineering at Stanford University and is a proud supporter of the Cardinal football team even through the worst times. Prior to college, Victoria was born and raised in Nanjing, China, and continues to draw inspiration from the boom in commerce innovation in Asia. ‍

Shardae joined QED Investors in June 2022 and brings more than a decade of experience in executive support, marketing leadership and operations across the hospitality and technology sectors. Prior to QED, Shardae served as Director of Marketing and Communications at IsI Enterprises, a cybersecurity and compliance firm. She spent seven years as Chief of Staff at Great American Restaurants, where she honed her expertise in operations and executive support within a high-volume hospitality environment. Earlier in her career, she served as Executive Assistant to the CEO at iCore Networks, where she provided direct support to the CEO and C-level management team, driving cross-departmental collaboration and taking on projects across the organization. Shardae studied Journalism and Promotional Communication at Cleveland State University. Outside of work, she is an avid international traveler with a passion for culinary exploration, enjoys hiking in national parks, and is a devoted Ohio State Buckeyes football fan.

Secil is an executive, entrepreneur and operator with two IPOs under his belt. He specializes in product strategy, M&A, strategic partnerships and scale-up. Secil started his career at McKinsey in Europe working on financial services projects in Paris, Milan and Istanbul offices. He went on to join Capital One in 2002, initially as the chief of staff to Nigel Morris, and transitioned to manage the new-to-credit segment. He was one of the early employees of Green Dot, joining in 2005, where he built the Green Dot Network, the cash and money movement division, into a $200M business at the time of their IPO. After his success with Green Dot Network, he took on the role of General Manager at FastPay, a vertically focused invoice finance and B2B payments platform for the media industry. FastPay was acquired by AvidXchange in July 2021, three months before its IPO. After the IPO, he played an integral role in running and integrating the FastPay business into Avid while launching an invoice accelerator product for the overall company. Secil has been an active angel in Silicon Beach and has been serving as a trustee and the finance chair at the Lycée International de Los Angeles. He holds an M.B.A. from Harvard Business School and a dual degree in Economics and Business Administration from Bosphorus University in Istanbul and is fluent in Turkish, French and Italian. He lives in Pasadena with his wife and three kids and enjoys ping-pong and outdoor activities in southern California.

Nigel Morris is the co-founder and managing partner of QED Investors, a fintech venture capital platform focused on disruptive, high-growth financial services companies. QED has made numerous unicorn investments, including Credit Karma, Nubank, Avant, SoFi, Klarna, GreenSky, and AvidXchange. Nigel is the chairman of ClearScore and Mission Lane and serves on the boards of Remitly, Bitso and Current and is a board observer for QuintoAndar and Albert. Additionally, he works in an advisory capacity with Oliver Wyman. Nigel previously worked on the boards of Capital One, The Economist, Brookings, National Geographic, Klarna, Braintree, TransUnion, London Business School, AvidXchange and Scotia’s Digital Advisory Council. He frequently keynotes at industry-leading conferences, including Money2020, Fintech Nexus, Finance Disrupted, and the Bernstein Annual Financials Summit. Prior to QED, Nigel co-founded Capital One Financial Services in 1994. Under Nigel’s leadership as president and chief operating officer, Capital One pioneered an information-based strategy that transformed the consumer lending industry. Although Nigel grew up mostly in England, he takes immense pride in the fact that he is at least half Welsh. He has an MBA with distinction from London Business School, where he is also a Fellow. Nigel was recognized as a Top 100 Venture Capitalist by CB Insights in 2019 and Midas List member for five consecutive years from 2021 to 2025. He is an avid cyclist, but he is happiest when he is at home in Virginia with his wife, four children and four grandchildren. ‍

Sandeep has led, operated and invested in companies of all sizes in consumer technology and financial services across the United States, the United Kingdom, India and Asia-Pacific over two and a half decades. Based in the San Francisco Bay area, Sandeep is a partner and head of Asia-Pacific at QED Investors. He leads the firm’s investing activity across Asia-Pacific, backing fintech and technology founders who combine sharp market insight with the operational discipline required to build lasting institutions. He has invested more than $250 million across a high-conviction portfolio and serves on 10 boards. Before QED, Sandeep was CEO and Managing Director at Truecaller in India, a consumer technology platform with more than 250 million monthly active users. He grew revenue five-fold to more than $110 million in three years, brought the company to profitability and paved the way for its IPO on Nasdaq Stockholm at a multi-billion-dollar valuation. Earlier, at Flipkart, he scaled the fintech business to serve 1.3 million borrowers, ran the home and furniture division as P&L owner and, as group head of strategy, helped engineer a $4 billion fundraise and the $21 billion acquisition by Walmart. He began his career at Capital One, Actis Capital and McKinsey & Company across the United States and the United Kingdom. Sandeep holds an MBA from the London Business School and a B.Tech. from the Indian Institute of Technology, Mumbai, India. Though an avid traveller, paragliding pilot and deep-sea diver, Sandeep’s most incredible adventures these days are with his two sons around Silicon Valley. ‍

Nick is Nigel Morris' chief of staff. Most recently, Nick was the deputy chief of staff to the CEO of Cognizant, a leading Fortune 200 technology and IT services company, where he was responsible for CEO client strategy, communications planning and executive committee agenda setting. He first joined Cognizant as a consultant focusing on organization design and change management. Prior to Cognizant, Nick served as the special assistant to U.S. Senator Rob Portman. During his tenure in the Senate, Nick held various roles for Senator Portman spanning policy, politics and operations. Nick holds an MBA from Georgetown University and graduated from Kenyon College with degrees in Economics and Political Science. He is a Cleveland, Ohio, native and currently resides in Washington, D.C. with his wife, Lillian.

Miles Reidy serves as a Partner Emeritus at QED. He advises QED portfolio companies and serves on a number of their boards.  Miles joined QED in 2014 and served as a Partner prior to becoming a Partner Emeritus at the end of 2018. Prior to QED, Miles served as the Chief Financial Officer for Audax Health, Inc., which offered a digital health engagement product, and was Chief Operating Officer and Chief Financial Officer for Network Solutions, one of the largest domestic providers of Internet hosting and marketing services to small businesses.  He also served as Executive Vice President and Chief Financial Officer for Sears Holdings Corporation. Miles spent almost a decade in several executive roles at Capital One Financial Corporation, a publicly traded consumer finance bank. These roles included:  Executive in Charge of Banking Integration, Chief Corporate Planning / Financial Strategy Officer and Chief Financial Officer of Capital One Bank and Credit Card.  Miles’s responsibilities included development and implementation of the corporation’s capital and financial strategies, oversight of the card businesses financials and consumer analytics, and strategic planning. Miles also serves on the Boards of the Royal Bank of Canada, US, Heinz School of Public Policy at Carnegie Mellon University, and the Easter Seals of Baltimore/Washington.  He holds a B.S. from Georgetown University and a M.S. from Carnegie-Mellon University.

Matt is a business operations associate. He joined QED in January 2025. Most recently, Matt was special assistant to Senator Young of Indiana, where he was responsible for briefing the senator prior to his commitments and executing his daily schedule. Additionally, Matt assisted in policy and political engagements. Matt is currently earning an MBA from the University of Virginia, Darden School of Business. He graduated from Taylor University with degrees in philosophy, political science, economics and law.

Matthew Risley serves as a Partner Emeritus at QED. Prior to QED, Matt has spent his career in fintech and payments in a variety of roles, including finance, marketing, product development, and risk management.  He has experience in both the U.S and in Europe, having spent much of his career working in Spain and Sweden.  Prior to joining QED, Matt served as the CFO & Chief Credit Officer at European payment unicorn Klarna where he managed Klarna’s machine learning strategy and equity offerings, among other initiatives.  Before joining Klarna, Matt advised fintech and large financial services providers on strategy and risk management with Treliant Risk Advisors, a financial services consulting firm.  Matt has also had leaderships positions in a peer-to-peer lender, digital student lender, and with Capital One. When not at a desk, Matt looks to be biking, running, climbing, or kayaking. Matt graduated with a B.S. in economics from Duke University and later dropped out of business school.

Mike is a partner and the head of QED growth funds. Previously, Mike was the head of LatAm, focusing on supporting the portfolio and finding new investment opportunities. He is passionate about finding the next wave of fintech’s disruptive entrepreneurs and business models, particularly in lending, payments, and anything that helps small businesses thrive. Prior to QED, Mike spent 10 years with Capital One working across several functions and business lines developing a skill set in strategy and analytics.  He has always been drawn to data-based strategies and has broad experience in credit risk management, product development, decision sciences, data analytics, testing strategies, marketing, and financial management.  In his last role at Capital One, Mike led Small Business lending and was charged with growing the portfolio in the face of growing fintech competition.  Mike’s prior responsibilities included leadership roles in account management, retail partnerships, and subprime credit card. Mike holds MBA degrees from Columbia Business School and London Business School and graduated from the University of Virginia with degrees in Systems Engineering and Economics.  Mike lives with his wife Maggie and two children in Tampa, Fla.

Maryalice is the vice president of administration & talent development for QED Investors. Throughout her career, Maryalice has proven herself as a strategic thinker, a dedicated leader and a versatile professional in hospitality, event management and human resources. Her commitment to lifelong learning, global perspectives and servant leadership has made her a respected figure in the industry, and she continues to encourage others through her expertise and passion. Having served as the vice president of organizational development at Modus Hotels, she played a pivotal role in driving strategic initiatives and creating a culture of growth, collaboration and excellence. One notable highlight in Maryalice's career was developing and implementing a hospitality and tourism management program in Honduras. This initiative demonstrated her commitment to empowering local communities and enhancing their tourism infrastructure, ultimately creating sustainable economic opportunities for the area. Maryalice holds a master’s degree in organizational leadership from Gonzaga University and is published in the International Journal of Servant Leadership . She is also a certified executive coach through the Berkeley Executive Coaching Institute, further deepening her capacity to support leadership development and personal growth. Beyond her professional achievements, she finds great joy in international travel and in theater, believing in the transformative power of experiencing different cultures in all its forms. ‍

Laura Bock is a partner at QED and focuses on U.S. fintech investments. Prior to QED, Laura spent time advising financial institutions on growth, product, operations and strategy as a consultant at management consulting firm Oliver Wyman. Her work focused on banks, insurers and payment companies across North America. Laura also spent time at the World Economic Forum, where she led an initiative focused on bringing better financial infrastructure to emerging economies. Laura lives in New York City. Outside of work, she enjoys pickleball, board games and live music. Laura studied biophysics and biochemistry at Princeton University.

Laura joined QED as director of tax in 2022. In this role, she manages QED’s internal tax process and coordinates with third-party service providers. She also works with the portfolio companies and QED investors to provide timely tax reporting and consult on tax strategies. Prior to QED, Laura spent seven years in public accounting with Grant Thornton.  During her rise to manager, she specialized in pass-through entity tax, specifically Subchapter K. Her focus also included individual income tax. Laura received her Master of Science in Taxation from James Madison University. She lives with her husband and son in Fairfax, Va. ‍

Kshitij is a principal at QED, focusing on investments in Asia. Prior to joining QED, Kshitij co-led fintech, crypto and gaming investments at Elevation Capital, a leading VC fund in India. At Elevation, he was instrumental in more than 20 investments across categories such as credit cards, SME financing, wealth management, fintech infrastructure and payments. He also published multiple influential market theses, podcasts and reports during his time at Elevation. Previously, Kshitij was a consultant at Bain & Company, advising private equity, automotive and financial services clients. Kshitij is an alumnus of IIT Bombay, where he graduated with a B.Tech and M.Tech in chemical engineering. ‍

Katya is the Vice President - Finance at QED, assisting the CFO with accounting policies and procedures, financial records and reporting. Prior to joining QED, Katya spent five years with Collage Group, a marketing research and strategy consulting firm specializing in multicultural insights. She has more than 15 years additional experience working at small to mid-sized rapid growth companies in a variety of industries including e-commerce, digital media, publishing, manufacturing and non-profit. Outside of QED, Katya serves on the Board of Directors of Bethesda Urban Partnership, Western Montgomery County Citizens Advisory Board, Bethesda Green, East Bethesda Citizens Association and Montgomery County Council of PTAs. Katya graduated Magna Cum Laude from New York University with a B.A. in Philosophy. She grew up in California and now enjoys living in Bethesda, MD with her husband and daughter.

John is an executive with broad and deep experience in financial services, credit management, and analytics. He has 20 years of experience as a manager, operator, and senior credit officer at Capital One followed by experience advising portfolio companies, mostly within LatAm, at QED, then as a partner at AQN Strategies providing strategy and analytic consulting to financial companies of all sizes across the western hemisphere. John has deep experience in consumer and small business products including deposits, credit cards, mortgage, auto, installment loans and lines of credit. Work experience ranges from well-known global banks to pre-launch startups in management, consulting and advisory. He is passionate about helping companies grow and win by using structured problem solving and data to make better decisions, and he is currently advising portfolio companies at QED in several countries focusing on starting and growing lending functions. John lives in Arlington, Va., holds a BSE from Princeton University and enjoys cooking, running and driving his 15 year old to sports practices and games all over the greater DC area. ‍

Karene Brown is vice president, investor relations and engagement at QED Investors, where she focuses on LP relationships, fundraising activities and the firm’s broader investor relations strategy. She also co-leads key firmwide events, with a particular focus on investor engagement. Karene joined QED in 2020 and has held several roles across the firm, most recently serving as a leader in QED’s executive office. In that capacity, she worked closely with the firm’s senior leadership and investment teams on strategic initiatives, executive engagement and relationship management across QED’s global network. Prior to QED, Karene spent more than 15 years in executive-facing and operational roles across financial and professional services, including positions at Capital One, Baker Hostetler and Hausfeld. She is a graduate of the University of Maryland, College Park. Outside of QED, Karene enjoys spending time with her rambunctious pup, Scooby Juneteenth Brown, traveling, and puttering around in her garden with more enthusiasm than expertise. ‍ ‍ ‍ ‍

Jamie is the chief financial officer for QED.  In his role, Jamie is responsible for all of the accounting, finance, compliance and back office operations at QED. Prior to joining QED, Jamie spent 14 years with Blue Water Capital, a venture capital firm, where he served as chief financial officer.  Jamie was also a founding partner of J. Loving & Company, where he worked as a part-time CFO for small and growing businesses for more than five years. Jamie spent the first six years of his career with Arthur Andersen LLP. Outside of QED, Jamie serves on the board of directors of Access Point Communications, Inc. and Renaps, Inc. as well as McLean Little League.  Jamie is married with two daughters and is active in coaching their softball teams. Jamie graduated Summa Cum Laude from Wake Forest University with a Bachelor of Science in accounting.

Gbenga is a partner at QED focusing on Africa and Middle East investments as part of the international team. Gbenga has spent his career working across fintech/tech and Africa in a variety of roles from product development to growth to marketing to partnerships. He has had experience working across Africa, Europe and the U.S. markets. Prior to joining QED, Gbenga was co-founder of Kanza Ventures, a boutique seed investment and advisory firm focused on fintech in Africa. Before that, Gbenga was product director for SMB growth at Wise (formerly TransferWise), a global cross-border remittance fintech. Prior to that, he was head of strategic partnerships at Revolut, Europe’s biggest neo-bank, managing teams responsible for product integrations such as Xero, Quickbooks and Expedia. Previously, Gbenga spent six years at Google in a variety of roles from managing telecom industry partnerships and strategy in Africa to leading Google’s mobile app business and strategy with clients spread for different companies from banking to travel to e-commerce companies across Nigeria, Kenya and South Africa. He was also a product partnerships lead in Europe and Africa where he worked on localizing Google Search in Africa and launched Google Events Search in Germany, the U.K., Spain and France. Gbenga is passionate about the tech ecosystem and mentors many founders, especially in Africa. He is a global advisory board member for Antler, a global startup accelerator, co-organizer for Stockholm Tech Fest and also a fellow of the Nigeria Leadership Initiative. Gbenga holds an MBA from London Business School and received his Bachelor of Science degree in economics from Obafemi Awolowo University in Nigeria. Gbenga is fluent in both English and Yoruba and has a basic working knowledge of Swedish. He is based in London. ‍

Fernando is a Partner and Head of Global Capital Strategy at QED Investors, where he works across the investment lifecycle—from sourcing and capital formation to portfolio growth and liquidity. As part of QED’s investment team, he has supported and helped scale a diverse set of high-growth companies globally. Previously, Fernando served as QED’s Entrepreneur in Residence, where he founded Coru, an AI-native fintech platform focused on democratizing financial services in Latin America. Coru is now led by seasoned operators—a testament to QED’s ability to build and transition high-impact ventures when needed. Before QED, Fernando spent over two decades at the intersection of technology, finance, and entrepreneurship. He held senior roles at comScore, where he led a business unit through a successful exit to Adobe, and at MicroStrategy, where he helped build the core enterprise analytics business during its early hypergrowth phase and led the incubation of a strategic product later acquired by Meta (formerly Facebook). Fernando holds an MBA from the University of Maryland and an engineering degree from Tec de Monterrey. He brings deep domain expertise across fintech infrastructure, AI, enterprise SaaS, and go-to-market strategy. An active angel investor, advisor, and mentor, Fernando is recognized for bridging hands-on operating experience with institutional investment rigor. He is an emerging leader in scaling QED into the premier global fintech-specialized venture fund, known for combining sharp investment discipline with hands-on operational expertise.

Frank is co-founder and partner emeritus. Prior to QED Investors, Frank was one of the early architects who helped create what became Capital One. In his 13-year Capital One journey, Frank was responsible for many “firsts” that helped lay the foundation for what Capital One is today. Frank graduated from the University of Virginia with degrees in Applied Mathematics (B.S.) and Systems Engineering (M.S.).

Enrique is a principal at QED based in London, focusing on early stage investments across Europe. Before joining QED, he spent seven years at Speedinvest, where he invested in fintech and marketplace companies from pre-seed to Series B. He joined as an intern and worked his way up to principal, leading investments in category-defining companies such as Wayflyer and Moove. He also played a key role in expanding the firm’s international presence, spending time on the ground in both Africa and the GCC. Born and raised in Barcelona in a German household, Enrique has lived and worked across Europe, the U.S., and the Middle East. He brings a global outlook and a hands-on approach to partnering with founders from day one. Enrique holds a Bachelor’s degree in management and finance from ESADE. Outside of work, he’s into just about every sport, a former triple and long jumper, and a longtime music lover, with tastes ranging from jazz to Berlin techno. ‍

Camila joined QED in 2022 as the company’s first employee based in Sao Paulo, Brazil, where she has a focus on early stage investments. As an investor and operator with experience working in different regions, Camila brings a well-rounded experience for the region where she will be able to connect founders and startups to valuable resources and leverage QED's deep fintech experience. Prior to joining QED, Camila spent her career in technology and financial services. She started her career at Moody’s, a credit rating agency, before joining Goldman Sachs to focus on corporate credit and economic risk. Later, as part of Goldman's investment banking division, Camila helped fintech, software and e-commerce companies raise capital and cross over from private to public markets. She went on to join the global strategy and corporate development teams at Ceridian, a global software company servicing more than 160 countries. More recently, Camila spent time at Hotmart, a Brazilian tech unicorn whose platform facilitates sales of digital products enabling creators to build, monetize, manage and grow globally. There, she led strategy and operations, ESG and investor relations.

Bill joined QED as a Special Advisor in the fall of 2014 and became a Partner in 2015. He is currently Head of Early Stage Investments after six years as Head of International, leading QED’s Investment teams in Latin America, Europe and Asia. Prior to joining QED, Bill spent nearly 20 years at Capital One, spanning several roles and leading several businesses. He spent the first 6 years of his career leading Marketing, product development and credit policy for Capital One’s subprime credit card business; ultimately having overall P&L responsibility, and growing the business to become the most significant player in the market. He moved on to spend 2 years in various new business development roles, spanning the telecom, medical finance and small business finance industries. Bill spent 3 years as Deputy Chief Credit Officer for the bank, playing nearly every role there was to play in the central credit function, after helping build the department from scratch in 2002. Bill then pivoted his career to general management, leading Capital One’s Canadian, and ultimately International businesses, over the course of 6 years. Profitability of the business grew significantly under Bill’s leadership, through new product and channel introductions, acquisitions, and significant cost take out. During Bill’s last 3 years at Capital One, he led its Co-Brand and Private Label credit card business, building the business nearly from scratch to one of the top few players in the US market, through a series of acquisitions, most notably including leading the acquisition and post-merger integration of HSBC’s US credit card business, which closed in May 2012. Bill graduated with a BA in economics from the University of Michigan, and competed the SEP program at Stanford GSB.

Ashley joined QED as the director of PR and communications in February 2021. Ashley has spent his entire career in communications and journalism. Prior to joining QED, he spent three years at Ackrill Media Group, where he was a senior reporter; five years with Major League Baseball Advanced Media as an editorial producer; and, most recently, five years with the United States Tennis Association where he was the assistant managing editor, corporate communications. He was previously shortlisted for Feature Writer of the Year at the Yorkshire Press Awards and was highly commended in the Young Journalist of the Year category at the O2 Media Awards. Ashley holds a B.A. (Hons) degree in journalism from the University of Central Lancashire in England, including study in journalism, mass media and communication from the State University of New York at Plattsburgh. Ashley is originally from England and is now based in Washington DC, where he lives with his wife and son. In his free time, he enjoys traveling, photography and playing tennis.

Anne Bailey is vice president, platform – investment operations at QED Investors. She is responsible for building and running the operating platform that supports QED’s investment team, working closely with finance and QED Central to ensure consistency, data integrity, and effective execution across the firm. She also provides direct support to partner, global head of early stage investments, Bill Cilluffo. Anne brings a broad background in business management and operations, with experience across sports media, technology, real estate and entrepreneurship. Prior to joining QED, she ran and successfully turned profitable a local gym during the pandemic—an experience that sharpened her operational judgment and reinforced the importance of adaptability and disciplined execution. Anne is an alumna of the University of Virginia. Outside of work, she enjoys cheering for the Wahoos, traveling, concerts and spending time with her daughters.

Ana Cristina is a principal at QED, where she focuses on international investments, particularly in Latin America. Ana Cristina is also the head of Fontes, QED’s $12 million fund for seed-stage companies in Latin America. Prior to QED, Ana Cristina founded Mosaico, a content platform for Latin America entrepreneurs, and spent time looking into starting her own fund focused on financial inclusion in the region. Prior to that, Ana Cristina spent four years in strategy consulting, where she helped companies better serve multicultural consumers in the U.S. Ana Cristina is passionate about democratizing access to financial services, supporting female and diverse founders and a big believer in business as a force for good. Ana Cristina holds an MBA from Harvard Business School and a B.S. in Management Science & Engineering from Stanford University. Outside of work, Ana Cristina enjoys running, tennis and traveling. Ana Cristina is originally from Guatemala City and currently lives in Miami.

Amias joined QED as a Partner in 2017 focusing on supporting the portfolio and finding new investment opportunities with a focus on back office technologies and infrastructure companies. Amias brings a deep background in financial markets, compliance, and RegTech to the QED team.  Most recently, Amias served as the President’s nominee and as Acting Assistant Secretary for Financial Institutions at the U.S. Department of the Treasury. In that role, he was the lead advisor to the Secretary on policies affecting financial institutions.  He also oversaw a number of programs focused on supporting small business lending and community development. He previously served as the Deputy Assistant Secretary for the Financial Stability Oversight Council, an interagency group of financial regulators charged with monitoring and mitigating potential threats to financial stability.  Prior to Treasury, Amias was a management consultant at Oliver Wyman. He also served in a number of policy roles and worked in East Africa for Save the Children.  Amias is a recipient of the Alexander Hamilton award, the Treasury’s highest honor. Amias graduated Magna Cum Laude from Harvard with a BA in Social Studies.

Amaree joined QED Investors in August 2026 as executive assistant to investment team members Yusef Özdalga, Gbenga Ajayi and Enrique Hausmann, supporting the firm’s investment activities across the U.K. and Europe and Africa and the Middle East. Amaree has over eight years’ experience partnering with senior executives, founders and investors across global financial services, including investment banking, venture capital, fintech, asset management and legal services. Before joining QED, she supported the co-head of EMEA Technology Investing within asset and wealth management at Goldman Sachs, where she also partnered with multiple managing directors and vice presidents across the division. During her tenure, she supported a private equity platform of more than 70 investment professionals. Earlier in her career, Amaree served as executive assistant to the CEO of an investment management firm and was one of the earliest employees of a high-growth business, supporting its expansion from five to 26 employees. Born and raised in South-East London, Amaree has a longstanding interest in architecture, particularly tropical modernism. Outside work, she enjoys melodic techno, travelling and playing backgammon with family and friends. ‍

Alex joined QED in December 2023 as a member of the growth team and will be working out of our New York office. Alex most recently was an investment banking associate at Goldman Sachs, focusing on debt financing for financial institutions, and then M&A and financing transactions for middle-market companies. Alex has also spent time with I-Lab Angels group, which invests in Israel-based seed through Series A companies with a focus on science and technology. Alex grew up in New Jersey and graduated from the University of North Carolina at Chapel Hill, majoring in business with a minor in sustainability. Outside of work, Alex enjoys playing golf, fishing, cooking and following his beloved Tarheels.

Adiam joined QED as an accounting manager in August 2023. She is responsible for overseeing the daily operations of the accounting department and assisting the finance team. Prior to joining QED, Adiam worked at Arabella Advisors where she was responsible for the oversight and execution of the company’s revenue reporting processes. She also worked for Lincoln Property Company as a senior accountant where she managed the accounting and financial operations of various commercial properties while providing timely and accurate monthly financial reporting. Adiam also worked for Bank of Montreal, in Toronto, Canada, in the technology and operations finance and controllership departments. Adiam holds a Bachelor’s degree in accounting from York University in Toronto, where she is from, and has amassed seven years of experience in the field. Outside of work, Adiam enjoys spending time with family and friends and exploring the DC area. She is based in the Alexandria, Va., office.

Ben Gottlieb is SleepSpace’s named historical iOS Frontend Developer in its2021–2022 issuer fundraising slide. It describes two decades of Apple-platform experience and five years engineering sleep-related iOS applications. The company’s current about page does not name him as current staff; this is an explicitly historical development affiliation, not an inferred present job or personal company investment.

Jeremiah J. Merrick is SleepSpace’s named historical Chief Technical Officer in its2021–2022 Wefunder issuer team slide. The slide describes22years of development experience and work with large datasets, email campaigns and customer service. He is not present in the current about-page founder roster, so the role and genuine named original portrait are retained as historical rather than a presumed current executive appointment.

Dan Roberts, PhD, is SleepSpace’s published sleep-science research collaborator; its older named fundraising slide calls the same company sleep researcher Daniel Roberts, PhD, Chief Science Officer, describing EEG analysis, auditory perception and machine-learning expertise. The current about page supplies a source-aged Penn State postdoctoral caption. This sleep researcher is distinct from the existing Scout Alarm co-founder and product officer Daniel Roberts; no unrelated biography or private investment is merged.

Samantha Marie Nagy, PhD, is a research collaborator named by SleepSpace with an undated University of Arizona postdoctoral-research caption. The issuer’s team-sam portrait matches that named collaborator. This source-aged academic collaboration is distinct from a verified current company employee, investor or present faculty appointment.

Sarah E. Emert, PhD, is a sleep research collaborator publicly named by SleepSpace, with an undated University of Arizona postdoctoral-research-fellow caption. Her genuine issuer portrait is stored under team-sarah. This affiliation is limited to the company’s published collaboration roster, without a presumed present university appointment, company employee status or personal financing.

Margeaux Grey, PhD, is the registered sleep technologist and sleep researcher named in SleepSpace’s published collaborator roster and labelled research-adviser collage. Its Penn State assistant-research-professor caption is source-aged context. The scope is a research collaboration, without a presumed company investment, executive job or independently verified current faculty appointment.

Orfeu Buxton, PhD, is the Penn State sleep researcher named and pictured in SleepSpace’s published collaborator roster and earlier research/adviser materials. Peer-reviewed disclosures describe academic subaward research from the company’s NSF/NIH projects. Academic collaboration and university subcontract funding are separate from a corporate equity check or a company employee appointment.

Daniel Taylor, PhD, is a sleep-science research collaborator publicly named by SleepSpace with University of Arizona professor and sleep-doctor context. The issuer also identifies him in its older research/adviser collage. This scoped collaboration does not automatically make him a company employee, current executive or investor; undated university titles require their own current appointment source.

Valorie Wolfe, PhD, is the psychology adviser named in SleepSpace’s about roster and pictured in its current named clinical testimonial. The about page spells Valorie while the home-page testimonial spells Valerie; the shared psychology/Kaiser context supports one source-qualified identity. The external Kaiser Permanente lead-psychology caption is undated context, not newly verified current employment or a personal investor allocation.

Randall Evens, MD, is the pulmonologist named and pictured in SleepSpace’s combined investor/adviser roster and research-adviser slide. The source establishes a published clinical advisory affiliation, not a venture-investment ticket or an independently dated current employment appointment.

Amy Coveny is publicly named in SleepSpace’s combined investor/adviser section and its earlier fundraising materials, which describe a Quake Capital operating/managing affiliation. Quake’s current leadership directory does not list her, so the outside manager caption is historical or source-aged rather than a new current Quake role. Institutional Quake investment and her advice are distinct from an unproved personal check.

Jeff Finkle is named in SleepSpace’s combined investor/adviser roster with the external caption Chairman of Arc Angels. This is a source-qualified venture-network affiliation; the undated caption does not independently establish his current outside title, a company director appointment or a personally allocated financing check.

Martin Babinec is the TriNet founder published in SleepSpace’s combined investors and advisers roster. His role supplies operating and entrepreneurship context, while the mixed roster does not establish a personal cash check, amount, date or current company board appointment. The issuer’s separate UpVentures institutional financing statement is not automatically a Martin personal investment. His current UpVentures biography identifies him as a Holdings co-founder. He founded TriNet in1988 and led it as CEO for its first twenty years, then chaired it through2010. His own Babinec.com biography identifies him as the founder of UpVentures Capital, StartFast Ventures and Upstate Venture Connect. These are distinct institutional affiliations; a corporate UpVentures investment does not establish a personal check.

Melissa Mueller is SleepSpace’s published co-founder and Chief Product Officer. Her primary biography describes more than two decades in product design, user research, product strategy, experience mapping, interface and brand development. She earned an honors psychology bachelor’s degree at Stanford and studied graphic design at Art Center College of Design.

SleepSpace is a sleep-health technology company combining phone and wearable sensing, a digital sleep diary, adaptive auditory stimulation, smart-bedroom light integration, and behavior-change programmes informed by cognitive behavioral therapy for insomnia. Its current products include a consumer app, clinician/research dashboards, Smart Bed or phone-based nearable sensing, sleep coaching and the Dr. Snooze AI conversational sleep coach. Sleep-stage estimates, consumer symptom support and research findings are distinct from a diagnostic authorisation or an independently established treatment claim. The company’s own science page explicitly distinguishes consumer sleep trends from diagnosing disorders; older crowdfunding promises of FDA approval in2022 do not establish an actual clearance. The current legal issuer is Proactive Life Inc., CIK1744917 and EIN270800635, independently named as the SleepSpace app’s Apple publisher and current NIH awardee. SEC submissions retain the previous Proactive Life LLC name; NIH/NSF and peer-reviewed investigator disclosures connect the earlier Mobile Sleep Technologies LLC sleep-research business to Proactive Life and the SleepSpace brand. This source-qualified legal history does not merge unrelated Proactive Life businesses, the Beta Service Agency app using a similar SleepSpace title, or Daniel Gartenberg’s personal investment in Neurosity. No exact incorporation or conversion day is inferred. The current issuer about page names founder/CEO Daniel Gartenberg and co-founder/Chief Product Officer Melissa Mueller, six combined investor/adviser affiliations, and six research collaborators. The combined investor/adviser section does not prove a personal check by each named person; external employer captions are undated context. Its2021–2022 crowdfunding team slide additionally names historical Chief Technical Officer Jeremiah J. Merrick, iOS Frontend Developer Ben Gottlieb and Chief Science Officer Daniel Roberts. Those earlier executive appointments are qualified historical, while the current site publishes Dan Roberts as a research collaborator. The SleepSpace sleep researcher is distinct from the Scout Alarm product-founder Daniel Roberts. Primary NIH records identify six separate fiscal-year NIA notices awarded to Proactive Life or its Mobile Sleep predecessor: USD348951 in2017,347058 in2018,1243520 in2020,1234826 in2021,50000 supplemental in2022, and499963 in2025. These are annual notice-award amounts, not duplicate full-project totals, equity rounds or bank-disbursement dates. NSF award1622766 separately reports224996USD obligated for its2016 STTR PhaseI project. The seven retrieved records total3949314USD; varying website claims of over3M/3.5M/4M are not added as additional financing. Research subawards to academic collaborators are not separately attributed as company equity. Its issuer-operated Wefunder page reports242414USD raised from67 investors, last fundedMarch2022. No exact closing day or unnamed crowd investors are invented. The same page describes more than1.2MUSD raised in a previous venture round including Quake Capital and UpVentures; because the precise amount/day/stage and allocation are unpublished, the retained prior-venture relationship keeps cash/day NULL. SEC lists2018 D/D-A and a2021 FormC; their inaccessible full documents remain a source gap, and offering targets are not treated as proceeds.

Satya Prasad P V is identified as HRBPManager in Circuitry.ai’s own public Hyderabad machine-learning job posting, and is named with a genuine individually associated portrait in its company employee directory. BalajiSridharG’s own joining announcement thanks him for interview and onboarding support. The linked individual profile names Circuitry.ai in Hyderabad; the exact published initials are retained rather than expanding an unproved legal name or merging another similar profile.

Balaji Sridhar G’s own professional profile announces joining Circuitry.ai as Product Designer at its Hyderabad office. He describes more than14 years of UX/UI work, focusing on design systems, user experience and visual design, and earlier user-experience work at Syncron. The issuer public employee directory names him and associates a genuine photographic portrait. His name is retained exactly as published; no expansion of the final initial or precise appointment day is invented.

Rod Langohr is individually named in Circuitry.ai’s own public company employee directory, linked to rodlangohr, and associated with a genuine named photograph. The issuer’s March2024 decision-intelligence webinar also identified him as its moderator. Those source-scoped affiliations are recorded without inventing an undisclosed current executive rank or merging an unrelated namesake career.

Sudhir Singh’s own professional profile and recent primary post explicitly identify him as Circuitry.ai VP of Platform Engineering. He leads work across DevOps, cloud infrastructure, security, FinOps and site reliability, partnering with engineering on enterprise AI product quality. His profile describes reliable, scalable decision-intelligence infrastructure for manufacturers. The issuer company directory individually names him and associates his authentic portrait; exact appointment day is unproved.

Dheeraj Inampudi currently describes himself on his personal website as building EigenH AI, working on patient access for independent healthcare practices. Circuitry.ai welcomed him as Head of Product Engineering in January2024 and identified him as Head of Engineering in its April2024 Product AIdvisor launch and October2024 Hyderabad AI R&D expansion. He previously served six years as CTO of Propellor.ai according to the issuer welcome. His historical Circuitry work included foundation models, data intelligence, conversational AI and technical analytics for manufacturer product/service applications. Exact departure and EigenH appointment dates are unpublished; his Circuitry affiliation remains explicitly historical. His authentic individually named personal-site photographic portrait is preserved.

Mike Woellert is identified as Circuitry.ai Digital Marketing Manager and media contact in its October1,2025 seed-financing announcement, and also in the2024 Hyderabad R&D expansion announcement. This establishes a dated company communications role; no current2026 executive status, wider career, ownership or authentic portrait is inferred where primary material is unavailable.

Nathan Tarpey was identified as Principal Product Manager at Circuitry.ai in its April22,2024 Product AIdvisor launch. He described conversational product discovery, clarifying customer needs and tailored product recommendations using generative AI and catalog knowledge. The recorded affiliation is scoped to that dated primary release, without assuming current2026 employment, other company affiliations or a fabricated portrait.

Lorien Pratt is a machine-learning and decision-intelligence author and practitioner whose appointment as Circuitry.ai advisor was announced February19,2024. The issuer describes her product-strategy and adoption remit,2023 Decision Intelligence Handbook, inductive-transfer work, and applied machine-learning experience involving the Human Genome Project, DOE, courts and DARPA. Her authentic named issuer portrait is preserved; the dated appointment does not independently prove current2026 continuation or company employment.

Mark Hessinger participates as a strategic advisor in Circuitry.ai’s publicly offered AI advisory-lab programme. The issuer describes more than30 years of service leadership experience at companies including3DSystems and GerberScientific, and publishes his genuine named photograph. The programme offers guidance on field-service AI use cases, implementation and business outcomes; this programme participation is not treated as proven full-time company employment or statutory board membership.

Bob Juno is identified as a Circuitry.ai Enterprise Account Executive in its own February2026 Field Service Medical team listing and is also named in its public company employee directory. The issuer publishes a genuine individually named2026 photograph. His role concerns enterprise service/support AI for equipment organisations; the medical conference does not establish clinical credentials or a physician role.

Lorna Dusti is Florida Opportunity Fund's published secretary and interim treasurer. The official leadership page provides her named portrait.

Matt Swanson is Florida Opportunity Fund's published interim president and executive director. The official page provides his named portrait.

Tom Iarossi is listed on Florida Opportunity Fund's board. The published biography identifies construction and development leadership in Tampa.

Brandon Detweiler is listed on Florida Opportunity Fund's board; the same page identifies a Lincoln Network product role.

Garrett W. Johnson is listed on Florida Opportunity Fund's board. The published biography identifies him as a Lincoln Network co-founder.

Susan Amat is listed on Florida Opportunity Fund's board, with entrepreneurship education affiliations at the University of Miami and Global Entrepreneurship Network.

A.J. Ripin chairs Florida Opportunity Fund's published board. Its leadership page identifies him with Merging Traffic in Orlando.

Vijay A. Balasubramaniyan is Pindrop’s currently published CEO and co-founder, with over two decades of experience in communications security and a Georgia Tech computer-science PhD. Codoxo’s originalJune12,2017 issuer funding announcement explicitly names him among personal investors in its1.5M seed. This personal check is distinct from his company and is not inferred from a board position.